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Abstract: The first project of this work involved the synthesis flexible heteroarotinoids for anti-
cancer activity. Flexible Heteroarotinoids (Flex-Hets) are a class of substituted di-aryl compounds 
that exhibit potent anti-cancer activity without toxicity. Previously, our group developed a sulfur 
containing heteroarotinoid S-Het-A2 (NSC 721689), exhibited promising activity against 62 
different cancer cell lines at micromolar concentration with excellent differentiation between 
normal and cancer cells. The primary goal of this work is to improve the activity of the lead 
compound S-Het-A2. To achieve this, we synthesized 42 modified heteroarotinoids and they were 
tested against human A2780 ovarian cancer cell line.  
 
 Altering the linker unit: The thiourea unit in S-Het-A2 was replaced by acrylamide, N-
benzylacetamide and thiazoline. Nitro- substitution on the ring B aryl group caused 
similar activity compared to S-Het-A2 for acrylamide linker. When N-benzylacetamide 
and thiazoline were used as linker, the compounds were completely devoid of activity. 
 Nitrogen containing heteroarotinoids: The sulfur atom in the cyclohexyl ring in S-Het-A2 
was replaced by nitrogen. Nitrogen heteroarotinods with a carbonyl group at C3 of ring A 
exhibited greater activity than the S-Het-A2, whereas a hydroxyl at C3 and Flex-Hets 
without a gem-dimethyl next to nitrogen atom trimmed the activity to a large extent. 
 Tethering bioactive motifs to S-Het-A2 rings: A fragment based approach was attempted 
by joining ring A and ring B of S-Het-A2 with bioactive compounds such as indole, 
quinoline, oxazoline, furfuryl and aspirin. None of these compounds exhibited even 
moderate activity. However, reducing the nitro group of S-Het-A2 to an amino group 
resulted in enhanced acivity. 
 
The second part of this work involved devising new methods for preparing biologically active 
compounds under metal free conditions. These methods are summarized below 
 Synthesis of isoquinolinones, naphthyridinones pyrazoloquinazolinones, 
pyrazolopyridopyrimid-inones and benzimidazoquinazolinones have been developed 
using an N-acylation - SNAr reaction sequence. The newly developed methods afforded 
better yields under milder reaction conditions compared to earlier reported methods.   
 The SNAr strategy was further extended to add enolates and amines to electron deficient 
vinylarenes. This method allowed enolates to add across unsubstituted and α-substituted 
electron deficient vinyl arenes. 
 An efficient, inexpensive approach to synthesis 1,3,4-oxadiazole was established using 
catalytic NH4Cl and also an efficient tandem reaction was designed to synthesize 4-
chromanone using 20 mol% of bismuth(III) triflate.    
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CHAPTER I 
 
 
SYNTHESIS OF FLEXIBLE HETEROATORINOIDS FOR ANTI-CANCER ACTIVITY 
1.1 Introduction: 
Ovarian cancer is the most lethal gynecological malignancy and represents 3% of all female 
cancers with 239,000 new cases detected per year and 152,000 deaths per year worldwide.1  In 
the United States alone, the detection rate for ovarian cancer is nearly 22,000 per year, with over 
14,000 deaths reported annually.2  The disease is also termed as the ‘silent killer’, as more than 
80% of patients exhibit no symptoms if it is limited within the ovaries.3  Over the last two 
decades, the 20% of patients diagnosed with early stage ovarian cancer had a five-year survival 
rate of over 90%.3  Although more effective surgery as well as treatment with optimized 
combinations of cytotoxic drugs have improved the survival rate over the past five years, the 
overall cure rate remains only at 30%.4 Thus there is a great demand to develop new agents to 
treat ovarian cancer and our research group has worked to combat this deadly disease by 
developing a new class of compounds called heteroarotinoids. 
Heteroarotinoids are a family of synthetic compounds with a heteroatom in the arotinoid structure 
(arotinoids are the poly-aromatic analogues of retinoic acid). The basic structural units of 
heteroarotinoids 1 are designed to mimic the anticancer activity of trans-retinoic acid (2).5 
Biological studies of 2, and related compounds, revealed that they possess high toxicity which 
limits their potential as a chemotherapeutic agents.6 The high toxicity of 2 is thought to derive 
from its oxidation to metabolites 3 – 6.6 Strategic placement of a heteroatom at C4 in 2 could 
avoid the oxidation at this position, which leads to toxic metabolites 4 and 5.5 This strategy has 
been validated, and further addition of the benzene ring fused across C5 and C6 of the cyclohexyl 
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and incorporating C1’ and C2’ of the pendent chain in 1 would also prevent epoxidation, and 
thereby avoid formation of 3 from 2.5, 7-8 These successful outcomes resulted in coining the new 
term heteroarotinoids 1 where they possess an aryl ring fused to a saturated five- or six-
membered ring containing a heteroatom (ring A) linked to another aromatic ring9 (ring B) as 
shown in structure 1 (Figure 1.1).  
 
Figure 1.1. Basic structure of heteroarotinoids and retinoic acid and their toxic metabolites. 
Intensive studies on the modification of heteroarotinoids have been reported involving the 
insertion of different linker fragments (L in 1) to connect the two aryl rings. Structures with two 
atom linkers such as an amide (9), an alkene (10), an ester (11) or an N-methoxyamide (12), have 
been synthesized. Structures with three-atom linkers, such as propenone as in (13), propanol as in 
(14), and α-hydroxyamide as in (15) have also been prepared. The 1,4-diketone 16, as a four-atom 
linker, has also been reported (Figure 1.2). All of these heteroarotinoids have shown potent 
anticancer activity with low toxicity.10-13 
1 Ring B 
 
2 Ring A 
 X = O, S, NR 
L = Linking group; amide, alkene, 
ester, urea, thiourea 
 
4 3 
5 6 
3 
 
 
Figure 1.2. Heteroarotinoids with different atom linkers. 
Flexible Heteroarotinoids (Flex-Hets) are heteroarotinoids compounds with three or more atom 
linkers. Incorporation of a more flexible linker between the aryl groups provides more degrees of 
freedom that can increase the binding affinity of the compound with the receptor. Derivatives 
incorporating a number of urea and thiourea linkers between the aryl groups have been 
investigated (Figure 1.3) and their increased flexibility resulted in a marked increase in activity of 
the compound.11, 14  These Flex-Hets have potential anticancer activity against various kinds of 
cancer cells. Of all the Flex-Hets prepared to date, a derivative with a sulfur in the fused 
heterocycle of ring A linked by a thiourea group to ring B bearing a nitro group at C4, named as 
S-Het-A2 (19) exhibited the most promising activity on 62 different cancer cell lines.15 
Furthermore, S-Het-A2 exerted inhibitory activity on cancer cells, with excellent differentiation 
9 10 
11 12
13 14
7 8 
15
4
16
4
4 
 
between normal and cancer cells.17 It also exhibited no mutagenicity, carcinogenicity, 
teratogenicity or toxicity and displayed a wide therapeutic window which suggested that its major 
metabolites were non-toxic.11, 15-21  
Figure 1.3. Examples of heteroarotinoids with three atom linker 
Recently, S-Het-A2 has been approved for phase 0 clinical trials and these studies are in progress. 
However, we were interested in improving the activity of S-Het-A2, and as a part of our 
continuing effort, this work involved synthesizing a new class of Flex-Hets with the following 
changes: 
1) altering the linker unit of S-Het-A2; 2) synthesizing nitrogen analogues of S-Het-A2; and  
3) tethering bioactive molecules to S-Het-A2 rings. 
1.2 Altering the linker unit of S-Het-A2 
1.2.1 Increasing the linker unit using acrylamide. 
Modifications to the linker units have been envisioned in S-Het-A2 and other Flex-Hets to 
enhance the activity and reduce the toxicity.22-26 It was noted that altering the linker units resulted 
in a marked increase in inhibitory activity from 21 to 23 (Figure 1.4). These compounds revealed 
the relationship between the linker and its anticancer activity. Recent progress by the Gurkan 
group demonstrated that structure 21, which contains an acrylamide linker,27 enhanced the 
biological activity of the compounds in a related synthetic retinoid family. Based on molecular 
Ring B 
Ring A 
S-Het-A2 
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modeling, we had previously predicted that allowing certain flexibility within the ring system of 
the molecule could specifically increase the H-bonding capabilities between the ligands and the 
binding pocket of the retinoic acid receptors.11 We found that structures with 3-atom linkers 
exhibited improved anti-cancer activity compared to 2-atom linkers presumably due, in part, to 
the increased flexibility of the molecule. Recently, two retinoid derivatives containing 4-atom 
linkers, as in compound 23, have been reported.27-28 
Building on these observations, we hypothesized that selected compounds with 4-atom linkers 
would possess increased flexibility and increased conjugation with the aromatic ring B, which 
might improve the efficacy of S-Het-A2. We subsequently designed and synthesized a new series 
of 11 compounds incorporating a cinnamamide linked to a sulfur containing heterocycle (ring A). 
This modification was projected to enhance the biological activity of the related S-Het-A2 system 
and would, hopefully, reduce the toxicity of these synthetic, modified retinoids. We now report 
the synthesis and the biological activity of these 4-atom linked second-generation Flex-Hets 
against the ovarian cancer cell line A2780.29 These new heteroarotinoids then were appraised 
relative to S-Het-A2. 
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Figure 1.4. Rationale for designing Flex-Hets with an acrylamide linker. 
1.2.2 Results and Discussion for increasing the linker unit using acrylamide 
The syntheses of cinnamide-linked Flex-Het analogues required 5-7 steps. Initially, 4-
acetamidothiophenol (24) was treated with mesityl oxide (25) in the presence of triethylamine 
(Scheme 1.1). A two-fold excess of mesityl oxide and base was required to perform this Michael 
reaction to afford the ketone product 26 in 70% yield.30 Notably, this Michael addition gave 
higher yields only when the reactants were added portion-wise. A standard, one-time addition 
gave the products in lower yields, along with recovered excess starting materials. 
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Scheme 1.1. Synthesis of intermediate 29 
Subsequent addition of methyllithium to 26 at -50 oC led to the formation of tertiary alcohol 27. 
Even in this reaction, the sequence of reactant addition played a critical role in the outcome. 
When the substrate was dissolved in tetrahydrofuran, followed by dropwise addition of 
methyllithium, a low conversion was observed, and product purification was difficult. With 
inverse addition, however, the reaction afforded a cleaner conversion of 26 to 27, and the 
purification process was simplified. Dehydration-cyclization of 27 by the action of AlCl3 in 
chlorobenzene generated the desired thiochroman derivative 28 in 89% yield. Refluxing 28 with 6 
M HCl in methanol furnished the desired aminothiochroman in 95% yield as its hydrochloride 
salt 29. 
Aminothiochroman 29 was joined with cinnamic acid derivatives 30a-f using a standard coupling 
promoted by 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC.HCl), 
hydroxy-benzotriazole (HOBt), and diisopropylethylamine (DIPEA) to generate the desired 
cinnamamides 31a-f (Scheme 1.2). The 4-carboxycinnamamide derivative 31g was prepared by 
saponifica- tion of 31a using lithium hydroxide in aqueous tetrahydrofuran. 
a) TEA, CHCl3, reflux 24 h; b) CH3Li, THF, -50 oC; c) AlCl3, chlorobenzene, 80 oC; d) 6 M HCl, MeOH 
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Scheme 1.2. Synthesis of Flex-Hets 31a-h and 33a-c 
The 4-aminocinnamamide congener 31h was realized by reduction of the corresponding 4-nitro 
derivative 31b using iron/ammonium chloride in ethanol. Furthermore, the acid 31g was 
converted to amides 33a-c, as illustrated (Scheme 1.2), using the standard coupling protocol. In 
order to anchor our spectral assignments, an X-ray structure determination was conducted for 
31a. With the exception of the fused tetrahydrothiopyran moiety, the perspective view of 31a 
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(Figure 1.5) shows a nearly planar structure with good conjugation of the two aromatic rings with 
the acrylamide linker. 
 
Figure 1.5. X-ray structure of 31a 
These Flex-Hets were screened to identify structural features important for cancer cell inhibition 
activity. S-Het-A2 was used as a standard for comparison. The biological effects of the 
compounds were assessed using a cytotoxicity assay on the human A2780 ovarian cancer cell line 
(Table 1.1). The three most active compounds 31b, 31f and 33c contained a nitro, a tertiary amino 
and an oxomorpholino group, respectively, as the ring B aryl substituent (Table 1.1). Compound 
31b, with a nitro substituent as in S-Het-A2, exhibited activity comparable to S-Het-A2. 
Replacement of the nitro substituent with a dimethylamino group (31f) reduced the efficacy, but 
not the potency. The oxomorpholino substituent (33c) slightly reduced the potency and efficacy. 
The efficacy and potency were reduced to a greater extent when the substituent was an amino 
group (31h), a methylamide group (33a), or the related cyclopropylamide group (33b). 
Compounds lacking a nitrogen atom at the para position of ring B exhibited potencies similar to 
S-Het-A2, but with 60 - 70% reduced efficacy (Table 1.1). The ethyl ester derivative 31a had 
only 43% efficacy compared to S-Het-A2, although the former was slightly more potent. Previous 
comparison of S-Het-A2 with the ethyl ester derivative S-Het-A3 (CO2Et in place of NO2) did not 
demonstrate improved potency in the context of thiourea linker containing compounds.31 
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Table 1.1. The activity data of Flex-Hets 31a-h and 33a-c 
 
Compound X Potency  
IC50 (µM) 
Efficacy 
(% SHetA2) 
Maximal Activity 
(% Growth Inhibition) 
Non-Nitrogen-Substituted Flex-Hets 
   
(SHetA2) 4-NO2 2.98 ±  0.10 100 93.17 ± 2.37 
31a 4-CO2Et 1.49 ± 0.13 43.19 ± 5.01 40.37 ± 4.88 
31c 4-CF3 1.09 ± 0.22 30.73 ± 8.65 28.61 ± 7.66 
31d 2,3,4,5,6-F 5.42 ± 0.36 31.16 ± 5.26 29.17 ± 5.33 
31e 3,4-OCH3 7.81 ± 0.23 37.07 ± 12.18 34.73 ± 11.44 
31g 4-CO2H >1000 0 0 
Nitrogen-Substituted Flex-Hets    
31b 4-NO2 2.17 ± 1.69 97.29 ± 10.75 85.07 ± 4.10 
31f 4-N(CH3)2 2.42 ± 0.14 71.33 ± 7.34 68.02 ± 10.27 
31h 4-NH2 5.18 ± 0.23 49.65 ± 0.34 52.02 ± 9.63 
33a 4-N-methylamide 5.04 ± 0.46 52.22 ± 5.00 47.67 ± 5.48 
33b 4-N-cyclopropylamide 5.52 ± 0.58 67.35 ± 5.50 45.11 ± 10.05 
33c 4-oxomorpholino 4.64 ± 0.24 89.32 ± 0.35 77.47 ± 1.11 
 
Interestingly, the related carboxylic acid derivative 31g was completely devoid of activity. The 
CF3 derivative 31c was about 30% as effective as S-Het-A2, but had a ca. three-fold higher 
potency. Compound 31d, which possessed a perfluorophenyl, was also about 30% as effective as 
S-Het-A2, and it had an almost two-fold reduced potency. The dimethoxy compound 31e 
exhibited 37% efficacy relative to S-Het-A2 and a ca. five-fold attenuated potency. The study 
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demonstrated that various substitutions at the para position on the aryl moiety had highly variable 
effects on the anticancer activity of Flex-Hets. Compound 31b (X = NO2), which was identical to 
S-Het-A2 except for the linker group, had similar but slightly reduced potency and efficacy, 
indicating the importance of the nitro group. The oxomorpholino derivative 33c was less potent 
than S-Het-A2, but the efficacy was only 10% lower than that of S-Het-A2. Other substitutions 
containing nitrogen atoms exhibited similar reduced activity, while substitutions lacking nitrogen 
atoms were the weakest, and the carboxyl group abolished activity. Recent studies revealed that 
S-Het-A2 binds to and disrupts protein interaction with mortalin.16, 32 
An overall appraisal of the four best derivatives 31b, 31f, 33b, and 33c revealed that a para 
electron donating group (31f-NH2) and several para electron withdrawing groups (31b-NO2; 33b-
(CO)-cyclopropylamino; 33c-C(O)-morpholino) exhibited reasonable efficacy within the 
experimental limits, although potency varied within less than a two-fold range. Compounds with 
the two larger para groups (33b and 33c) had reduced potency compared to 31b and 31f and may 
reflect steric hindrance. All four of these compounds have polar components, and, thus, there is 
not a simple rationale for the observed activity.  
1.2.3 Altering the linker unit using N-benzylacetamide.  
Based on the input from our collaborator (for N-benzylacetamide). 
1.2.4 Results and Discussion for altering the linker unit N-benzylacetamide  
The syntheses of Flex-Hets 43a-c and 44 required 7–8 steps with the first 4 steps following the 
reported procedure.33 Treating 4-bromo-3-methylphenol (34) with sodium hydride in 
tetrahydrofuran and reacting with dimethylacryloyl chloride (35) in tetrahydrofuran at 0 oC, and 
warming to room temperature (Scheme 1.3), afforded ester 36 in 96% yield. Treatment of 36 with 
aluminum chloride in dichloromethane at 0 oC and stirring at room temperature for 24 h provided 
ring-closed chromanone 37 and 37a in a ratio of 3:1. Notably, running this reaction under ice-
cold conditions for longer decreased the isomer ratio to 1:1. Therefore, the ice bath was removed 
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immediately after the addition was complete. The regioisomers were separated by column 
chromatography. Addition of methyllithium to 37 at 0 oC in ether, followed by stirring at room 
temperature for 48 h, gave an 81% yield of diol 38. Dehydration-cyclization of 38 was achieved 
using concentrated phosphoric acid at 100 oC for 1 h to afford the 6-bromo-2,2,4,4-
tetramethylchroaman (39) in nearly quantitative yield. Cyanation of 39 was performed using a 
modified Rosenmund-von Braun procedure wherein L-proline promoted the CuCN cyanation of 
the aryl bromide,34-35 to afford  40 in 63% yield. Several milder reduction procedures, such as 
Kagan’s reagent (SmI2),36 NiCl2.6H2O,37 and CoCl2.6H2O38 were attempted for the reduction of 
cyano compound 40. Unfortunately, these methods failed on our system. Surprisingly, a clean 
conversion of 40 to 41 (71% yield) was observed using lithium aluminum hydride in refluxing 
tetrahydrofuran.  
 
 
 
 
a) NaH/THF, 0 oC to rt; b) AlCl3, 0 oC to rt, 24 h; c) MeLi/THF, 0 oC to rt, 48 h; d) H3PO4, 110 oC; e) 
CuCN, L-proline, DMF, 140 oC; f) LAH, THF, reflux 
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Scheme 1.3. Synthesis of Flex-Hets 43a-c and 44 
Chroman 41 was condensed with phenylacetic acid (42a-c) derivatives using a standard coupling 
promoted by EDC.HCl, HOBt, and DIPEA to generate the desired N-benzylacetamides 43a-c 
(Scheme 1.3). Thioamide 44 was obtained by treating 43a with Lawesson’s reagent at room 
temperature and then refluxing for 6 h to afford the thioamide 44 in 72% yield.  
The biological activities of these Flex-Hets were assessed using a cytotoxicity assay on the 
human A2780 ovarian cancer cell line.  Of these 4 compounds, the most active compound was 
43c containing a trifluoromethoxy with an acetamide linker. This compound retained nearly 70% 
of the activity of S-Het-A2 with a slight decline in potency (Table 1.2), whereas the 
trifluoromethyl derivative 43b showed only 56% of the activity. Surprisingly, the nitro-
substituted acetamide 43a, and thioacetamide 44 were almost completely devoid of activity in the 
cytotoxic assay, in defiance of the modelling study predictions. 
 
 
 
 
 
 
 
 
 
 
 
Table 1.2. Activity data for Flex-Hets 43a-c and 44 
 
Compound X Y Potency  
IC50 (µM) 
Efficacy 
(% SHetA2) 
Maximal Activity 
(% Growth 
Inhibition) 
(SHetA2) 2.71 100 83.75 
43a 4-NO2 O 4.64 11.5 8.6 
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43b 4-CF3 O 4.199 56.13001 47.0092 
43c 4-OCF3 O 4.644 79.55297 66.62607 
44 4-NO2 S No fit 0 0 
 
1.2.5 Altering the linker unit with a thiazoline ring 
As has already been discussed, molecular modeling has predicted that allowing flexibility within 
the ring system of the molecule could specifically increase the H-bonding capabilities between 
the ligands and the binding pocket of retinoic acid receptors.11 We found that structures with 
three-atom linkers exhibited improved anti-cancer activity compared to two-atom linkers, 
presumably due in part, to the increased flexibility of the molecule. However, there is a lack of 
evidence suggesting that flexibility is essential. Therefore, we sought to study the activity profile 
of S-Het-A2 by replacing the thiourea linker unit with a system that has the same elements but 
more restricted flexibility.  
 
 
 
 
 
Figure 1.6. Structural comparison of S-Het-A2 and its modified compound 45 with a thiazoline 
instead of a thiourea 
 
The amino-thiazoline ring system was chosen, because it has the necessary elements and also the 
same number and type of elements as in thiourea linker, and at the same time, it will restrict the 
flexibility since it is fused to the aryl ring. Moreover, thiazoline and its derivatives are well-
known for their versatile pharmacological activity as antibiotics, radioprotectives, pheromones, 
S-Het-A2 45 
15 
 
and metal chelators, as well as anticancer and anti-HIV agents.39 Based on the above 
considerations, S-Het-A2 was modified as illustrated in Figure 1.6. 
1.2.6 Results and discussion for altering the linker unit with the thiazoline ring 
The synthesis of 45 was performed according to the synthetic procedure used to prepare the key 
intermediate 29. Michael reaction of 4-bromobenzenethiol (46) with mesityl oxide (25) in the 
presence of triethylamine afforded ketone 47 in 90% yield. Addition of methyllithium to 47 at -50 
oC provided the tertiary alcohol 48 in 80% yield. Subsequent treatment with aluminum chloride in 
refluxing dichloroethane afforded the thiochroman derivative 49. This compound was used for 
the next step without further purification. Following the modified Ullmann reaction40 and 
purification by column chromatography, 45 was isolated in 70% yield. 
Assessing compound 45, using a cytotoxicity assay on the human A2780 ovarian cancer cell line 
revealed that the compound lost its activity completely, confirming the importance of flexibility 
in the linker despite of the existence of the same elements.   
 
 
Scheme 1.4. Synthesis of thiazoline ring system 45 
1.3 Synthesizing nitrogen containing heteroarotinoids 
(a) TEA, CHCl3, reflux 24 h; (b) CH3Li, THF, -50 oC; (c) AlCl3, dichloroethane, 80 oC; (d) CuI, L-
proline, DMF, K2CO3, 140 oC 
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Nitrogen heterocycles are among the most significant structural components of pharmaceuticals. 
A recent study reports that, out of 1994 pharmaceuticals approved  by the U.S. FDA, 89% of 
them contain at least one nitrogen atom.41 The study also reveals that at least 59% of unique 
small-molecule drugs contain a nitrogen heterocycle. These numbers are incredibly high 
percentages compared to sulfur (26%), fluorine (13%) or other heteroatoms. Surprisingly, the 
average number of nitrogen atoms per drug is 2.3 for all the small-molecule drugs, while it is 3.1 
for those that contain a nitrogen heterocycle.41 
As part of our ongoing effort to improve the activity of S-Het-A2, we sought to insert a nitrogen 
in place of sulfur or oxygen in ring A of the heteroarotinoid ring system to get a 
tetrahydroquinoline ring system. Tetrahydroquinolines are important structural motifs in many 
biologically active molecules. It is prevalent in many natural products and pharmaceutical 
products as well. Its prevalence in natural products can be substantiated with a few examples. 
Helquinoline (51) a relatively simple molecule with significant antibiotic properties. Similarly, 
cuspareine (52a) and related compounds 52b and 52c have shown antibacterial as well as 
cytotoxic activity. More complex systems include (+)-aspernomine (53), a potent cytotoxic agent, 
and (−)-isoschizogaline (54), a potentially useful antibiotic. Finally, (−)-martinellic acid (55) is 
known to be a non-peptide antagonist for the bradykinin B1 and B2 receptors (Figure 1.7).42 
17 
 
 
 
 
Figure 1.7. Natural products incorporating a tetrahydroquinoine moiety. 
The 1,2,3,4-tetrahydroquinoline nucleus is prevalent in many synthetic pharmaceuticals, and it 
can be understood with the following examples. Nicainoprol (56) is an antiarrhythmic drug, 
oxamniquine (57) is a schistosomicide, and virantmycin (58) is an antiviral antibiotic that also 
possesses antifungal activity. Additionally, compound 59 is being evaluated for use in the 
treatment of HIV, and compound 60 is gathering attention as a means to slow the onset of 
Alzheimer’s disease. Compound 61 is currently being evaluated as an antimalarial agent. 
Furthermore, compound 62 has demonstrated activity as a cholesterol ester transfer protein 
(CETP) inhibitor and would be useful for treating hypercholesterolipidemia, while L-689,560 
(63) is a neuroprotective agent with potential to minimize ischemic nerve damage following a 
stroke or heart attack (Figure 1.8).42 
51 
Helquinoline 
antibacterial 
52 
a) S-(-)-cuspareine (R = R’ = Me) 
b) S-(-)-cuspareine (R = R’ = CH2) 
c) S-(-)-cuspareine (R = OH, R’ = Me) 
Antibacterial and cytotoxic 
 
a)  
b)  
53 
(+)-aspernomine 
Cytotoxic 
54 
(-)-isoschizogaline 
antibacterial 
55 
(-)-martinellic acid 
Bradkykinin receptor antagonist 
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Figure 1.8. Examples of pharmaceuticals containing the tetrahydroquinoine moiety. 
Based on the above facts and our earlier results with related heteroarotinoids, we assumed these 
new derivatives (with nitro, amino, trifluoromethyl and trifluoromethoxy groups) would have 
greater potential as anticancer agents with low toxicity. Additionally, we believed that the 
nitrogen atom had a greater ability to hydrogen bond, which could allow these new derivatives to 
easily fit into the binding pocket of the receptor. Furthermore, to overcome the solubility problem 
with heteroarotinoids containing sulfur or oxygen, these nitrogen containing heteroarotinoids 
would increase the hydrophilicity of the molecule thereby increasing the absorption and 
distribution of the drug in the blood stream and could be formulated as a salt. 
1.3.1 Results and Discussion for synthesizing nitrogen containing heteroarotinoids 
58 
Viratmycin 
antibiotic 
57 
Oxamniquine 
schistosomicide 
 
56 
Nicainoprol 
antiarrhythmic 
59 – Anti-HIV 60 - Alzheimer’s disease 
 
61 – Anti-malarial 
62 – CETP inhibitor 63 - Neuroprotectant 
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Nitrogen heteroarotinoids 73a-e were prepared starting from 4-bromoaniline (64) and 3-
methylbut-2-enoyl chloride (Scheme 1.5). Initially, treating a 1:1 ratio of 4-bromoaniline and 3-
methylbut-2-enoyl chloride in the presence of triethylamine at 0 oC and stirring at room 
temperature for 18 h gave the non-conjugated amide 65a in 87% yield. Although this method 
provided the amide 65a in excellent yield, Friedel-Crafts reaction of this compound using 1.5 
equivalent of aluminum chloride in refluxing dichloroethane gave only a moderate yield (53%) of 
66.  We attempted to optimize the Friedel-crafts reaction by varying the solvent and molar ratio 
of aluminum chloride, hoping to increase the yield of 66. Unfortunately, all our attempts failed 
and we planned to generate 65a, in order to perform additional experiments to optimize Friedel-
Crafts reaction. At this time, in an effort to reduce the reaction time of amidation, we treated 2.0 
equivalent of 4-bromoaniline with an equivalent of 3-methylbut-2-enoyl chloride in refluxing 
chloroform. Interestingly, these conditions afforded the conjugated amide 65 exclusively (75%), 
and subjecting 65 to Friedel-Crafts reaction conditions with 1.5 equivalent of AlCl3 gave a 76% 
yield of 66.  
 
 
 
a) 3-methylbut-2-enoyl chloride, CHCl3, reflux, 5 h; b) 3-methylbut-2-enoyl chloride, TEA, 0 oC to rt, 
18 h; c) AlCl3, dichloroethane, 80 oC; d) BH3-DMS, toluene, 0 oC to 110 oC; e) n-BuLi, Boc2O, THF;  
f) NaN3, DMF, L-proline, 140 oC; g) H2, Pd/C, MeOH 
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Scheme 1.5. Synthesis of key intermediate 70 
The yield of 66, after 2 steps, was greater with 65 than with 65a. Hence, we followed this 
procedure to generate 65 on a gram scale. Treating 66 with borane-dimethylsulfide complex at 0 
oC and refluxing for 3 h afforded 67 in 90% yield, and the resulting secondary amine was 
protected with Boc-anhydride using n-butyllithium. Conceivably, the Boc-group would not 
withstand the harsh reaction conditions for the direct conversion of aryl bromides to aryl amines 
using ammonium hydroxide,40 we converted the aryl bromide to the aryl azide using an L-proline 
promoted, CuI-catalyzed coupling Ullmann-type reaction to generate 69.43 The azide compound 
69 was then subjected to Pd/C catalyzed hydrogenation to afford the key intermediate amine 70 in 
62% yield after two steps.  
 
 
 
Scheme 1.6. Synthesis of nitrogen heteroarotinoids 73a-e 
The aryl amine 70 was added to aryl iso(thio)cyanates 71a-d (Scheme 1.6) in tetrahydrofuran at 
room temperature to afford the Boc-protected (thio)urea compounds 72a-d, and this was followed 
by secondary amine deprotection using trifluoroacetic acid in dichloromethane. The pure 
compounds 73a-d were obtained in excellent yield (83–92%) by acid-base workup and 
crystallization from a mixture of pentane/ether. The quarternary ammonium salt 73e was obtained 
71 a: X =  S; Y = NO2 
     b: X = O; Y = NO2 
     c: X =  S; Y = CF3 
     d: X = S; Y = OCF3 
 
72     73     
73e    
70 
73b    
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in 62% yield, by reacting 73b with methyl iodide using cesium carbonate in a sealed tube at room 
temperature for 24 h.   
The another series of nitrogen heteroarotinoids outlined in Schemes 1.7 and 1.8 were also 
prepared starting from 4-bromoaniline (64) in 7–8 steps. Dihydroquinoline 74 was prepared in 
62% yield by the Skraup reaction of acetone with 4-bromoaniline (64)44 using bismuth(III) 
trifluoromethane- sulfonate (reflux, 3d). Attempts were made to reduce the reaction time and 
improve the yield using other reagents and methods such as scandium triflate,45 zirconium 
chloride, ceric ammonium nitrate47 and Amberlyst 15 as well as microwave assisted synthesis of 
dihydroquinoline using indium trichloride.46 These approaches however, resulted in lower yields 
as well as longer reaction times. 
 
 
 
Methylation of the secondary amine in 74 using sodium hydride and methyl iodide in 
dimethylformamide, followed by hydroboration of the conjugated double bond provided alcohol 
76 in 57% yield.48 The hydroxyl group was oxidized by the Swern procedure to generate 
quinolinone 77 and this was used without purification for the next step. Notably, the 
chlorosulfonium ion generated using oxalyl chloride and DMSO should be added dropwise to a 
solution of 76 in dichloromethane at -78 oC. Addition of 76 to the generated sulfonium ion 
resulted in very poor yield of ketone 77. The tetramethyl ketone 78 was obtained by generating 
a) acetone, Bi(OTf)3, reflux, 3d; b) NaH, CH3I, DMF, r.t. 24 h; c) BH3-THF complex, THF, 10 – 15oC; 
3M NaOH, 30% H2O2
 
d) (COCl)2, DMSO, TEA, CH2Cl2, 0 – 5 oC; e) LiHMDS, CH3I, THF; f) CuI, L-
proline, aq.NH3, DMF 
Scheme 1.7. Synthesis of tetrahydroquinolinone 79 
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the enolate of 77 using LiHMDS followed by dropwise addition of methyl iodide in 
tetrahydofuran. The aryl amine 79 was obtained by modified Ullmann reaction condition40 as 
described above. 
The hindered ketoaniline 79 was added to iso(thio)cyanate 71(a-f) in tetrahydrofuran at room 
temperature to generate nitrogen containing heteroarotinoids 80(a-f) (Scheme 1.8). Compounds 
82(a-f) were obtained by reduction of 79 using lithium aluminium hydride and treating the 
resultant alcohol 81 with iso(thio)cyanates 71(a-f). 
 
 
 
 
 
Scheme 1.8. Synthesis of nitrogen heteroarotinoids 80a-f and 82a-f 
These compounds were all tested using a cytotoxicity assay against the human ovarian cancer cell 
line A2780. Of these, 17 compounds (73a-e, 80a-f, 82a-f), compounds 80a, 80b, 80d, 80e and 
80f exhibited better activity compared to the standard compound S-Het-A2. The potency and 
efficacy of 80e and 80f were reasonably higher than that observed for S-Het-A2. On the other 
hand, the derivatives having the nitro substituent with the urea linker 80d and the thiourea linker 
80a, and the trifluoromethyl subtituent 80b showed an increase in efficacy and a slight decline in 
79 80a-f     
82a-f     79     81     
71 a: X = S; Y = NO2 
     b: X = S: Y = CF3  
     c: X = S: Y = OCF3 
     d: X = O; Y = NO2 
     e: X = O; Y = CF3 
     f: X = O; Y = OCF3 
 
71 a: X = S; Y = NO2 
     b: X = S; Y = CF3  
     c: X = S; Y = OCF3 
     d: X = O; Y = NO2 
     e: X = O; Y = CF3 
     f: X = O; Y = OCF3 
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potency, compared to S-Het-A2. Their increase in activity can be attributed to the presence of the 
carbonyl functional group at C3, which increases the hydrogen bonding to the receptor.  
 
 
 
 
 
 
 
 
 
 
Table 1.3. Activity data for Flex-Hets 80a-f 
 
 
Compound X Y Potency 
 IC50 (µM) 
Efficacy 
(% SHetA2) 
Maximal 
Activity 
(% Growth 
Inhibition) 
(SHetA2) 2.71 100 83.75 
80a NO2 S 5.099 102.4907 83.40909 
80b CF3 S 3.344 105.2334 85.6411 
80c OCF3 S 3.376 46.97892 39.34511 
80d NO2 O 4.096 105.4367 88.30383 
80e CF3 O 2.641 103.1104 86.3557 
80f OCF3 O 2.495 102.0376 85.45706 
 
Compounds 82(a-f) containing a hydroxyl group at the C3 of ring A, are expected to have 
improved activity because the hydroxyl group, together with the ring nitrogen should increase the 
hydrogen bonding ability and the hydrophilicity of the compound, thereby increasing the 
solubility.  Unfortunately, all of these compounds (82a-f) exhibited no inhibitory activity against 
24 
 
the human ovarian cancer cell line A2780. These findings lead one to draw the conclusion that 
ring A, can accommodate a neutral functional group like a carbonyl as in compound 80(a-f) and 
retain the moderate activity. Compound 82a, with a close resemblance to S-Het-A2 but with a 
hydroxyl group at C3 and an N-methyl instead of sulfur lost its activity completely. This 
observation anchors our conclusions about these compounds. 
 
Table 1.4. Activity data for Flex-Hets 82a-f 
 
Compound X Y Potency 
 IC50 (µM) 
Efficacy 
(% SHetA2) 
Maximal Activity 
(% Growth 
Inhibition) 
(SHetA2) 2.71 100 83.75 
82a NO2 S 6.343 20.65407 16.80871 
82b CF3 S 7.852 19.93126 16.22047 
82c OCF3 S 5.172 21.08904 17.1627 
82d NO2 O 6.156 13.84531 11.26761 
82e CF3 O 20 9.146878 7.660562 
82f OCF3 O 7.829 18.33266 14.9195 
 
Compounds 73a-e, without a gem-dimethyl next to a nitrogen atom, was also devoid of activity. 
None of these compounds exhibited even moderate activity against the human ovarian cancer cell 
line A2780, signifying the importance of the gem-dimethyl group next to a heteroatom. 
Compound 73e, a quarternary ammonium compound, inhibiting only 12% of the cancer cell line. 
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Table 1.5. Activity data for Flex-Hets 73a-e 
 
 
 
1.4 Tethering bioactive molecules to S-Het-A2 rings. 
Our common approach to improve the activity of our lead compound S-Het-A2 involved 
systematic changes of ring A, such as replacing sulfur by nitrogen or oxygen and increasing the 
length of the  linker unit. Though these efforts have given convincing results, the time, the effort 
and cost of these systematic changes are enormous. As a part of this work, we sought to change 
our lead compound by tethering the ring A or ring B to known bioactive molecules such as 
quinolone, oxazole, indole, furfuryl, and 2-acetylsalicyl derivatives. Amino derivatives of 
quinolone, oxazole, indole are commercially available and hence condensing with thiocyanates or 
Compound X Y Potency 
IC50 (µM) 
Efficacy 
(% SHetA2) 
Maximal Activity 
(% Growth 
Inhibition) 
(SHetA2) 2.71 100 83.75 
73a NO2 S 3.3 11.9 9.04 
73b CF3 S 5.2 41.77 31.83 
73c OCF3 S >200 NA NA 
73d NO2 O >200 NA NA 
73e 2.4 15.49 11.78 
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isothicyanates to install ring B were achieved easily, thereby reducing the cost and time. It also 
allowed us to assess the activity of these compounds at a faster rate. The same explanation holds 
for the furfuryl and acetyl salicylic acid compound, because furfuryl isothocyanates and acetyl 
salicylic acid are commercially available. Hence, it could be condensed with ring A of S-Het-A2 
readily. 
The current approach is similar to fragment based drug discovery, in which a large number of 
bioactive molecules would be screened against known protein targets.49 This method is efficient 
for identifying fragments (hit molecules) quickly. Further buildup of the fragments would then 
help to identify a lead compound.49 However, in our case, we designed our lead compound, and 
the current effort is to improve its activity further. 
1.4.1 Results and discussion for tethering bioactive molecules to S-Het-A2 rings 
Compounds 84(a,b), 86(a,b) and 88(a,b) were obtained by reacting the corresponding (Scheme 
1.9) amino compound with 4-nitrophenyl isocyanate 71d or its isothiocyanate 71a. Compound 91 
was obtained in 82% yield by treating 89 with 2-(isothiocyanatomethyl)furan 90. Structure 93 
was obtained in 87% yield by acid-amine coupling of 92 and 89. Finally drug candidate 95 was 
prepared by treating S-Het-A2 with iron powder and ammonium chloride in ethanol at 82 oC. The 
reaction mass was filtered through Celite® and passed through a silica gel column in order to 
ensure complete removal of metal impurities. 
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Scheme 1.9. Tethering of bioactive motifs to ring A or ring B of S-Het-A2  
These 9 compounds were assessed by cytotoxic assay against the human ovarian cancer cell line 
A2780 and it revealed that amino compound 95 is the most active compound (Table 1.7), because 
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its potency and efficacy were slightly greater than the standard compound S-Het-A2. The 
remaining compounds were inactive. 
Table 1.6. Activity data for bioactive compounds tethered to S-Het-A2 rings. 
 
 
 
 
 
 
 
 
 
1.5 Conclusion 
In summary, we have synthesized 42 heteroarotiniods in an effort to improve the activity of our 
lead compound S-Het-A2 and these were assessed using cytotoxic assay against the human 
ovarian cancer cell line A2780. 
1.5.1 Altering the linker unit of S-Het-A2 
In this study, we developed a new route to synthesize Flex-Hets with an acrylamide linker (31a-h, 
33a-c), an N-benzylacetamide linker (43a-c and 44) and a compound with a thiazoline ring linker 
(45). These compounds were evaluated for biological activity against the human A2780 ovarian 
cancer cell line.  Changing from a 3-atom linker to a 4-atom linker resulted in a range of 
Compound 
Potency 
IC50 (µM) 
Efficacy 
(% S-Het-A2) 
Maximal Activity 
(% Growth Inhibition) 
(SHetA2) 2.71 100 83.75 
84a >50 NIL NIL 
84b 8.3 31.70 24.68 
86a 6.02 NIL NIL 
86b 2.5 NIL NIL 
88a 4.9 NIL NIL 
88b >50 NIL NIL 
91 >50 NIL NIL 
93 6.02 NIL NIL 
95 2.4 104.67 81.42 
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activities. Compound 31b with a NO2 substituent, and an acrylamide linker displayed comparable 
activity to that of our lead compound S-Het-A2. On the other hand, compounds 43a and 44 with a 
nitro substituents and N-benzylacetamide and thioacetamide linkers, respectively, were 
completely devoid of activity, which explains the importance of the thiourea linker. The 
importance of thiourea unit was further justified by compound 45, which was completely inactive 
due to lack of flexibility in thiazoline ring system. 
1.5.2 Synthesizing nitrogen containing heteroarotinoids 
In an effort to improve the activity of S-Het-A2, 17 nitrogen heterarotinoids were synthesized and 
tested. Of these nitrogen heteroarotinoids, compounds with a keto at C3 exhibited good activity 
against the human ovarian cancer cell line A2780. Compounds that are significantly better than S-
Het-A2 are 80b, 80d-f. Compound 80b with a CF3 substituent and a thiourea linker and 
compound 80d with a nitro substituent and a urea linker exhibited a slight increase in potency and 
efficacy compared to S-Het-A2. While compounds 80e and 80f possessing the urea linker unit 
with CF3 and OCF3 substituents exhibited greater potency and efficacy. However, nitrogen 
heteroarotinoids with a hydroxyl group and without a gem-dimethyl next to the nitrogen atom 
were completely devoid of activity.  
1.5.3 Tethering bioactive molecules to S-Het-A2 rings 
Finally, an approach similar to fragment based drug discovery allowed us to access and assess the 
acitivity of nine heteroarotinoids, that were prepared by tethering bioactive molecules like 
quinolone, indole, oxazole, furfuryl and acetylsalicylic acid to the S-Het-A2 A or B ring.  
Unfortunately, eight of these compounds proved completely devoid of activity. Surprisingly, 
reducing the nitro group of S-Het-A2 to an amino group furnished compound 95 with the highest 
potency and efficacy of all compounds. 
1.6 Chemistry 
1.6.1 Increasing the linker unit using acrylamide 
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General methods: Commercial anhydrous N,N-dimethylformamide was stored under dry N2 and 
transferred by syringe into reactions when needed. Tetrahydrofuran was dried over potassium 
hydroxide pellets and distilled from lithium aluminum hydride prior to use. All other commercial 
reagents and solvents were used as received. Unless otherwise indicated, all reactions were 
carried out under dry N2 in oven-dried glassware. Reactions were monitored by thin layer 
chromatography (TLC, Analtech No 21521) using silica gel GF plates. Preparative separations 
were performed by column chromatography on silica gel (Davisil®, grade 62, 60 - 200 mesh) 
containing UV-active phosphor (Sorbent Technologies No UV-05) slurry packed into quartz 
columns. Band elution for all chromatographic separations was monitored using a hand-held UV 
lamp. Melting points were uncorrected. IR spectra were run as chloroform solutions on NaCl 
disks. The 1H- and 13C-NMR spectra were measured in the indicated solvent at 400 MHz and 100 
MHz, respectively, using tetramethylsilane as the internal standard with coupling constants (J) 
given in Hz. 
 N-{4-[(2-Methyl-4-oxopentan-2-yl)thio]phenyl}acetamide (26). To a stirred solution of 
acetamidothiophenol (24) (25.0 g, 149.7 mmol) in dry chloroform (200 mL) was added 
triethylamine (21.0 mL, 149.7 mmol), followed by addition of mesityl oxide (25) (17.0 mL, 149.7 
mmol). The resulting slurry was heated to reflux (bath temperature 70 oC). Two additional 
portions of triethylamine (10.5 mL, 74.5 mmol) and mesityl oxide (8.6 mL, 74.5 mmol) were 
added at regular intervals of 4 h, and the resulting solution was refluxed for 16 h after the final 
addition. The resulting reaction mixture was cooled, filtered through Celite® and washed with 
chloroform (2 x 50 mL). The combined organic layers were washed with water (2 x 100 mL), 
saturated aqueous NaCl, dried (MgSO4), and concentrated under vacuum to give a yellow oil. 
The crude reaction mixture was then purified by silica gel column chromatography and eluted 
with dichloromethane:ethyl acetate (1:1) to afford 26 (27.8 g, 70%) as a pale yellow solid, mp 49-
51 oC. IR: 3310, 1699, 1676 cm-1; 1H NMR (CDCl3): δ 7.90 (br s,1H), 7.53 (d, 1H, J = 8.8 Hz, 
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2H), 7.45 (d, J = 8.8 Hz, 2H), 2.65 (s, 2H), 2.19 (s, 3H), 2.15 (s, 3H), 1.36 (s, 6H); 13C NMR 
(CDCl3): δ 206.9, 168.6, 139.0, 138.3, 126.2, 119.6, 54.3, 47.0, 32.1, 28.0, 24.5. 
N-{4-[(4-Hydroxy-2,4-dimethylpentan-2-yl)thio]phenyl}acetamide (27). To a stirred solution 
of methyllithium in ether (198 mL, 316.5 mmol, 1.6 M) in tetrahydrofuran (300 mL) at -50 oC 
was added dropwise 26 (28 g, 105.5 mmol) in tetrahydrofuran (200 mL) over 30 - 45 min. The 
reaction mixture formed a white precipitate, which was slowly warmed to room temperature over 
a period of 3 h. Finally, the mixture was stirred at room temperature for 1 h. The reaction mass 
was then cooled to 0 oC, and the mixture was quenched by dropwise addition to ice water (150 
mL). After adjusting the solution to pH 6-7 by addition of 6 M aqueous HCl, the solution was 
extracted with ethyl acetate (2 x 250 mL). The combined organic extracts were washed with 
saturated aqueous NaCl (1 x 150 mL), dried (MgSO4), and concentrated under vacuum to afford a 
dark brown liquid. To the crude mixture was added chloroform (60 mL) with cooling to 0 oC for 
1 h, which afforded a yellow solid. The solid was then filtered and dried under vacuum to afford 
27 (18 g, 61%) as a pale yellow solid, mp 141-142 oC. IR: 3400, 3303, 1676 cm-1; 1H NMR 
(CDCl3): δ 7.68 (br, s, 1H), 7.52 (m, 4H), 3.50 (br s, 1H), 2.19 (s, 3H), 1.77 (s, 2H), 1.34 (s, 6H), 
1.33 (s, 6H); 13C NMR (CDCl3): δ 168.4, 138.8, 138.1, 126.3, 119.6, 72.0, 52.0, 49.2, 32.2, 30.8, 
24.6. 
N-(2,2,4,4-Tetramethylthiochroman-6-yl)acetamide (28). To a stirred solution of 27 (18 g, 
63.9 mmol) in chlorobenzene (125 mL) at room temperature was added portion-wise anhydrous 
aluminum chloride (10.22 g, 76.7 mmol) over a period of 45 min, and reaction mixture was 
refluxed for 90 min. The reaction mixture was cooled to room temperature and quenched with ice 
cold water (150 mL) to give a thick suspension. The solid was removed by filtration through 
Celite® and washed with ethyl acetate (2 x 100 mL). The layers were separated, and the aqueous 
layer was extracted with additional ethyl acetate (2 x 100 mL). The combined organic extracts 
were washed with saturated aqueous NaCl, dried (MgSO4), and concentrated under vacuum to 
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give a crude yellow oil. The crude product was purified on a silica gel column using 
hexanes:ethyl acetate (1:1) to afford the product 28 (15.0 g, 89%) as a pale yellow solid, mp 105-
107 oC. IR: 3295, 1662 cm-1; 1H NMR (CDCl3): δ 7.60 (br s, 1H), 7.27 (d, J = 2.3 Hz, 1H), 7.20 
(dd, J = 8.2, 2.3 Hz, 1H), 7.04 (d, J = 8.2 Hz, 1H), 2.16 (s, 3H), 1.92 (s, 2H), 1.39 (s, 6H), 1.35 (s, 
6H); 13C NMR (CDCl3): δ 168.3, 143.4, 135.1, 128.4, 128.2, 118.7, 118.2, 54.4, 42.0, 35.7, 32.4, 
31.4, 24.4. 
2,2,4,4-Tetramethylthiochroman-6-amine hydrochloride (29). To a stirred solution of 28 (15.0 
g, 56.9 mmol) in methanol (75 mL) was added 6 M aqueous HCl (75 mL). The reaction mixture 
was heated to 90 oC for 1 h, followed by cooling to room temperature. The reaction was 
concentrated to 1/4 of its initial volume. The resulting crude mixture was cooled to 0 oC and 
maintained at this temperature for 1 h to yield a solid. This material was filtered and dried under 
vacuum to afford 29 as a white solid (14.0 g, 95%), mp 208-209 oC. IR: 2922, 2853 cm-1; 1H 
NMR (DMSO-d6): δ 10.08 (s, 2H), 7.48 (s, 1H), 7.22 (d, J = 8.3 Hz, 1H), 7.09 (d, J = 8.3 Hz, 
1H), 1.94 (s, 2H), 1.42 (s, 6H), 1.40 (s, 6H); 13C NMR (DMSO-d6): δ 144.2, 132.0, 130.0, 129.1, 
122.0, 121.2, 53.5, 42.6, 35.8, 32.6, 31.6. 
General procedure for synthesizing cinnamamides (31a-f). To a stirred solution of each cinna- 
mic acid 30a-f (0.5 mmol) in N,N-dimethylformamide (5 mL) was added diisopropylethylamine 
(1.5 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.55 mmol), and 1-
hydroxylbenzotriazole (0.55 mmol). After stirring for 1 h at room temperature, 2,2,4,4-tetra- 
methyl-6-aminothiochroman hydrochloride (16, 0.55 mmol) was added. The resulting mixture 
was stirred at room temperature for 12 h. The reaction mixture was poured into ice (approx. 100 
g) and was stirred for 30 min. The aqueous layer was then extracted with ethyl acetate (3 x 100 
mL). The combined organic layers were washed with saturated aqueous NaCl (2 x 50 mL), dried 
(MgSO4), and concentrated under vacuum to afford the corresponding crude cinnamamide 
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derivatives. The compounds were further purified by silica gel column chromatography and 
eluted with hexanes:ethyl acetate (1:1) to afford the pure cinnamamides 31a-f. 
Ethyl-4-{3-Oxo-3-[(2,2,4,4-tetramethylthiochroman-6-yl)amino]prop-1-en-1-yl}benzoate 
(31a). Yield: 195 mg (0.46 mmol, 92%) as a white solid, mp 184-185 oC; IR: 3288, 1716, 1646  
cm-1; 1H NMR (CDCl3): δ 8.05 (d, J = 8.2 Hz, 2H), 7.80 (br s, 1H), 7.78 (d, J = 15.4 Hz, 1H), 
7.58 (m, 1H), 7.55  (d, J = 8.2 Hz, 2H), 7.30 (m, 1H), 7.10 (d, J = 8.4 Hz, 1H), 6.66 (d, J = 15.6 
Hz, 1H), 4.39 (q, J = 7.0 Hz, 2H), 1.95 (s, 2H), 1.41 (s, 6H), 1.40 (t, 3H, J = 7.0 Hz), 1.40 (s, 6H); 
13C NMR (CDCl3): δ 166.1, 163.2, 143.7, 140.9, 138.9, 135.1, 131.4, 130.1, 128.8, 128.6, 127.7, 
123.1, 118.7, 118.1, 61.2, 54.4, 42.2, 35.8, 32.5, 31.6, 14.3. Anal. Calcd for C25H29NO3S: C, 
70.89; H, 6.90; N, 3.31. Found: C, 70.71; H, 6.76, N, 3.30. 
3-(4-Nitrophenyl)-N-(2,2,4,4-tetramethylthiochroman-6-yl)acrylamide (31b). Yield: 188 mg 
(0.48 mmol, 95%) as a yellow solid, mp 212-213 oC; IR: 3281, 1662, 1521, 1340 cm-1; 1H NMR 
(DMSO-d6): δ 10.3 (s, 1H), 8.30 (d, J = 8.8 Hz, 2H), 7.89 (d, J = 8.8 Hz, 2H), 7.80 (d, J = 2.0 Hz, 
1H), 7.70 (d, J = 15.8 Hz, 1H), 7.51 (dd, J =  8.4, 2.1 Hz, 1H), 7.05 (d, J = 8.4 Hz, 1H), 6.98 (d, J 
= 15.8 Hz, 1H), 1.92 (s, 2H), 1.37 (s, 6H), 1.35 (s, 6H); 13C NMR (DMSO-d6): δ 165.4, 143.5, 
140.5, 139.5, 138.8, 137.2, 128.9, 128.5, 127.2, 126.5, 125.7, 118.6, 118.3, 54.1, 42.6, 35.9, 32.9, 
31.9. Anal. Calcd for C22H24N2O3S: C, 66.64; H, 6.10; N, 7.07. Found: C, 66.28; H, 6.13; N, 7.03. 
N-(2,2,4,4-Tetramethylthiochroman-6-yl)-3-[4-(trifluoromethyl)phenyl]acrylamide (31c). 
Yield: 184mg (0.44 mmol, 88%) as a white solid, mp 185-186 oC; IR: 3272, 1662, 1532, 1323 
cm-1; 1H NMR (DMSO-d6): δ 10.3 (s, 1H), 8.31 (d, J = 8.8 Hz, 2H), 7.89 (d, J = 9.0 Hz, 2H), 7.80 
(d, J = 2.1 Hz, 1H), 7.70 (d, J = 15.8 Hz, 1H), 7.52 (dd, J = 8.4, 2.2 Hz, 1H), 7.05 (d, J = 8.4 Hz, 
1H), 7.00 (d, J = 15.8 Hz, 1H), 1.92 (s, 2H), 1.37 (s, 6H), 1.35 (s, 6H); 13C NMR (DMSO-d6): δ 
163.5, 143.5, 139.5, 138.8, 137.2, 130.0 (q, J = 31.3 Hz), 129.0, 128.5, 127.2, 126.6 (q, J = 3.7 
Hz), 125.8, 124.8 (q, J = 273.7 Hz), 118.6, 118.3, 54.2, 42.6, 36.0, 32.9, 31.9. Anal.Calcd for 
C23H24F3NOS: C, 65.85; H, 5.77; N, 3.34. Found: C, 65.57; H, 5.79; N, 3.32. 
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3-(2,3,4,5,6-Pentafluorophenyl)-N-(2,2,4,4-tetramethylthiochroman-6-yl)acrylamide (31d). 
Yield: 207 mg (0.47 mmol, 94%) as a yellow solid, mp 143-144 oC; IR: 3276, 1664, 1523, 1498 
cm-1; 1H NMR (CDCl3): δ 7.80 (d, J = 2.0 Hz, 1H), 7.77 (d, J = 15.8 Hz, 1H), 7.39 (br s, 1H), 
7.29 (dd, J = 8.4, 2.1 Hz, 1H), 7.12 (d, J = 8.4 Hz, 1H), 6.88 (d, J = 15.8 Hz, 1H), 1.95 (s, 2H), 
1.42 (s, 6H), 1.40 (s, 6H); 13C NMR (CDCl3): δ 162.6, 145.6 (dm, J = 254.5 Hz), 143.7, 141.5 
(dm, J = 264.6 Hz), 137.8 (dm, J = 254.5 Hz), 134.9, 129.2, 128.6, 128.5, 125.9, 118.8, 118.1, 
110.7 (td, J = 13.1, 4.0 Hz), 54.3, 42.2, 35.8, 32.5, 31.6. Anal. Calcd for C22H20F5NOS: C, 59.86; 
H, 4.57; N, 3.17. Found: C, 59.99; H, 4.75; N, 3.13. 
3-(3,4-Dimethoxyphenyl)-N-(2,2,4,4-tetramethylthiochroman-6-yl)acrylamide (31e). Yield: 
162 mg (0.41 mmol, 82%) as a white solid, mp 182-183 oC; IR: 3286,1660,1260 cm-1; 1H NMR 
(CDCl3): δ 7.77 (br s, 1H), 7.68 (d, J = 15.4 Hz, 1H), 7.40 (br s, 1H), 7.23 (s, 1H), 7.07 (d, J = 8.4 
Hz, 2H), 7.00 (s, 1H), 6.84 (d, J = 8.4 Hz, 1H), 6.43 (d, J = 15.4 Hz, 1H), 3.88 (s, 3H), 3.86 (s, 
3H), 1.92 (s, 2H), 1.38 (s, 6H), 1.37 (s, 6H); 13C NMR (CDCl3): δ 164.4, 150.7, 149.1, 143.6, 
141.9, 135.7, 128.5, 128.3, 127.7, 122.1, 118.9, 118.7, 118.1, 111.1, 109.9, 55.9, 55.8, 54.4, 42.2, 
35.8, 32.5, 31.6. Anal. Calcd for C24H29NO3S: C, 69.43; H, 7.14; N, 3.37. Found: C, 69.34; H, 
7.05; N, 3.42. 
3-[4-(Dimethylamino)phenyl]-N-(2,2,4,4-tetramethylthiochroman-6-yl)acrylamide (31f). 
Yield: 189 mg (0.48 mmol, 96%) as a yellow solid, mp 196-197 oC; IR: 3284, 1642, 1595, 1526 
cm-1; 1H NMR (CDCl3): δ 7.82 (br s, 1H), 7.69 (d, J  = 15.2 Hz, 1H), 7.40 (d and obscured signal, 
J = 8.9 Hz, 3H), 7.24 (br s, 1H), 7.08 (d, J = 8.2 Hz, 1H), 6.65 (d and an obscured signal, J = 9.0 
Hz, 2H), 6.35 (d, J = 15.6 Hz, 1H), 3.00 (s, 6H), 1.93 (s, 2H), 1.40 (s, 6H), 1.39 (s, 6H); 13C NMR 
(CDCl3): δ 164.9, 151.5, 143.5, 142.6, 135.8, 129.5, 128.4, 127.8, 122.5, 118.6, 118.0, 115.3, 
111.8, 54.4, 42.1, 40.1, 35.8, 32.5, 31.5. Anal. Calcd for C24H30N2OS: C, 73.06; H, 7.66; N, 7.10. 
Found: C, 72.85; H, 7.70; N, 7.08. 
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4-{3-Oxo-3-[(2,2,4,4-tetramethylthiochroman-6-yl)amino]prop-1-en-1-yl}benzoic acid (31g). 
To a stirred solution of 31a (0.1 g, 0.241 mmol) in THF (12 mL), was added lithium hydroxide 
(11.5 mg, 0.482 mmol) in water (8 mL), and the reaction was stirred for a 4 h at room 
temperature. The resulting mixture was concentrated under vacuum to 1/2 of its volume and 
further diluted with water (10 mL). The aqueous layer was washed with ethyl acetate (3 x 20 
mL), and the resulting water layer was acidified to pH 1-2 with 6 M HCl. The final solution was 
extracted with ethyl acetate (3 x 20 mL). The combined organic extracts were washed with 
saturated aqueous NaCl (50 mL), dried (MgSO4), and concentrated under vacuum to afford 31g 
(88 mg, 95%) as a yellow solid, mp 219-220 oC. IR: 3600, 2400, 1682 cm-1; 1H NMR (DMSO-
d6): δ 13.1 (s, 1H), 10.3 (s, 1H), 8.00 (d, J = 8.0 Hz, 2H), 7.80 (d, J = 2.2 Hz, 1H), 7.73 (d, J = 8.1 
Hz, 2H), 7.62 (d, J = 15.7 Hz, 1H), 7.49 (dd, J = 8.5, 2.2 Hz, 1H), 7.03 (d, J = 8.4 Hz, 1H), 6.91 
(d, J = 15.7 Hz, 1H), 1.92 (s, 2H), 1.37 (s, 6H), 1.35 (s, 6H); 13C NMR (DMSO-d6): δ 167.3, 
163.5, 143.4, 139.4, 139.2, 137.0, 131.8, 130.4, 128.3, 128.2, 127.0, 125.0, 118.4, 118.1, 54.0, 
42.4, 35.8, 32.7, 31.7. Anal. Calcd for C23H25NO3S: C, 69.85; H, 6.37; N, 3.54. Found: C, 69.53; 
H, 6.39; N, 3.53. 
3-(4-Aminophenyl)-N-(2,2,4,4-tetramethylthiochroman-6-yl)acrylamide (31h). To a stirred 
solution of 31b (0.45 g, 1.2 mmol) and iron powder (0.42 g, 7.5 mmol) in ethanol:water (4:1, 20 
mL) was added NH4Cl (0.15 g, 2.8 mmol), and the resulting mixture was refluxed for 18 h. The 
reaction mass was cooled to room temperature and filtered through a bed of Celite®. The Celite® 
was washed with ethanol (3 x 20 mL), and the solution was concentrated under vacuum at 45 oC 
to give 0.6 g of a yellow solid. The yellow solid was purified by silica gel column 
chromatography and eluted with dichloromethane:ethyl acetate (7:3) to afford 31h (0.42 g, 95%) 
as a yellow solid, mp 115-116 oC. IR: 3439, 3351, 3203, 1641, 1594 cm-1; 1H NMR (CDCl3): δ 
7.80 (br s, 1H), 7.67 (d, J = 15.2 Hz, 1H), 7.42 - 7.21 (complex, 4H), 7.09 (d, J = 8.2 Hz, 1H), 
6.64 (d, J = 8.4 Hz, 2H), 6.35 (d, J = 15.2 Hz, 1H), 3.91 (br s, 2H), 1.94 (s, 2H), 1.40 (s, 6H), 
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1.39 (s, 6H); 13C NMR (CDCl3): δ 163.7, 148.4, 143.6, 142.4, 135.7, 129.7, 128.5, 128.1, 125.0, 
118.7, 118.1, 116.5, 114.9, 54.4, 42.1, 35.8, 32.5, 31.6. Anal. Calcd for C22H26N2OS: C, 72.09; H, 
7.15; N, 7.64. Found: C, 71.74; H, 7.17; N, 7.61. 
General procedure for synthesizing benzamides (33a-c). To a stirred solution of acid 31g (198 
mg, 0.5 mmol) in N,N-dimethylformamide (5 mL) was added diisopropylethylamine (1.5 mmol), 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.55 mmol), and 1-
hydroxylbenzotriazole (0.55 mmol). After stirring for 1 h at room temperature, the corresponding 
amine 32 a, b or c (0.55 mmol) was added. The resulting mixture was stirred at room temperature 
for 12 h. The mixture was poured into ice (approx. 100 g) and stirred for 30 min. The aqueous 
layer was then extracted with ethyl acetate (3 x 100 mL). The combined organic extracts were 
washed with saturated aqueous NaCl (2 x 50 mL), dried (MgSO4), and concentrated under 
vacuum to afford the crude benzamides. The compounds were further purified via a silica gel 
column chromatography using hexanes:ethyl acetate (1:1) to afford the desired pure benzamides 
33a - c. 
N-Methyl-4-{3-oxo-3-[(2,2,4,4-tetramethylthiochroman-6-yl)amino]prop-1-en-1-
yl}benzamide (33a). Yield: 182 mg (0.445 mmol, 89%) as a yellow solid, mp 273-274 oC; IR: 
1628, 1529, 1475, 1313 cm-1; 1H NMR (DMSO-d6): δ 10.2 (s, 1H), 8.50 (d, J = 4.7 Hz, 1H), 7.89 
(d, J = 8.2 Hz, 2H), 7.79 (d, J = 1.5 Hz, 1H), 7.69 (d, J = 8.2 Hz, 2H), 7.60 (d, J = 15.6 Hz, 1H), 
7.49 (dd, J = 8.2, 1.6 Hz, 1H), 7.03 (d, J = 8.6 Hz, 1H), 6.88 (d, J = 15.6 Hz, 1H), 2.79 (d, J = 3.9 
Hz, 3H), 1.91 (s, 2H), 1.35 (s, 6H), 1.34 (s, 6H); 13C NMR (DMSO-d6): δ 166.4, 163.5, 143.3, 
139.4, 137.7, 137.1, 135.6, 128.3, 128.2, 128.0, 126.9, 124.3, 118.3, 118.1, 54.0, 42.4, 35.8, 32.7, 
31.7, 26.7. Anal. Calcd for C24H28N2O2S: C, 70.56; H, 6.91; N, 6.86. Found: C, 70.28; H, 6.78; N, 
6.83. 
N-Cyclopropyl-4-{3-oxo-3-[(2,2,4,4-tetramethylthiochroman-6-yl)amino]prop-1-en-1-
yl}benzamide. (33b). Yield: 202 mg (0.465 mmol, 93%) as a yellow solid, mp 228-229 oC; IR: 
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1635, 1531 cm-1; 1H NMR (DMSO-d6): δ 10.2 (s, 1H), 8.48 (d, J = 4.3 Hz, 1H), 7.86 (d, J = 8.2 
Hz, 2H), 7.77 (d, J = 2.0 Hz, 1H), 7.66 (d, J = 8.2 Hz, 2H), 7.58 (d, J = 15.6 Hz, 1H), 7.48 (dd, J 
= 8.6, 2.2 Hz, 1H), 7.01 (d, J = 8.6 Hz, 1H), 6.87 (d, J = 15.6 Hz, 1H), 2.86 (m, 1H), 1.89 (s, 2H), 
1.34 (s, 6H), 1.32 (s, 6H), 0.68 (m, 2H), 0.56 (m, 2H); 13C NMR (DMSO-d6): δ 167.0, 163.3, 
143.1, 139.1, 137.5, 136.9, 135.3, 128.1, 127.7, 126.7, 124.1, 118.1, 117.8, 53.7, 42.2, 35.5, 32.5, 
31.5, 23.3, 6.0 (1 aromatic C unresolved). Anal. Calcd for C26H30N2O2S: C, 71.86; H, 6.96; N, 
6.45. Found: C, 71.56; H, 6.84; N, 6.31. 
3-[4-(Morpholine-4-carbonyl)phenyl]-N-(2,2,4,4-tetramethylthiochroman-6-yl)acrylamide 
(33c). Yield: 211 mg (0.455 mmol, 91%) as a yellow solid, mp 181-182 oC; IR: 1614, 1530, 
1470, 1278, 1115 cm-1; 1H NMR (DMSO-d6): δ 8.19 (br s, 1H), 7.87 (br s, 1H), 7.66 (d, J = 15.3 
Hz, 1H), 7.44 (d, J = 8.2 Hz, 2H), 7.39 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.0 Hz, 1H), 7.10 (d, J = 
8.5 Hz, 1H), 6.48 (d, J = 15.3 Hz, 1H), 3.77 - 3.46 (m, 8H), 1.95 (s, 2H), 1.41 (s, 6H), 1.40 (s, 
6H); 13C NMR (DMSO-d6): δ 170.0, 163.5,158.1, 143.5, 140.2, 136.5, 136.0, 135.6, 128.5, 128.1, 
127.5, 122.8, 118.7, 118.0, 66.8, 54.4, 42.1, 35.8, 32.5, 31.5 (1 aliphatic C unresolved). Anal. 
Calcd for C27H32N2O3S: C, 69.80; H, 6.94; N, 6.03. Found: C,69.53; H, 6.96; N, 6.01. 1.2b  
1.6.2 Altering the linker unit N-benzylthioacetamide 
General methods: Commercial anhydrous N,N-dimethylformamide was stored under dry N2 and 
transferred by syringe into reactions when needed. Tetrahydrofuran was dried over potassium 
hydroxide pellets and distilled from lithium aluminum hydride prior to use. All other commercial 
reagents and solvents were used as received. Unless otherwise indicated, all reactions were 
carried out under dry N2 in oven-dried glassware. Reactions were monitored by thin layer 
chromatography (TLC, Analtech No 21521) using silica gel GF plates. Preparative separations 
were performed by column chromatography on silica gel (Davisil®, grade 62, 60 - 200 mesh) 
containing UV-active phosphor (Sorbent Technologies No UV-05) slurry packed into quartz 
columns. Band elution for all chromatographic separations was monitored using a hand-held UV 
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lamp. Melting points were uncorrected. IR spectra were run as chloroform solutions on NaCl 
disks. The 1H- and 13C-NMR spectra were measured in the indicated solvent at 400 MHz and 100 
MHz, respectively, using tetramethylsilane as the internal standard with coupling constants (J) 
given in Hz. 
4-Bromo-3-methylphenyl 3-methylbut-2-enoate (36). A clean, dried 100-mL, three-necked, 
round-bottomed flask fitted with a nitrogen inlet, an addition funnel and a stopper was charged 
60% sodium hydride in mineral oil (1.28 g, 32.0 mmol). The oil was removed from NaH by 
washing with 2 x 20 mL of hexane. The sodium hydride was suspended in 25 mL of THF and 
cooled to 0 oC, at which time 34 (5.0 g, 26.7 mmol) in 10 mL of THF was added dropwise. The 
reaction was stirred for 15 min at 0 oC and 35 (3.0 g, 26.7 mol) in 15 mL THF was added 
dropwise.  The reaction was warmed to room temperature gradually and stirred for 18 h.  The 
crude reaction mixture was carefully poured into an ice-cold water and extracted with ether (3 x 
25 mL).  The combined organic layers were washed with saturated NaCl solution, and dried 
(MgSO4) and concentrated under vacuum to afford product 36 (6.9 g, 25.6 mmol, 96%) as a 
colorless oil. IR: 1735, 1647, 1123 cm-1; 1H NMR (CDCl3): δ 7.50 (d, J = 8.5 Hz, 1H), 6.99 (d, J 
= 2.0 Hz, 1H), 6.81 (dd, J = 8.5, 2.5 Hz, 1H), 5.89 (s, 1H), 2.38 (s, 1H), 2.22 (s, 3H), 1.00 (s, 3H); 
13C NMR (CDCl3): δ 164.6, 160.5, 149.7, 139.1, 132.9, 124.2, 121.1, 120.8, 114.9, 27.7, 23.1, 
20.5. 
6-Bromo-4,4,7-trimethylchroman-2-one (37). A clean, dried 250-mL three-necked, round-
bottomed flask fitted with a nitrogen inlet, an addition funnel and a stopper was charged with 
aluminum chloride (4.75 g, 36.0 mmol) and 80 mL of dichloromethane.  The resulting suspension 
was cooled to 0 oC and 36 (6.0 g, 22.3 mmol) in 40 mL dichloromethane was added dropwise. 
The ice bath was removed after the addition, and the mixture was allowed to stir at room 
temperature for 24 h.  After TLC analysis indicated the complete absence of starting material, the 
reaction was quenched by dropwise addition of ice-cold 1 M HCl solution. The organic layer was 
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separated, and the aqueous layer was extracted with ether (2 x 75 mL).  The combined organic 
layers were washed successively with saturated aqueous NaHCO3, saturated aqueous NaCl, dried 
(MgSO4) and concentrated under vacuum. The required regioisomer 37 was separated from 37a 
by column chromatography and eluted with hexanes:ether (4:1) to afford 37 (3.5 g, 13.2 mmol, 
59%) as a yellow solid, mp 87-88 oC; IR: 1778, 1373, 1085 cm-1; 1H NMR (CDCl3): δ 7.44 (s, 
1H), 6.94 (s, 1H), 2.60 (s, 2H), 2.37 (s, 3H), 1.34 (s, 6H); 13C NMR (100 MHz): δ 167.6, 149.6, 
138.1, 131.1, 128.1, 119.8, 119.2, 43.4, 33.2, 27.6, 22.6. 
6-Bromo-4,4,5-trimethylchroman-2-one (37a). Yield: 1.2 g (4.5 mmol, 20%) as a yellow solid, 
mp 97–101 oC; IR: 1785, 1771, 1237 cm-1; 1H NMR (400 MHz): δ 7.46 (d, J = 8.0 Hz, 1H)), 6.80 
(d, J = 8.0 Hz, 1H), 2.60 (s, 2H), 2.57 (s, 3H), 1.48 (s, 6H); 13C NMR (100 MHz): δ 167.5, 150.7, 
136.0, 132.0, 122.5, 116.9, 45.7, 36.0, 27.5, 22.7. 
4-Bromo-2-(4-hydroxy-2,4-dimethylpentan-2-yl)-5-methylphenol (38). A clean, dried 250-mL 
three-neck, round-bottomed flask fitted with a nitrogen inlet, an addition funnel and a stopper was 
charged with 37 (3.5 g, 13.0 mmol) and 20 mL ether.  The resulting solution was cooled to 0 oC, 
and 1.6 M methyllithium solution in ether (20.3 mL, 32.5 mmol) was added dropwise over a 
period of 30 min. The suspension was stirred at room temperature for 48 h and quenched with 
saturated aqueous NH4Cl at 0 oC. The resulting suspension was diluted with ether and the organic 
layers were separated. The product was extracted in ether and the combined organic layers, were 
washed with saturated aqueous NaCl, dried (MgSO4) and concentrated.  The crude product was 
purified by column chromatography and eluted with hexane:ether (1:1) to give 38 (3.17 g, 10.53 
mmol, 81%) as a white solid, mp 134-137 oC. IR: 3547, 3245, 2968, 1396, 1382 cm-1; 1H NMR 
(CDCl3): δ 7.38 (s, 1H), 6.55 (s, 1H), 2.26 (s, 3H), 2.17 (s, 2H), 1.82 (br s, 1H), 1.43 (s, 6H), 1.15 
(s, 6H); 13C NMR (CDCl3): δ 154.1, 136.7, 134.6, 131.2, 120.0, 115.5, 73.4, 52.5, 37.3, 31.1, 
31.0, 22.2. 
40 
 
6-Bromo-2,2,4,4,7-pentamethylchromane (39). A clean, dried 100-mL, one-neck round-
bottomed flask fitted with refluxed condenser and a nitrogen inlet was charged with 38 (3 g, 9.96 
mmol) and 20 mL of phosphoric acid.  The resulting mixture was heated to 110 oC for 1 h.  The 
reaction mixture cooled to room temperature and poured into an Erlenmeyer flask containing 
crushed ice. The product was extracted with ether (3 x 50 mL), and the combined organic layers 
were washed with saturated aqueous NaHCO3, saturated aqueous NaCl, dried (MgSO4) and 
concentrated. The crude product was purified by column chromatography and eluted with 
hexane:ether (3:2) to give 39 (2.5 g, 8.7 mmol, 90%) as a colorless oil. IR: 1555, 1478, 1374, 
1165 cm-1; 1H NMR (CDCl3): δ 7.37 (s, 1H), 6.68 (s, 1H), 2.29 (s, 3H), 1.79 (s, 2H), 1.33 (s, 6H), 
1.31 (s, 6H); 13C NMR (CDCl3): δ 151.7, 136.3, 131.2, 130.2, 120.1, 115.4, 74.7, 48.9, 32.8, 30.8, 
28.5, 22.5. 
2,2,4,4,7-Pentamethylchromane-6-carbonitrile (40). A clean, dried 250-mL Chemglass® 
pressure vessel (CG-1880-R-03) was charged with 39 (2.5 g, 8.7 mmol), copper cyanide (1.6 g, 
17.4 mmol), L-proline (1.0 g, 8.7 mmol) and 25 mL of DMF.  The reaction vessel was closed and 
heated to 110 oC for 24 h. The reaction mass was cooled to room temperature, filtered through 
Celite® and washed with ethyl acetate. The organic layer was separated, and the filtrate was 
extracted further using ethyl acetate, which was dried (MgSO4) and concentrated under vacuum. 
The resulting dark brown residue was purified by column chromatography to provide 40 (1.26 g, 
5.5 mmol, 63%) as a yellow oil. IR: 2217, 1615, 1495, 1149 cm-1; 1H NMR (CDCl3): δ 7.49 (s, 
1H), 6.69 (s, 1H), 2.42 (s, 3H), 1.84 (s, 2H), 1.36 (s, 6H), 1.34 (s, 6H); 13C NMR (CDCl3): δ 
156.3, 140.9, 132.1, 130.0, 119.5, 119.0, 104.4, 75.8, 48.4, 32.5, 30.6, 28.5, 20.0. 
(2,2,4,4,7-Pentamethylchroman-6-yl)methanamine (41). A clean, dried 100-mL three-necked, 
round bottomed flask fitted with reflux condenser and a nitrogen inlet was charged with 40 (1.2 g, 
5.2 mmol) and tetrahydrofuran (20 mL). The resulting solution was cooled to 0 oC and lithium 
aluminum hydride (0.4 g, 10.4 mmol) was added lot-wise. The resulting slurry was allowed to 
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warm up to room temperature and slowly heated to reflux temperature with stirring for 4 h.  At 0 
oC, water (10 mL), 3 N NaOH (10 mL) and water (10 mL) were slowly added in sequence. The 
reaction mass was filtered through a Celite® bed and washed with ethyl acetate. The layers was 
separated and the aqueous phase was extracted with ethyl acetate (3 x 70 mL). The combined 
organic layers were dried (Na2SO4), concentrated under vacuum and purified by column 
chromatography (dichloromethane/methanol 19:1) to provide 41 (0.86 g, 3.7 mmol,71%) as a 
yellow oil. IR: 3437, 3365, 1567, 1156 cm-1; 1H NMR (CDCl3): δ 7.18 (s, 1H), 6.61 (s, 1H), 3.81 
(s, 2H), 2.28 (s, 3H), 1.81 (s, 2H), 1.33 (s, 12H); 13C NMR (CDCl3): δ 151.3, 134.6, 132.5, 128.9, 
126.1, 119.5, 74.3, 49.3, 43.7, 32.9, 30.6, 28.5, 18.5. 
General procedure for amide formation (43a-c). To a stirred solution of 42a-c (1.44 mmol) in 
dimethylformamide (5.0 mL), was added EDC.HCl (280 mg, 1.44 mmol) and DIPEA (0.37 mL, 
2.14 mmol), and the mixture was stirred at room temperature for 30 min.  To the resulting 
solution was added HOBt (139 mg, 1.44 mmol) and 41 (200 mg, 1.2 mmol) and stirring was 
continued at room temperature until TLC analysis indicated the complete consumption of starting 
material. The reaction mass was poured into water, and the product was extracted with ethyl 
acetate (2 x 30 mL). The combined organic layers were washed successively with saturated 
aqueous NaHCO3, saturated aqueous NaCl, and water. The organic layer was dried (MgSO4), 
filtered and concentrated. The amide product was purified by column chromatography. 
2-(4-Nitrophenyl)-N-((2,2,4,4,7-pentamethylchroman-6-yl)methyl)acetamide (43a). Yield: 
295 mg (0.74 mmol, 62%) as a yellow solid, mp 136-137 oC; IR: 3284, 1645, 1520, 1346 cm-1; 
1H NMR (CDCl3): δ 8.20 (d, J = 8.4 Hz, 2H), 7.48 (d, J = 8.4 Hz, 2H), 7.01 (s, 1H), 6.61 (s, 1H), 
5.50 (s, 1H), 4.36 (d, J = 5.1 Hz, 2H), 3.65 (s, 2H), 2.17 (s, 3H), 1.80 (s, 2H), 1.34 (s, 6H), 1.28 
(s, 6H); 13C NMR (CDCl3): δ 168.5, 152.2, 147.2, 142.4, 135.5, 130.1, 129.1, 127.6, 127.2, 124.0, 
119.7, 74.5, 49.0, 43.3, 42.1, 32.8, 30.5, 28.5, 18.6; Anal. Calcd. for C23H28N2O4: C, 69.68; H, 
7.12; N, 7.07. Found: C, 69.32; H, 7.35; N, 7.18. 
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N-((2,2,4,4,7-Pentamethylchroman-6-yl)methyl)-2-(4-(trifluoromethyl)phenyl)acetamide 
(43b). Yield: 302 mg (0.72 mmol, 60%) as a white solid, mp 143-144 oC; IR: 3277, 1643, 1325, 
1125 cm-1; 1H NMR (CDCl3): δ 7.60 (d, J = 7.9 Hz, 2H), 7.42 (d, J = 7.9 Hz, 2H), 6.96 (s, 1H), 
6.60 (s, 1H), 5.47 (br s, 1H), 4.35 (d, J = 5.2 Hz, 2H), 3.62 (s, 2H), 2.15 (s, 3H), 1.79 (s, 2H), 
1.32 (s, 6H), 1.26 (s, 6H); 13C NMR (CDCl3): δ 169.3, 152.0, 139.0, 135.3, 129.6, 129.5, 129.0, 
127.5, 127.2, 125.8 (q, J = 272.1 Hz), 119.7, 74.5, 49.0, 43.5, 41.9, 32.7, 30.5, 28.5, 18.6; Anal. 
Calcd. for C24H28F3NO2: C, 68.72; H, 6.73; N, 3.34. Found: C, 68.95; H, 6.57; N, 3.03. 
N-((2,2,4,4,7-Pentamethylchroman-6-yl)methyl)-2-(4-(trifluoromethoxy)phenyl)acetamide 
(43c). Yield: 340 mg (0.78 mmol, 65%) as a white solid, mp 102-103 oC; IR: 3276, 1643, 1261, 
1223 cm-1; 1H NMR (CDCl3): δ 7.32 (d, J = 8.3 Hz, 2H), 7.18 (d, J = 8.3 Hz, 2H), 6.98 (s, 1H), 
6.60 (s, 1H), 5.45 (s, 1H), 4.35 (d, J = 5.2 Hz, 2H), 3.58 (s, 2H), 2.15 (s, 3H), 1.79 (s, 2H), 1.32 
(s, 6H), 1.27 (s, 6H); 13C NMR (CDCl3): δ 169.8, 152.0, 148.4, 135.4, 133.7, 130.7, 129.0, 127.5, 
127.2, 121.4, 120.4 (q, J = 256.9 Hz), 119.7, 74.5, 49.0, 43.0, 41.9, 32.8, 30.5, 28.5, 18.5; Anal. 
Calcd. for C24H28F3NO3: C, 66.19; H, 6.48; N, 3.22. Found: C, 65.89; H, 6.54; N, 3.45. 
2-(4-Nitrophenyl)-N-((2,2,4,4,7-pentamethylchroman-6-yl)methyl)ethanethioamide (44). To 
a stirred solution of 43a (200 mg, 0.5 mmol) in tetrahydrofuran (5.0 mL) was added Lawesson’s 
reagent (102 mg, 0.25 mmol) at room temperature, and the reaction was heated at reflux for 6 h. 
The crude reaction mixture was cooled to room temperature, concentrated under vacuum and 
purified by column chromatography (hexanes:ethyl acetate 2:1) to afford 27 (149 mg, 0.36 mmol, 
72%) as a yellow solid, mp 68-70 oC. IR: 3332, 1520, 1346 cm-1; 1H NMR (CDCl3): δ 8.19 (d, J = 
8.3 Hz, 2H), 7.50 (d, J = 8.3 Hz, 2H), 7.07 (br s, 1H), 7.05 (s, 1H), 6.63 (s, 1H), 4.67 (d, J = 4.5 
Hz, 2H), 4.13 (s, 2H), 2.13 (s, 3H), 1.80 (s, 2H), 1.33 (s, 6H), 1.28 (s, 6H); 13C NMR (CDCl3): δ 
199.3, 152.7, 147.4, 143.2, 135.8, 130.0, 129.4, 128.4, 125.6, 124.0, 119.9, 74.7, 52.5, 49.2, 48.9, 
32.8, 30.5, 28.5, 18.6; Anal. Calcd. for C23H28N2O3S: C, 66.96; H, 6.84; N, 6.79. Found: C, 67.13; 
H, 6.92; N, 6.54. 
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1.6.3 Altering the linker with thiazoline ring 
General methods: Commercial anhydrous N,N-dimethylformamide was stored under dry N2 and 
transferred by syringe into reactions when needed. Tetrahydrofuran was dried over potassium 
hydroxide pellets and distilled from lithium aluminum hydride prior to use. All other commercial 
reagents and solvents were used as received. Unless otherwise indicated, all reactions were 
carried out under dry N2 in oven-dried glassware. Reactions were monitored by thin layer 
chromatography (TLC, Analtech No 21521) using silica gel GF plates. Preparative separations 
were performed by column chromatography on silica gel (Davisil®, grade 62, 60 - 200 mesh) 
containing UV-active phosphor (Sorbent Technologies No UV-05) slurry packed into quartz 
columns. Band elution for all chromatographic separations was monitored using a hand-held UV 
lamp. Melting points were uncorrected. IR spectra were run as chloroform solutions on NaCl 
disks. The 1H- and 13C-NMR spectra were measured in the indicated solvent at 400 MHz and 100 
MHz, respectively, using tetramethylsilane as the internal standard with coupling constants (J) 
given in Hz. 
4-((4-Bromophenyl)thio)-4-methylpentan-2-one (47). To a stirred solution of 4-
bromothiophenol (46) (5.0 g, 26.4 mmol) in chloroform (35 mL) was added trimethylamine (3.5 
mL, 26.4 mmol), followed by mesityl oxide (25) (3.0 mL, 26.4 mmol).  The resulting solution 
was heated to reflux (bath temperature 70 oC). Two additional portions of trimethylamine (3.5 
mL, 26.4 mmol) and mesityl oxide (3.0 mL, 26.4 mmol) were added at regular intervals of 4 h, 
and the resulting solution was cooled, filtered through Celite® and washed with dichloromethane 
(2 x 25 mL).  The combined organic layers were washed with water (2 x 50 mL), saturated 
aqueous NaCl, dried (MgSO4), and concentrated to give the crude product as a yellow oil.  The 
crude material was purified by column chromatography (hexanes/ether 2:1) to afford 47 (6.8 g, 
23.8 mmol, 90%) as a colorless oil; IR: 1713, 1468, 1010 cm-1; 1H NMR (CDCl3): δ 7.48 (d, J = 
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8.4 Hz, 2H), 7.39 (d, J = 8.3 Hz, 2H), 2.65 (s, 2H), 2.15 (s, 3H), 1.38 (s, 6H); 13C NMR (CDCl3): 
δ 206.4, 139.1, 131.9, 130.6, 124.0, 54.3, 47.4, 32.2, 28.2. 
4-((4-Bromophenyl)thio)-2,4-dimethylpentan-2-ol (48). To a stirred solution of methyllithium 
in ether (478.0 mL, 34.8 mmol, 1.6 M) at -50 oC was added dropwise 47 (5 g, 17.4 mmol) in 
tetrahydrofuran (75 mL) over 30-45 min. The resulting reaction mixture was warmed to room 
temperature and stirred for 3 h. The reaction mixture was then cooled to 0 oC, and quenched by 
dropwise addition of saturated NH4Cl solution (20 mL), and the solution was extracted with ethyl 
acetate (3 x 50 mL). The combined organic extracts were washed with saturated aqueous NaCl 
(50 mL), dried (MgSO4), and concentrated under vacuum to afford a dark brown liquid.  The 
crude product was purified by column chromatography (hexane/ether 1:1) to afford 48 (4.2 g, 
13.9 mmol, 80%) as a colorless oil; IR: 3450, 1468, 1010 cm-1; 1H NMR (CDCl3): δ 7.46 (s, 4H), 
3.19 (br s, 1H), 1.79 (s, 2H), 1.37 (s, 6H), 1.33 (s, 6H); 13C NMR (CDCl3): δ 138.8, 131.8, 130.8, 
123.8, 71.9, 52.4, 49.5, 32.2, 30.9. 
6-Nitro-N-(2,2,4,4-tetramethylthiochroman-6-yl)benzo[d]thiazol-2-amine (45). To a stirred 
solution of 48 (4.0 g, 13.2 mmol) in dichloromethane (40 mL) at room temperature was added 
portion-wise anhydrous aluminum chloride (2.1 g, 15.8 mmol) over a period of 30 min, and 
reaction was refluxed for 1 h. The reaction mixture was cooled to 0 oC and quenched with ice 
cold water (20 mL) to give a suspension which was, filtered through Celite® and washed with 
dichloromethane (30 mL). The layers were separated, and the aqueous layer was extracted with 
dichloromethane (2 x 20 mL). The combined organic extracts were washed with saturated 
aqueous NaCl, dried (MgSO4) and concentrated to give 49 as brown residue.   
The residue was dissolved in dimethylformamide (30 mL) and transferred to a 250 mL 
Chemglass® pressure vessel (CG-1880-R-03). To the resulting solution was added potassium 
carbonate (3.6 g, 26.4 mmol), copper iodide (0.5 g, 2.64 mmol), L-proline (0.6 g, 5.28 mmol) and 
6-nitrobenzo[d]thiazole-2-amine (50) (3.1 g, 15.84 mmol).  The reaction vessel was immersed 
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into a pre-heated oil bath at 140 oC and stirred for 18 h. The crude reaction mixture cooled to 
room temperature and poured into water (100 mL), filtered through Celite®, and washed with 
ethyl acetate (50 mL). The layers were separated and the aqueous phase was extracted with ethyl 
acetate (2 x 25 mL), dried (MgSO4) and concentrated under vacuum to provide brown oil. The 
product was purified by column chromatography (hexanes:ether 1:1) to afford 45 as a orange 
solid (3.7 g, 9.2 mmol, 70%), mp 59-60 oC. IR: 3210, 2247, 1341 cm-1; 1H NMR (CDCl3): δ 8.41 
(d, J = 2.5 Hz, 1H), 8.31 (dd, J = 8.3, 4.4 Hz, 2H), 7.43 (d, J = 8.9 Hz, 1H), 7.29 (d, J = 2.5 Hz, 
1H), 7.21 (br s, 1H), 7.07 (d, J = 8.2 Hz,1H), 6.80 (dd, J = 8.2, 2.1 Hz, 2H), 1.94 (s, 2H), 1.42 (s, 
6H), 1.37 (s, 6H); 13C NMR (CDCl3): δ 144.7, 144.1, 143.5, 134.4, 129.5, 128.2, 127.4, 126.9, 
126.3, 121.3, 115.2, 53.8, 42.4, 35.8, 32,4, 31.6. Anal. Calcd. for C20H21N3O2S2: C, 60.13; H, 
5.30; N, 10.52. Found: C, 60.28; H, 5.12; N, 10.76. 
1.6.4 Synthesizing nitrogen containing heteroarotinoids 
General methods: Commercial anhydrous N,N-dimethylformamide was stored under dry N2 and 
was transferred by syringe into reactions when needed. Tetrahydrofuran was dried over potassium 
hydroxide pellets and distilled from lithium aluminum hydride prior to use. All other commercial 
reagents and solvents were used as received. Unless otherwise indicated, all reactions were 
carried out under dry N2 in oven-dried glassware. Reactions were monitored by thin layer 
chromatography (TLC, Analtech No 21521) using silica gel GF plates. Preparative separations 
were performed by column chromatography on silica gel (Davisil®, grade 62, 60 - 200 mesh) 
containing UV-active phosphor (Sorbent Technologies, No UV-05) slurry packed into quartz 
columns. Band elution for all chromatographic separations was monitored using a hand-held UV 
lamp. Melting points were uncorrected. IR spectra were run as chloroform solutions on NaCl 
disks or in nujol. The 1H- and 13C-NMR spectra were measured in the indicated solvent at 400 
MHz and 100 MHz, respectively, using tetramethylsilane as the internal standard with coupling 
constants (J) given in Hz. 
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N-(4-Bromophenyl)-3-methylbut-2-enamide (65). A solution of 3-methylbut-2-enoyl chloride 
(3.4 mL, 29.0 mmol) in chloroform (25 mL) was added dropwise to a stirred solution of 4-
bromoaniline (64) (10 g, 58.1 mmol) in chloroform (250 mL). The resulting cloudy reaction 
mixture was refluxed for 5 h, and then cooled to room temperature and filtered through Celite®. 
The filtrate was washed with 1 M HCl (100 mL), saturated aqueous NaHCO3, and saturated 
aqueous NaCl, dried (MgSO4), concentrated under vacuum and recrystallized from ethanol to 
afford 65 as a white solid (5.5 g, 21.8 mmol, 75%), mp 118-119 oC; IR: 3294, 1663, 1643, 826 
cm-1; 1H NMR (CDCl3): δ 7.43 (s, 4H), 7.01 (br s, 1H), 5.69 (s, 1H), 2.22 (s, 3H), 1.91 (s, 3H); 
13C NMR (CDCl3): δ 154.4, 151.4, 137.3, 131.9, 118.3, 27.4, 20.0. 
N-(4-Bromophenyl)-3-methylbut-3-enamide (65a). A solution of 3-methylbut-2-enoyl chloride 
(3.4 mL, 12.7 mmol) in chloroform (5 mL) was added dropwise to a stirred, ice-cooled solution 
containing 4-bromoaniline (64) (2.0 g, 11.6 mmol) and triethylamine (3.23 mL, 23.2 mmol) in 
dichloromethane (25 mL).  The reaction was stirred at room temperature for 18 h and then diluted 
with dichloromethane (25 mL), washed with water (3 x 50 mL), saturated aqueous NaCl (50 mL).  
The organic phase was dried (MgSO4) and concentrated under vacuum to provide 65a as a yellow 
solid (2.5 g, 10.1 mmol, 87%), mp 108-110 oC; IR: 3288, 1660, 1392, 814 cm-1; 1H NMR 
(CDCl3): δ 7.42 (s, 4H), 5.09 (s, 1H), 5.01 (s, 1H), 3.12 (s, 2H), 1.85 (s, 3H); 13C NMR (100 
MHz): δ 168.4, 140.2, 136.8, 132.0, 121.3, 116.9, 116.5, 47.5, 22.5. 
6-Bromo-4,4-dimethyl-3,4-dihydroquinolin-2(1H)-one (66). To a stirred solution of 65 (5.0 g, 
19.6 mmol) in dichloroethane was added aluminum chloride (3.9 g, 29.5 mmol) portion-wise and 
the mixture was heated to reflux for 1 h. The reaction was cooled to 0 oC, quenched with ice-cold 
water (20 mL), filtered through Celite® and washed with dichloromethane (2 x 50 mL). The 
layers were separated, washed the organic phase with saturated aqueous NaHCO3 (1 x 50 mL), 
saturated aqueous NaCl (1 x 50 mL) and dried (MgSO4). The organic layer was concentrated 
under vacuum and purified by column chromatography (to afford 66 as a brown solid (3.8 g, 14.9 
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mmol, 76%), mp 151-153 oC; IR: 3201, 1681, 1488, 1368 cm-1; 1H NMR (CDCl3): δ 9.36 (s, 1H), 
7.39 (s, 1H), 7.27 (d, J = 8.4 Hz, 1H), 6.75 (d, J = 8.4 Hz, 1H), 2.48 (s, 2H), 1.34 (s, 6H); 13C 
NMR (CDCl3): δ 171.2, 135.1, 134.6, 130.4, 127.7, 117.5, 116.1, 44.9, 34.1, 27.5. 
6-Bromo-4,4-dimethyl-1,2,3,4-tetrahydroquinoline (67). To a stirred, ice-cooled solution of 66 
(3.5 g, 13.8 mmol) in distilled toluene (35 mL) was added borane-dimethyl sulfide complex (1.4 
mL, 14.4 mmol) dropwise, and then mixture was refluxed for 3h. The reaction was cooled to 
room temperature and quenched carefully by dropwise addition of 10% aqueous Na2CO3 (10 
mL). The resulting biphasic mixture was stirred at room temperature for 15 min and the layers 
were separated and dried (MgSO4) and concentrated under vacuum and gave 67 as a colorless oil 
(3.0 g, 12.4 mmol, 90%), IR: 3414, 1495, 1282 cm-1; 1H NMR (CDCl3): δ 7.29 (d, J = 2.3 Hz, 
1H), 7.07 (dd, J = 8.3, 2.31 Hz, 2H), 6.52 (d, J = 8.5 Hz, 1H), 3.33 (t, J = 5.8 Hz, 2H), 1.76 (t, 5.8 
Hz, 2H), 1.29 (s, 6H); 13C NMR (CDCl3): δ 140.4, 133.7, 129.5, 129.4, 117.1, 110.6, 38.4, 36.4, 
32.0, 30.8. 
tert-Butyl 6-bromo-4,4-dimethyl-3,4-dihydroquinoline-1(2H)-carboxylate (68). A Tetrahyd-
rofuran (50 mL) solution containing 67 (3.0 g, 12.4 mmol), was cooled to -78 oC, and 2.5 M n-
butyllithium (6 mL, 14.9 mmol) was added dropwise over a period of 30 min. The solution was 
stirred for 30 min and di-tert-butyl dicarbonate (3.3 g, 14.9 mmol) in tetrahydrofuran (15 mL) 
was added dropwise over a period of 30 min. The reaction was allowed to attain room 
temperature gradually, with stirring for 18 h, and then cooled to 0 oC. The reaction mixture was 
quenched by dropwise addition of saturated aqueous NH4Cl solution (20 mL). The layers were 
separated and the aqueous phase was extracted with ether (2 x 50 mL). The combined organic 
extracts were dried (MgSO4), concentrated and purified by column chromatography to provide 68 
as a brown oil (3.8 g, 11.4 mmol, 92%), IR: 1679, 1483, 1367, 1152 cm-1; 1H NMR (CDCl3): δ 
7.52 (s,1H), 7.36 (d, J = 2.4 Hz, 2H), 7.21 (dd, J = 6.6, 2.3 Hz, 1H), 3.72 – 3.69 (m, 2H), 1.74 – 
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1.71 (m, 2H), 1.51 (s, 9H), 1.28 (s, 6H); 13C NMR (CDCl3): δ 153.6, 140.2, 136.3, 128.7, 128.6, 
126.0, 116.4, 81.1, 41.7, 38.1, 33.4, 30.8, 30.0, 28.4. 
tert-Butyl 6-amino-4,4-dimethyl-3,4-dihydroquinoline-1(2H)-carboxylate (70). A mixture of 
68 (3.5 g, 10.3 mmol), sodium azide (1.3 g, 20.6 mmol), CuI (0.2 g, 1.03 mmol), L-proline (0.35 
g, 3.1 mmol), NaOH (0.12 g, 3.14 mmol) and ethanol/water (7:3, 20mL) was heated to 90 oC in a 
Chemglass pressure vessel (Chem-Glass No. CG-1880-01) for 18 h. The reaction was cooled to 
room temperature, filtered through Celite® and washed with ethyl acetate (50 mL). The filtrate 
was washed with water (2 x 30 mL), saturated aqueous NaCl (1 x 50 mL), dried (MgSO4) and 
concentrated under vacuum to provide 69 as a brown oil. The resulting brown oil was dissolved 
in methanol (100 mL), and 10% Pd/C (0.3 g, 10% w/w) was added under nitrogen atmosphere.  
The reaction vessel was flushed with hydrogen gas, and stirring was continued at room 
temperature under hydrogen atmosphere for 6 h. The catalyst was removed by filtering through 
Celite® and washing with methanol (25 mL). The filtrate was concentrated and purified by 
column chromatography (hexanes:ether 4:1) to afford 70 (1.8 g, 6.4 mmol, 62%) as a brown oil. 
IR: 3448, 3362, 1685, 1503, 1380, 1154 cm-1; 1H NMR (CDCl3): δ 7.61 (d, J = 8.2 Hz, 1H), 7.28 
(dd, J = 7.8, 1.6 Hz, 2H), 7.12 (td, J = 7.2, 1.6 Hz, 1H), 7.03 (td, J = 7.2, 1.6 Hz, 1H), 3.75-3.72 
(m, 2H), 1.76-1.73 (m, 2H), 1.52 (s, 9H), 1.30 (s, 6H); 13C NMR (CDCl3): δ 154.0, 142.1, 139.1, 
128.7, 125.5, 113.1, 112.2, 80.3, 41.6, 38.8, 33.2, 30.2, 28.5, 28.4. 
General procedure to synthesize 73a-d. To a stirred solution of 70 (0.2 g, 0.7 mmol) in 
tetrahydrofuran (5 mL) was added iso(thio)cyanates 71a-d (0.7 mmol) in tetrahydrofuran (2 mL) 
dropwise at room temperature under nitrogen atmosphere. The mixture was stirred until the TLC 
analysis indicated that 70 was completely consumed. The solvent was evaporated under vacuum 
to afford the Boc protected (thio)urea derivatives 72a-d. To the resulting Boc-protected 
compound in dichloromethane (5 mL) was slowly added trifluoroacetic acid (200 µL, 2.6 mmol) 
and the mixture was stirred until TLC indicated the absence of 72a-d. The solvent was evaporated 
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completely under vacuum; two additional portions of dichloromethane (2 x 10 mL) were added 
and then were removed under vacuum. Water (20 mL) was added to the resulting residue and the 
mixture was washed with ether (2 x 20 mL). The aqueous layer was basified using NaHCO3 
powder and extracted with ethyl acetate (3 x 20 mL). The combined organic extracts were washed 
with water (2 x 20 mL), saturated aqueous NaCl (1 x 20 mL), dried (MgSO4) and evaporated 
under vacuum. The crude products were purified by recrystallization from pentane/ether to afford 
73a-d. 
1-(4,4-Dimethyl-1,2,3,4-tetrahydroquinolin-6-yl)-3-(4-nitrophenyl)thiourea (73a). Yield: 164 
mg (0.46mmol, 66%) as a red solid, mp 150-152 oC; IR: 3333, 1509, 1334, 1263 cm-1; 1H NMR 
(CDCl3): δ (ppm) 8.19 (d, J = 8.6 Hz, 2H), 7.78 (d, J = 8.6 Hz, 2H), 7.71 (br s, 2H), 7.09 (s, 1H), 
6.88 (d, J = 8.3 Hz, 1H), 6.50 (d, J = 8.3 Hz, 2H), 4.19 (br s, 2H), 3.39-3.36 (m, 2H), 1.76-1.74 
(m, 2H), 1.30 (s, 6H); 13C NMR (CDCl3): δ 179.5, 144.3, 144.2, 131.6, 125.1, 124.8, 124.4, 
123.4, 122.7, 114.9, 38.2, 36.2, 32.0, 30.6; Anal. Calcd. for C18H20N4O2S: C, 60.65; H, 5.65; N, 
15.72. Found: C, 60.53; H, 5.82; N, 15.87. 
1-(4,4-Dimethyl-1,2,3,4-tetrahydroquinolin-6-yl)-3-(4-(trifluoromethyl)phenyl)thiourea 
(73b). Yield: 169 mg (0.44 mmol, 63%) as a yellow solid, mp 104-105 oC; IR: 3346, 1512, 1324 
cm-1; 1H NMR (CDCl3): δ 7.65 (d, J = 8.2 Hz, 2H), 7.58 (d, J = 8.2 Hz, 2H), 7.11 (d, J = 4.0 Hz, 
1H), 6.89 (dd, J = 8.0, 4.0 Hz, 1H), 6.49 (d, J = 8.0 Hz, 1H), 3.36 (t, J = 8.0 Hz, 2H), 1.75 (t, J = 
8.0 Hz, 2H), 1.29 (s, 6H); 13C NMR (CDCl3): δ 180.1, 143.9, 141.4, 131.5, 125.9, 125.2, 124.9, 
123.8, 123.4 (q, J = 271.5 Hz), 114.8, 38.9, 36.3, 32.0, 30.6; Anal. Calcd. for C19H20F3N3S: C, 
60.14; H, 5.31; N, 11.07. Found: C, 60.28; H, 5.12; N, 11.28. 
1-(4,4-Dimethyl-1,2,3,4-tetrahydroquinolin-6-yl)-3-(4-(trifluoromethoxy)phenyl)thiourea 
(73c). Yield: 164 mg (0.42 mmol, 60%) as a yellow solid, mp 69-71 oC; IR: 3348, 3186, 1509, 
1257 cm-1; 1H NMR (CDCl3): δ 7.69 (br s, 1H), 7.49 (d, J = 12.0 Hz, 2H), 7.18 (d, J = 12.0 Hz, 
2H), 7.11 (d, J = 4.0 Hz, 1H), 6.89 (dd, J = 8.0, 4.0 Hz, 1H), 6.48 (d, J = 8.0 Hz, 1H), 3.35 (t, J = 
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4.0 Hz, 2H), 1.74 (t, J = 4.0 Hz, 2H), 1.29 (s, 6H); 13C NMR (CDCl3): δ 180.4, 146.7, 143.8, 
136.8, 131.4, 126.1, 125.2, 124.9, 121.3, 120.4 (q, J = 257.4 Hz), 114.8, 38.2, 36.3, 31.9, 307; 
Anal. Calcd. for C19H20F3N3OS: C, 57.71; H, 5.10; N, 10.63. Found: C, 57.56; H, 5.23; N, 10.37. 
1-(4,4-Dimethyl-1,2,3,4-tetrahydroquinolin-6-yl)-3-(4-nitrophenyl)urea (73d). Yield: 153 mg 
(0.45 mmol, 64%) as a yellow solid, mp 219-220 oC; IR: 1698, 1548, 1180, 851 cm-1; 1H NMR 
(DMSO-d6): δ 9.23 (s, 1H), 8.36 (s, 1H), 8.16 (d, J = 8.9 Hz, 2H), 7.66 (d, J = 8.9 Hz, 2H), 7.18 
(s, 1H), 6.91 (d, J = 8.5 Hz, 1H), 6.39 (d, J = 8.5 Hz, 1H), 5.54 (s, 1H), 3.16 (s, 2H), 1.61 (s, 2H), 
1.22 (s, 6H); 13C NMR (DMSO-d6): δ 152.6, 147.4, 141.0, 129.4, 127.6, 125.6, 119.5, 118.7, 
117.6, 114.1, 37.8, 37.3, 31.9, 31.3; Anal. Calcd. for C18H20N4O3: C, 63.52; H, 5.92; N, 16.46. 
Found: C, 63.36; H, 6.08; N, 16.51. 
1,1,4,4-Tetramethyl-6-(3-(4-nitrophenyl)ureido)-1,2,3,4-tetrahydroquinolin-1-ium iodide 
(73e). To a stirred solution of 73d (0.2 g, 0.6 mmol) in dimethylformamide (5 mL) in a 15 mL 
Chemglass pressure vessel (No. CG-1880-01) was added Cs2CO3 (390 mg, 1.2 mmol), methyl 
iodide (1.0 mL, 16.0 mmol). The vessel was closed, and the reaction was stirred at room 
temperature for 24 h. Water (5.0 mL) was added and filtered, The solid was stirred with ethanol 
(10 mL) for 15 min and filtered to provide 73e as a yellow solid (185 mg, 0.37 mmol, 62%), mp 
249-251 oC; IR: 3297, 3260, 1724, 1598, 843 cm-1; 1H NMR (CDCl3): δ 9.59 (s, 1H), 9.21 (s, 
1H), 8.21 (d, J = 8.0 Hz, 2H), 7.88 (d, J = 8.0 Hz, 1H), 7.71 (d, J = 8.0 Hz, 2H), 7.67 (s, 1H), 7.51 
(d, J = 12.0 Hz, 1H), 3.89 (s, 6H), 3.56 (s, 6H), 2.11(s, 2H), 1.36 (s, 6H); 13C NMR (CDCl3): δ 
151.4, 145.4, 140.7, 139.7, 139.4, 135.0, 124.5, 121.3, 117.4, 116.7, 59.4, 56.1, 31.6, 30.5, 26.8; 
Anal. Calcd. for C20H25IN4O3: C, 48.40; H, 5.08; N, 11.29. Found: C, 48.65; H, 5.23; N, 11.52. 
6-Bromo-2,2,4-trimethyl-1,2-dihydroquinoline (74). Bismuth(III) triflate (19.0 g, 30.0 mmol) 
was added to a solution of 4-bromoaniline (64) (25.0 g, 145 mmol) in acetone (500 mL), and the 
mixture was stirred at reflux temperature for 3 days. The solvent was removed completely under 
vacuum and the residue was partitioned between ether (300 mL) and water (200 mL). The layers 
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were separated and the aqueous phase was extracted with ether (200 mL). The organic layer was 
washed with saturated aqueous NaCl (200 mL) and evaporated under vacuum. The crude product 
was purified by column chromatography increasing concentrations of (ether in hexanes) to afford 
74 as a brown solid (23 g, 89.9 mmol, 62%), mp 83-85 oC; IR: 3382, 1486, 1257, 806 cm-1; 1H 
NMR (CDCl3): δ 7.13 (d, J = 2.2 Hz, 1H), 7.05 (dd, J = 8.4, 2.2 Hz, 1H), 6.31 (d, J = 8.4 Hz, 
1H), 5.33 (s, 1H), 3.71 (br s, 1H), 1.95 (s, 3H), 1.26 (s, 6H); 13C NMR (CDCl3): δ 142.2, 130.7, 
129.4, 127.6, 126.2, 123.4, 114.3, 108.6, 51.9, 30.9, 18.4.  
6-Bromo-1,2,2,4-tetramethyl-1,2-dihydroquinoline (75). Sodium hydride (4.5 g, 113.0 mmol) 
was added to dimethylformamide (190 mL) under a nitrogen atmosphere, and the mixture was 
cooled to 15 oC.  A solution of 74 (19.0 g, 75.3 mmol) in dimethylformamide (75 mL) was added 
dropwise, stirred for 30 min, and then methyl iodide (43 mL, 300 mmol) in dimethylformamide 
(75 mL) was added dropwise. The reaction was warmed to room temperature gradually and stir 
for 18 h. The crude reaction was added to water and extracted with ether (2 x 100 mL). The 
combined organic extracts were washed with saturated aqueous NaCl, dried (MgSO4) and 
concentrated to provide the 75 (16.4 g, 62 mmol, 82%) as a yellow oil. IR: 1488, 1406, 797 cm-1; 
1H NMR (CDCl3): δ 7.12 (d, J = 8.4 Hz, 1H), 7.11 (d, J = 2.4 Hz, 1H), 6.36 (d, J = 8.4 Hz, 1H), 
5.32 (d, J = 1.5 Hz, 1H), 2.76 (s, 3H), 1.95 (s, 3H), 1.29 (s, 6H); 13C NMR (CDCl3): δ 144.2, 
131.2, 130.9, 127.3, 125.8, 125.2, 125.2, 112.2, 108.4, 56.3, 30.7, 27.1, 18.5. 
7-Bromo-1,2,2,4-tetramethyl-1,2,3,4-tetrahydroquinolin-3-ol (76). A 1.0 M borane/THF 
solution (97.0 mmol, 98 mL) was added dropwise to an ice-cooled solution of 75 (13.0 g, 48.8 
mmol) in THF (250 mL), and the mixture was stirred at 15 oC for 6 h. A 1:1 solution of THF/H2O 
(60 mL) was added dropwise to the reaction mixture over 30 min, followed by dropwise addition 
of aqueous sodium hydroxide (3 N, 50 mL) for 30.0 min. To this mixture was added 30% 
aqueous hydrogen peroxide (16.0 mL) and stirring was continued at room temperature for 2 h. 
The crude reaction mixture was poured into water and extracted with ethyl acetate (3 x 150 mL). 
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The combined organic layers were washed with saturated aqueous NaHCO3, saturated aqueous 
NaCl and dried (anhydrous Na2SO4). The solvent was evaporated under reduced pressure, and the 
residue was purified by flash chromatography (hexane/ethyl acetate 7:3) to afford 76 as a 
colorless oil (7.9 g, 27.8 mmol, 57%), IR: 3406, 1589, 1490 cm-1; 1H NMR (CDCl3): δ 7.24 (d, J 
= 2.4 Hz, 1H), 7.17 (dd, J = 8.8, 2.4 Hz, 1H), 6.47 (d, J = 8.8 Hz, 1H), 3.27 (d, J = 9.36 Hz, 1H), 
2.79 (s, 6H), 2.76-2.68 (m, 1H); 1.90 (br s, 1H), 1.41 (d, J = 10.5 Hz, 3H), 1.36 (s, 6H), 1.01 (s, 
3H); 13C NMR (CDCl3): δ 144.3, 129.9, 129.7, 128.2, 113.8, 109.0, 58.0, 36.1, 31.6, 24.9, 18.1, 
17.0. 
6-Bromo-1,2,2,4,4-pentamethyl-1,4-dihydroquinolin-3(2H)-one (78). DMSO (2.3 mL, 31.7 
mmol) was added dropwise to a solution of oxalyl chloride (1.4 mL, 17.3 mmol) in 
dichloromethane (60 mL) at -60 oC, and the resultant solution was stirred for 10 min.  This 
solution was transferred via syringe to a solution of 76 (4.1 g, 14.4 mmol) in dichlormethane (60 
mL) at -60 oC. The mixture was stirred for 15 min, before triethylamine (10 mL, 72.0 mmol) was 
added dropwise over 15 min. The reaction was stirred 1 h and quenched by dropwise addition of 
water (20 mL). The mixture was stirred with warming to room temperature, and the layers were 
separated. The organic layer was washed with water (2 x 20 mL), dried (MgSO4) and 
concentrated to give 77. The crude obtained was used directly for next step without further 
purification. 
To a solution of 77 in THF (20 mL) was added dropwise 26% lithium bis(trimethylsilyl)amide in 
THF (25 mL, 38.0 mmol) over 10 min at -50 oC. The reaction was warmed to -20 oC and 
iodomethane (2.4 mL, 38.0 mmol) in THF (20 mL) was added dropwise, and stirring was 
continued with warming to room temperature for 3 h. The reaction mixture was poured into ice-
cold water and extracted with ethyl acetate (2 x 50 mL). The combined organic layers were 
washed with saturated aqueous NaCl and dried (anhydrous Na2SO4). Concentration under 
vacuum, purification by column chromatography (hexanes/ethyl acetate 3:2) gave 78 (2.6 g, 8.9 
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mmol, 62%) as a colorless oil. IR: 1719, 1486   cm-1; 1H NMR (CDCl3): δ 7.33 (dd, J = 8.6, 2.3 
Hz, 1H), 7.29 (d, J = 2.3 Hz, 1H), 6.08 (d, J = 8.6 Hz, 1H), 2.83 (s, 3H), 1.45 (s, 6H), 1.28 (s, 
6H); 13C NMR (CDCl3): δ 214.4, 144.6, 132.7, 130.4, 127.5, 115.7, 112.4, 64.2, 47.6, 30.9, 23.3, 
22.9. 
6-Amino-1,2,2,4,4-pentamethyl-1,4-dihydroquinolin-3(2H)-one (79). Into a 250 mL Chem-
glass pressure vessel (No. CG-1880-R-03) was added 78 (1.9 g, 6.42 mmol), copper iodide (0.61 
g, 3.2 mmol), L-proline (0.74 g, 6.42 mmol), dimethylformamide (4.0 mL) and aqueous ammonia 
(19.0 mL). The reaction mixture was heated to 110 oC for 24 h and then cooled to room 
temperature and quenched with water (200 mL). The resulting mixture was extracted with ethyl 
acetate (3 x 100 mL) and the extract was dried (MgSO4), concentrated under vacuum and purified 
by column chromatography to give 78 (0.9 g, 3.9 mmol, 65%) as a brown oil. IR: 3422, 3357, 
1711, 1501    cm-1; 1H NMR (CDCl3): δ 7.66-7.60 (m, 3H), 3.35 (br s, 2H), 2.78 (s, 3H), 1.44 (s, 
6H), 1.25 (s, 6H); 13C NMR (CDCl3): δ 215.8, 139.6, 138.6, 132.0, 115.0, 114.5, 112.7, 64.3, 
47.7, 31.0, 23.0. 
General procedure to synthesize 80(a-f). To a stirred solution of 79 (0.2 g, 0.86 mmol) in 
tetrahydrofuran (5 mL), was added iso(thio)cyanates 71a-f (0.86 mmol) in tetrahydrofuran (2 mL) 
dropwise at room temperature under a nitrogen atmosphere. The reaction was stirred until TLC 
analysis indicate the complete consumption of 57. The solvent was evaporated under vacuum, 
purified by column chromatography, and crystallized from ether in pentane (3:7) to afford the    
80a-f. 
1-(4-Nitrophenyl)-3-(1,2,2,4,4-pentamethyl-3-oxo-1,2,3,4-tetrahydroquinolin-6-yl)thiourea 
(80a). Yield: 0.23 g (0.56 mmol, 65%) as a yellow solid, mp 145-147 oC; IR: 3308, 1715, 1532, 
1498, 1332 cm-1; 1H NMR (CDCl3): δ 8.20 (d, J = 8.7 Hz, 2H), 7.83 (s, 1H), 7.75 (d, J = 8.7 Hz, 
2H), 7.69 (s, 1H), 7.21 (dd, J = 8.6, 2.4 Hz, 1H), 7.14 (d, J = 2.4 Hz, 1H), 6.88 (d, J = 8.5 Hz, 
1H), 2.91 (s, 3H), 1.45 (s, 6H), 1.32 (s, 6H); 13C NMR (CDCl3): δ 213.6, 179.4, 145.7, 144.5, 
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144.0, 132.7, 127.0, 125.7, 124.5, 123.0, 122.8, 115.1, 64.4, 47.7, 31.1, 23.7, 23.0; Anal. Calcd. 
for C21H24N4O3S: C, 61.15; H, 5.86; N, 13.58. Found: C, 61.38; H, 5.52; N, 13.37. 
1-(1,2,2,4,4-Pentamethyl-3-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-3-(4-
trifluoromethyl)phenyl)thiourea (80b). Yield: 0.25 g (0.58 mmol, 67%) as a brown solid, mp 
149-151 oC; IR: 3291, 3206, 1716, 1615, 1324 cm-1; 1H NMR (CDCl3): δ 7.88 (s, 1H), 7.65 (s, 
1H), 7.60 (s, 4H), 7.22 (dd, J = 8.5, 2.6 Hz, 1H), 7.15 (d, J = 2.4 Hz, 2H), 7.15 (d, J = 8.5 Hz, 
1H), 2.90 (s, 6H), 1.48 (s, 6H), 1.32 (s, 6H); 13C NMR (CDCl3): δ 214.0, 179.8, 145.3, 141.1, 
132.3, 126.05 (q, J = 1.2 Hz), 125.6, 124.1, 123.9 (q, J = 272.0 Hz), 122.7, 115.0, 64.4, 47.6, 
31.1, 23.6, 23.0. Anal. Calcd. for C22H24F3N3OS: C, 60.67; H, 5.55; N, 13.09. Found: C, 60.94; H, 
5.23; N, 13.28. 
1-(1,2,2,4,4-Pentamethyl-3-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-3-(4-
(trifluoromethoxy)phenyl)thiourea (80c). Yield: 0.24 g (0.52 mmol, 60%) as a brown solid; mp 
83-85 oC; IR: 3291, 3213, 1716, 1501 cm-1; 1H NMR (CDCl3): δ 7.70 (s, 1H), 7.52 (s, 1H), 7.47 
(d, J = 8.7, 2.0 Hz, 2H), 7.24-7.20 (m, 3H), 7.15 (d, J = 2.4 Hz, 1H), 6.85 (d, J = 8.5 Hz, 1H), 
2.89 (s, 3H), 1.48 (s, 6H), 1.31 (s, 6H); 13C NMR (CDCl3): δ 214.0, 147.1, 145.3, 136.4, 132.2, 
128.0 (q, J = 2.4 Hz), 126.5, 125.9, 122.9, 121.6, 121.1 (q, J = 257.3 Hz), 114.9, 64.4, 47.6, 31.0, 
23.6, 23.0. Anal. Calcd. for C22H24F3N3O2S: C, 58.52; H, 5.36; N, 9.31. Found: C, 58.29; H, 5.12; 
N, 9.07. 
1-(4-Nitrophenyl)-3-(1,2,2,4,4-pentamethyl-3-oxo-1,2,3,4-tetrahydroquinolin-6-yl) urea 
(80d). Yield: 0.25 g (0.64 mmol, 74%) as an orange solid, mp 200-201 oC; IR (nujol): 1718, 
1655, 1556 cm-1; 1H NMR (DMSO-d6): δ 9.35 (s, 1H), 8.73 (s, 1H), 8.18 (d, J = 8.0 Hz, 2H), 7.68 
(d, J = 8.0 Hz, 1H), 7.35 (s, 1H), 7.31 (d, J = 8.8 Hz, 1H), 6.82 (d, J = 8.6 Hz, 1H), 2.79 (br s, 
1H), 1.39 (s, 6H), 1.20 (s, 6H); 13C NMR (DMSO-d6): δ 151.5, 146.0, 140.4, 140.2, 131.1, 129.6, 
124.5, 118.2, 116.7, 115.4, 113.7, 63.1, 46.5, 30.2, 22.2; Anal. Calcd. for C21H24N4O4: C, 63.62; 
H, 6.10; N, 14.13. Found: C, 63.39; H, 6.26; N, 14.27. 
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1-(1,2,2,4,4-Pentamethyl-3-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-3-(4-
(trifluoromethyl)phenyl) urea (80e). Yield: 0.28 g (0.67 mmol, 78%) as a brown solid, mp 198-
199 oC; IR (nujol): 3328, 1720, 1656 cm-1; 1H NMR (DMSO-d6): δ 9.01 (s, 1H), 8.61 (s, 1H), 
7.63 (q, J = 9.3 Hz, 4H), 7.32 (d, J = 2.4 Hz, 1H), 7.30 (dd, J = 8.5, 2.4 Hz, 1H), 6.80 (d, J = 8.6 
Hz, 1H), 2.79 (s, 3H), 1.39 (s, 6H), 1.19 (s, 6H); 13C NMR (DMSO-d6): δ 213.7, 152.1, 141.8, 
140.0, 138.7, 131.6, 129.6, 121.1, 119.6 (q, J = 255.2 Hz), 118.6, 117.9, 115.2, 113.7, 63.1, 46.5, 
30.2, 22.1; Anal. Calcd. for C22H24F3N3O2: C, 63.00; H, 5.77; N, 10.02. Found: C, 63.12; H, 5.59; 
N, 10.29. 
1-(1,2,2,4,4-Pentamethyl-3-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-3-(4-
(trifluoromethoxy)phenyl)urea (80f). Yield: 0.27 g (0.62 mmol, 72%) as a brown solid, mp 
191-192 oC; IR (nujol): 3318, 1716, 1648 cm-1; 1H NMR (DMSO-d6): δ 8.78 (s, 1H), 8.52 (s, 1H), 
7.54 (d, J = 8.5 Hz, 2H), 7.32 (d, J = 8.5 Hz, 2H), 7.27-7.25 (m, 3H), 6.79 (d, J = 8.6 Hz, 1H), 
2.82 (s, 3H), 1.38 (s, 6H), 1.19 (s, 6H); 13C NMR (CDCl3): δ 213.7, 151.8, 143.1, 140.1, 131.4, 
129.6, 125.5, 125.4 (q, J = 3.5 Hz), 124.0 (q, J = 272.4 Hz), 118.1, 117.1, 115.3, 113.7, 63.1, 
46.5, 30.2, 22.2; Anal. Calcd. for C22H24F3N3O3: C, 60.68; H, 5.56; N, 9.65. Found: C, 60.79; H, 
5.76; N, 9.83. 
General procedure to synthesize 82(a-f). To a stirred solution of 79 (0.2 g, 0.86 mmol) in 
tetrahydrofuran (10 mL) was added potion-wise lithium aluminum hydride (65.0 mg, 1.72 mmol) 
at 0 oC. The reaction was stirred at room temperature for 4 h, quenched with saturated sodium 
sulfate solution at 0 oC, filtered through Celite® and washed with ethyl acetate (20 mL). The 
organic layer was washed with water (20 mL), saturated aqueous NaCl (20 mL), dried (anhydrous 
Na2SO4) and concentrated to give 81 as a brown oil. The residue was dissolved in tetrahydrofuran 
(5 mL) and added dropwise at room temperature to iso(thio)cyanate 71a-f (0.86 mmol) in 
tetrahydrofuran. After TLC analysis indicated the disappearance of 56, the reaction mixture was 
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concentrated under vacuum and purified by column chromatography. Concentration of the major 
fraction and crystallization from dichloromethane/ether mixture (2:8, 7 mL) afforded 82a-f.  
1-(3-Hydroxy-1,2,2,4,4-pentamethyl-1,2,3,4-tetrahydroquinolin-6-yl)-3-(4-
nitrophenyl)thiourea (82a). Yield: 0.22 g (0.53 mmol, 62%) as a yellow solid, mp 161-163 oC; 
IR (nujol): 3444, 1645, 1377 cm-1; 1H NMR (DMSO-d6): δ 10.01 (s, 1H), 10.02 (s, 1H), 8.17 (d, J 
= 8.7 Hz, 2H), 7.81 (d, J = 8.7 Hz, 2H), 7.23 (s, 1H), 7.13 (d, J = 8.7 Hz, 1H), 6.54 (d, J = 8.8 Hz, 
1H), 5.21 (d, J = 6.3 Hz, 1H), 3.23 (d, J = 6.4 Hz, 1H), 2.74 (s, 3H),1.25 (s, 6H), 1.15 (s, 3H), 
1.09 (s, 3H); 13C NMR (DMSO-d6): δ 177.9, 146.0, 141.4, 141.3, 131.5, 127.4, 123.7, 122.2, 
121.3, 120.5, 110.9, 77.9, 57.9, 37.1, 31.0, 28.5, 26.8, 22.9, 17.9; Anal. Calcd. for C21H26N4O3S: 
C, 60.85; H, 6.32; N, 13.52. Found: C, 60.58; H, 6.42; N, 13.71. 
1-(3-Hydroxy-1,2,2,4,4-pentamethyl-1,2,3,4-tetrahydroquinolin-6-yl)-3-(4-
(trifluoromethyl)phenyl)thiourea (82b). Yield: 0.23 g (0.52 mmol, 60%) as a brown solid, mp 
105-107 oC; IR: 3345, 1615, 1501, 1067 cm-1; 1H NMR (DMSO-d6): δ 9.79 (s, 2H), 7.73 (d, J = 
8.5 Hz, 2H), 7.64 (d, J = 8.5 Hz, 2H), 7.20 (s, 1H), 7.11 (d, J = 8.7 Hz, 1H), 6.53 (d, J = 8.7 Hz, 
1H), 5.20 (d, J = 6.4 Hz, 1H), 3.23 (d, J = 6.4 Hz, 1H), 2.74 (s, 3H), 1.25 (s, 3H), 1.24 (s, 3H), 
1.15 (s, 3H), 1.09 (s, 3H); 13C NMR (DMSO-d6): δ 178.4, 143.1, 141.3, 131.5, 127.6, 124.8 (q, J 
= 3.6 Hz), 123.9 (q, J = 252.2 Hz), 122.4, 121.9, 121.5, 110.9, 77.9, 57.9, 37.1, 31.0, 28.5, 26.8, 
22.9, 17.8; Anal. Calcd. for C22H26F3N3OS: C, 60.39; H, 5.99; N, 9.60. Found: C, 60.28; H, 6.12; 
N, 9.47. 
1-(3-Hydroxy-1,2,2,4,4-pentamethyl-1,2,3,4-tetrahydroquinolin-6-yl)-3-(4-
(trifluoromethoxy)phenyl)thiourea (82c). Yield: 0.24 g (0.52 mmol, 60%) as a brown solid, mp 
97-99 oC; IR: 3419, 1605, 1501, 1376 cm-1; 1H NMR (DMSO-d6): δ 9.62 (s, 1H), 9.55 (s, 1H), 
7.57 (d, J = 8.6 Hz, 2H), 7.29 (d, J = 8.5 Hz, 2H), 7.17 (s, 1H), 7.08 (d, J = 8.5 Hz, 1H), 6.52 (d, J 
= 8.8 Hz, 1H), 5.19 (d, J = 6.4 Hz, 1H), 3.22 (d, J = 6.4 Hz, 1H), 2.73 (s, 3H), 1.25 (s, 3H), 1.24 
(s, 3H), 1.14 (s, 3H), 1.09 (s, 3H); 13C NMR (DMSO-d6): δ 179.82, 144.75, 142.35, 139.50, 
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132.59, 128.69, 125.49, 123.65, 122.74, 121.46, 121.33 (q, J = 255.5 Hz), 112.01, 79.02, 58.93, 
38.21, 32.03, 29.57, 27.82, 23.94, 18.92; Anal. Calcd. for C22H26F3N3O2S: C, 58.26; H, 5.78; N, 
9.27. Found: C, 58.34; H, 5.57; N, 9.31. 
1-(3-Hydroxy-1,2,2,4,4-pentamethyl-1,2,3,4-tetrahydroquinolin-6-yl)-3-(4-nitrophenyl)urea 
(82d). Yield: 0.27 g (0.69 mmol, 80%) as a yellow solid, mp 215-217 oC; IR: 3473, 3251, 1659, 
1556 cm-1; 1H NMR (DMSO-d6): δ 9.27 (s, 1H), 8.51 (s, 1H), 8.17 (d, J = 8.7 Hz, 2H), 7.67 (d, J 
= 8.8 Hz, 2H), 7.27 (s, 1H), 7.11 (d, J = 8.6 Hz, 1H), 6.51 (d, J = 8.8 Hz, 1H), 5.17 (d, J = 6.4 Hz, 
1H), 3.23 (d, J = 6.4 Hz, 1H), 2.71 (s, 3H), 1.26 (s, 3H), 1.23 (s, 3H), 1.16 (s, 3H), 1.06 (s, 3H); 
13C NMR (DMSO-d6): δ 151.5, 146.2, 140.0, 139.8, 132.1, 128.0, 124.5, 117.9, 117.1, 116.5, 
111.4, 78.2, 57.7, 37.2, 30.9, 28.8, 26.5, 22.9, 17.6; Anal. Calcd. for C21H26N4O4: C, 63.30; H, 
6.58; N, 14.06. Found: C, 63.62; H, 6.81; N, 14.16. 
1-(3-Hydroxy-1,2,2,4,4-pentamethyl-1,2,3,4-tetrahydroquinolin-6-yl)-3-(4-
(trifluoromethyl)phenyl)urea (82e). Yield: 0.26 g (0.61 mmol, 71%) as a brown solid; mp 213-
215 oC; IR: 3308, 1647, 1605 cm-1; 1H NMR (DMSO-d6): δ 8.92 (s, 1H), 8.38 (s, 1H), 7.64 (d, J = 
8.7 Hz, 2H), 7.60 (d, J = 8.7 Hz, 2H), 7.25 (d, J = 2.3 Hz, 1H), 7.10 (dd, J = 8.7, 2.3 Hz, 1H), 
6.50 (d, J = 8.7 Hz, 1H), 5.16 (d, J = 6.4 Hz, 1H), 3.22 (d, J = 6.4 Hz, 1H), 2.70 (s, 3H), 1.26 (s, 
3H), 1.22 (s, 3H), 1.16 (s, 3H), 1.06 (s, 3H); 13C NMR (DMSO-d6): δ 151.9, 143.3, 139.6, 132.1, 
128.4, 125.4 (q, J = 4.4 Hz), 124.6 (q, J = 265.5 Hz), 117.7, 117.0, 116.9, 111.4, 78.2, 57.7, 37.2, 
30.9, 28.8, 26.5, 22.9, 17.6; Anal. Calcd. for C22H26F3N3O2: C, 62.70; H, 6.22; N, 9.97. Found: C, 
62.58; H, 6.48; N, 10.12. 
1-(3-Hydroxy-1,2,2,4,4-pentamethyl-1,2,3,4-tetrahydroquinolin-6-yl)-3-(4-
(trifluoromethoxy)phenyl)urea (82f). Yield: 0.25 g (0.57 mmol, 66%) as a brown solid, mp 
188-189 oC; IR: 3467, 3310, 1648, 1554 cm-1; 1H NMR (DMSO-d6): δ 8.68 (s, 1H), 8.28 (s, 1H), 
7.53 (d, J = 8.7 Hz, 2H), 7.26 (s, 1H), 7.23 (d, J = 8.7 Hz, 1H), 7.09 (dd, J = 8.7, 2.5 Hz, 1H), 
6.49 (d, J = 8.8 Hz, 1H), 5.16 (d, J = 6.4 Hz, 1H), 3.32 (s, 3H), 3.22 (d, J = 6.4 Hz, 1H) 2.70 (s, 
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3H), 1.26 (s, 3H), 1.22 (s, 3H), 1.16 (s, 3H), 1.05 (s, 3H); 13C NMR (DMSO-d6): δ 152.2, 139.5, 
138.9, 132.1, 128.7, 121.0, 119.6 (q, J = 255.1 Hz), 118.5, 117.7, 117.0, 111.5, 78.2, 57.7, 37.2, 
30.9, 28.8, 26.5, 22.9, 17.5; Anal. Calcd. for C22H26F3N3O3: C, 60.40; H, 5.99; N, 9.61. Found: C, 
60.28; H, 6.15; N, 9.38. 
1.6.5 Tethering bioactive molecules to S-Het-A2 rings 
General methods: Commercial anhydrous N,N-dimethylformamide was stored under dry N2 and 
transferred by syringe into reactions when needed. Tetrahydrofuran was dried over potassium 
hydroxide pellets and distilled from lithium aluminum hydride prior to use. All other commercial 
reagents and solvents were used as received. Unless otherwise indicated, all reactions were 
carried out under dry N2 in oven-dried glassware. Reactions were monitored by thin layer 
chromatography (TLC, Analtech No 21521) using silica gel GF plates. Preparative separations 
were performed by column chromatography on silica gel (Davisil®, grade 62, 60-200 mesh) 
containing UV-active phosphor (Sorbent Technologies No UV-05) slurry packed into quartz 
columns. Band elution for all chromatographic separations was monitored using a hand-held UV 
lamp. Melting points were uncorrected. IR spectra were run as chloroform solutions on NaCl 
disks or in nujol. The 1H- and 13C-NMR spectra were measured in the indicated solvent at 400 
MHz and 100 MHz, respectively, using tetramethylsilane as the internal standard with coupling 
constants (J) given in Hz. 
General methods to synthesize 84(a,b), 86(a,b), 88(a,b) and 91. To a stirred solution of the 
corresponding amino compound (0.5 mmol) in tetrahydrofuran (5 mL), was added 
iso(thio)cyanates 71a, 71d, 90 (0.5 mmol) in tetrahydrofuran (2 mL) dropwise at room 
temperature under nitrogen atmosphere. The reactions were stirred until TLC analysis indicated 
complete conversion of the amino compound. The solvent was evaporated under vacuum and 
each product was purified by column chromatography. The eluted products were stirred with 
ether/pentane (3:7) to afford the crystalline urea or thiourea derivatives. 
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1-(4-Nitrophenyl)-3-(quinolin-6-yl)urea (84a). Yield: 142 mg (0.46 mmol, 92%) as a yellow 
solid, mp 266-267 oC; IR: 3404, 1716, 1620, 1573, 1374 cm-1; 1H NMR (DMSO-d6): δ 9.56 (s, 
1H), 9.29 (s, 1H), 8.77 (d, J = 2.3 Hz, 1H), 8.29 (d, J = 8.4 Hz, 1H), 8.22 (d, J = 8.7 Hz, 3H), 7.98 
(d, J = 8.7 Hz, 1H), 7.74 (d, J = 8.8 Hz, 3H), 7.49 (dd, J = 6.5, 1.4 Hz, 1H); 13C NMR (DMSO-
d6): δ 152.5, 149.1, 146.7, 144.8, 141.6, 137.5, 135.7, 130.1, 128.9, 125.6, 123.5, 118.1, 114.25; 
Anal. Calcd. for C16H12N4O3: C, 62.33; H, 3.92; N, 18.17. Found: C, 62.18; H, 3.74; N, 17.98. 
1-(4-Nitrophenyl)-3-(quinolin-6-yl)thiourea (84b). Yield: 144 mg (0.44 mmol, 89%) as a 
yellow solid, mp 172-173 oC; IR: 3144, 1594, 1563, 1496, 1336 cm-1; 1H NMR (DMSO-d6): δ 
10.55 (d, J = 13.1 Hz, 2H), 8.85 (d, J = 4.1 Hz, 1H), 8.34 (d, J = 8.3 Hz, 1H), 8.23 (d, J = 8.9 Hz, 
3H), 8.11 (s, 1H), 8.0 (d, J = 9.0 Hz, 1H), 7.89-7.85 (m, 3H), 7.52 (dd, J = 8.2, 4.1 Hz, 1H); 13C 
NMR (DMSO-d6): δ 180.1, 150.3, 146.6, 145.9, 142.9, 137.5, 136.1, 129.6, 128.5, 124.9, 122.3, 
122.2, 120.8; Anal. Calcd. for C16H12N4O2S: C, 59.25; H, 3.73; N, 17.27. Found: C, 59.18; H, 
3.76; N, 17.48. 
1-(1H-Indol-5-yl)-3-(4-nitrophenyl)urea (86a). Yield: 141 mg (0.48 mmol, 95%) as a yellow 
solid, mp 243-244 oC; IR: 3329, 1685, 1636, 1598, 1567, 1375 cm-1; 1H NMR (DMSO-d6): δ 
10.99 (s, 1H), 9.35 (s, 1H), 8.66 (s, 1H), 8.18 (d, J = 8.8 Hz, 2H), 7.70-7.68 (m, 3H), 7.32 (d, J = 
8.5 Hz, 2H), 7.10 (d, J = 8.7 Hz, 1H), 6.37 (s, 1H); 13C NMR (DMSO-d6): δ 152.7, 147.3, 141.1, 
133.1, 131.1, 128,1, 126.4, 125.6, 117.7, 115.4, 111.8, 111.0, 101.4; Anal. Calcd. for C15H12N4O3: 
C, 60.81; H, 4.08; N, 18.91. Found: C, 60.63; H, 4.12; N, 19.04. 
1-(1H-Indol-5-yl)-3-(4-nitrophenyl)thiourea (86b). Yield: 140 mg (0.45 mmol, 90%) as a 
yellow solid, mp 171-172 oC; IR: 3451, 3421, 1586, 1512, 1375 cm-1; 1H NMR (DMSO-d6): δ 
11.14 (s, 1H), 10.18 (s, 1H), 10.12 (s, 1H), 8.18 (d, J = 8.6 Hz, 2H), 7.86 (d, J = 8.6 Hz, 2H), 7.58 
(s, 1H), 7.40 (s, 1H), 7.37 (s, 1H), 7.09 (d, J = 8.8 Hz, 1H), 6.44 (s, 1H); 13C NMR (DMSO-d6): δ 
179.9, 147.2, 142.5, 134.5, 130.7, 128.1, 126.7, 124.7, 122.0, 119.6, 116.7, 111.9, 101.8; Anal. 
Calcd. for C15H12N4O2S: C, 57.68; H, 3.87; N, 17.94. Found: C, 57.82; H, 3.92; N, 18.04. 
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1-(Benzo[d]oxazol-6-yl)-3-(4-nitrophenyl)urea (88a).  Yield: 142 mg (0.48 mmol, 95%) as a 
brown solid, mp 255-257 oC; IR: 3356, 3269, 1654, 1556, 1335 cm-1; 1H NMR (DMSO-d6): δ 
9.51 (s, 1H), 9.22 (s, 1H), 8.65 (s, 1H), 8.21 (d, J = 8.8 Hz, 2H), 8.09 (s, 1H), 7.72 (d, J = 8.5 Hz, 
3H), 7.31 (d, J = 8.7 Hz, 1H); 13C NMR (DMSO-d6): δ 154.1, 152.5, 150.2, 146.7, 141.6, 137.6, 
135.2, 125.6, 120.4, 118.0, 116.7, 101.5; Anal. Calcd. for C14H10N4O4: C, 56.38; H, 3.38; N, 
18.79. Found: C, 56.45; H, 3.11; N, 18.94. 
1-(Benzo[d]oxazol-6-yl)-3-(4-nitrophenyl)thiourea (88b). Yield: 141 mg (0.45 mmol, 90%) as 
a yellow solid, mp 166-167 oC; IR: 3147, 1596, 1553, 1374 cm-1; 1H NMR (DMSO-d6): δ 10.45 
(d, J = 6.8 Hz, 2H), 8.74 (s, 1H), 8.22 (d, J = 8.8 Hz, 2H), 8.04 (s, 1H), 7.85 (d, J = 8.9 Hz, 2H), 
7.78 (d, J = 8.5 Hz, 1H), 7.41 (d, J = 8.7 Hz, 1H); 13C NMR (DMSO-d6): δ 179.1, 154.0, 148.6, 
145.6, 141.8, 136.3, 136.1, 123.8, 121.2, 120.8, 119.1, 106.3; Anal. Calcd. for C14H10N4O3S: C, 
53.50; H, 3.21; N, 17.83. Found: C, 53.67; H, 3.43; N, 18.10.  
1-(Furan-2-ylmethyl)-3-(2,2,4,4-tetramethylthiochroman-6-yl)thiourea (91). Yield: 148 mg 
(0.41 mmol, 82%) as a yellow solid; mp 164-166 oC; IR: 3386, 1532, 1475 cm-1; 1H NMR 
(DMSO-d6): δ (ppm) 7.61 (s, 1H), 7.33 (dd, J = 1.7, 0.8 Hz, 2H), 7.21 (d, J = 2.3 Hz, 1H), 7.15 
(d, J = 8.3 Hz, 1H), 6.32-6.31 (m, 1H), 6.28 (dd, J = 3.2, 0.6 Hz, 3H), 6.21 (t, J = 5.3 Hz, 1H), 
4.85 (d, J = 5.2 Hz, 1H), 1.94 (s, 2H), 1.42 (s, 6H), 1.33 (s, 6H); 13C NMR (DMSO-d6): δ 180.5, 
150.2, 144.8, 142.4, 132.8, 132.4, 129.5, 124.1, 122.9, 110.5, 108.2, 53.8, 42.5, 42.3, 35.8, 32.5, 
31.6; Anal. Calcd. for C19H24N2OS2: C, 63.30; H, 6.71; N, 7.77. Found: C, 63.47; H, 6.53; N, 
7.89.  
2-((2,2,4,4-Tetramethylthiochroman-6-yl)carbamoyl)phenyl acetate (93). To a stirred solution 
of acetyl salicylic acid 92 (90 mg, 0.5 mmol) in N,N-dimethylformamide (5 mL) was added 
DIPEA (261 µL, 1.5 mmol), EDC.HCl (105 mg, 0.55 mmol), and HOBt (74 mg, 0.55 mmol). 
After stirring for 1 h at room temperature, 89 (110 mg, 0.5 mmol) in N,N-dimethylformamide (2 
mL) was added dropwise. The resulting mixture was stirred at room temperature for 12 h. The 
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reaction mixture was poured into ice (approx. 50 g) and was stirred for 30 min. The aqueous layer 
was then extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed 
with saturated aqueous NaCl (2 x 50 mL), dried (MgSO4), and concentrated under vacuum to 
afford the corresponding crude amide 93. It was purified by silica gel column chromatography 
eluted with hexanes:ethyl acetate (1:1) to afford the pure amide 93 (167 mg, 0.43 mmol, 87%) as 
a white solid; mp 130-132 oC; IR: 3307, 1767, 1659, 1525 cm-1; 1H NMR (CDCl3): δ 7.96 (s, 1H), 
7.86 (dd, J = 7.9, 1.8 Hz, 1H), 7.73 (d, J = 2.3 Hz, 1H), 7.52 (td, J = 7.9, 1.8 Hz, 1H), 7.37 (t, J = 
7.6 Hz, 1H), 7.26 (dd, J = 8.0, 2.5 Hz, 1H), 7.16 (dd, J = 8.0, 2.5 Hz, 1H), 7.12 (d, J = 8.4 Hz, 
1H), 2.35 (s, 3H), 1.96 (s, 2H), 1.42 (s, 6H), 1.41 (s, 6H); 13C NMR (CDCl3): δ 169.3, 163.5, 
147.8, 143.7, 135.1, 132.1, 129.9, 128.8, 128.6, 126.6, 123.3, 118.6, 118.1, 54.3, 42.2, 35.8, 32.5, 
31.6, 21.1; Anal. Calcd. for C22H25NO3S C, 68.90; H, 6.57; N, 3.65. Found: C, 69.13; H, 6.23; N, 
3.31.  
1-(4-Aminophenyl)-3-(2,2,4,4-tetramethylthiochroman-6-yl)thiourea (95). To a stirred 
solution of S-Het-A2 (0.45 g, 1.3 mmol) and iron powder (0.39 g, 7.02 mmol) in an ethanol:water 
mixture (4:1, 20 mL) was added NH4Cl (0.14 g, 2.6 mmol), and the resulting mixture was 
refluxed for 4 h. The reaction mass was cooled to room temperature and filtered through a bed of 
Celite®. The Celite® was washed with ethanol (3 x 20 mL), and the solution was concentrated 
under vacuum at 45 oC to give a yellow solid. The crude product was purified by silica gel 
column chromatography eluted with dichloromethane:ethyl acetate (7:3) to afford 95 (0.46 g, 
1.23 mmol, 95%) as a yellow solid, mp 156-157 oC; IR: 3309, 3190, 1334 cm-1; 1H NMR 
(CDCl3): δ 8.21 (d, J = 8.7 Hz, 2H), 8.03 (s, 1H), 7.80 (s, 1H), 7.75 (d, J = 8.7 Hz, 2H), 7.32 (s, 
1H), 7.22 (d, J = 8.3 Hz, 1H), 7.02 (d, J = 8.3 Hz, 1H), 1.98 (s, 2H), 1.45 (s, 6H), 1.40 (s, 6H); 
13C NMR (CDCl3): δ 179.0, 145.2, 144.6, 143.9, 134.2, 132.0, 129.7, 124.6, 124.2, 123.1, 122.9, 
53.7, 42.5, 35.9, 32.5, 31.6. Anal. Calcd for C20H25N3S2: C, 64.65; H, 6.78; N, 11.31. Found: C, 
64.81; H, 6.98; N, 11.42. 
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CHAPTER II 
 
METAL FREE SYNTHETIC APPROACHES TO BIOACTIVE MOLECULES 
2.1 Introduction 
In recent years, the use of transition metals has dominated organic synthesis to a greater extent. 
This overuse of rare metals in organic reactions, would result in depletion of natural resources as 
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well as generation of more toxic waste that could destroy the environment for future generations. 
Though transition metals have helped to achieve some useful transformations that were 
impossible 50 years ago, our work has cast doubt on the necessity of metals in certain organic 
reactions these catalysts often require special purification technique to remove them from 
products as well. Viable alternatives that could minimize or avoid the usage of metals catalysts 
are needed to protect reserves of precious metals and to simplify purification procedures. 
Improvement in the synthetic methodology attempted on sildenafil citrate is noteworthy. 
Sildenafil citrate is an active ingredient in ViagraTM and RevatioTM. ViagraTM  needs no 
introduction, in its first year on the market it achieved sales of $1 billion.50 RevatioTM is an 
important medicine to treat pulmonary hypertension in adults and children. The alternative 
strategy of developing new synthetic routes to avoid tin(II) chloride in the synthesis eliminated 
30,000 tons of chemical waste between 1997 and 2003.51  
Our research group, is involved primarily in synthesizing new drug molecules as anti-cancer and 
anti-bacterial agents. However, we also have expertise in developing cost effective and atom 
efficient synthetic approaches to bioactive molecules such as quinolinones, quinazolinones, 
napthyridinones, chromanes and many others. As a part of this dissertation work, new methods 
have been developed to prepare isoquinolin-1(2H)-ones, 1,6-naphthyridin-5(6H)-ones, 
pyrazoloquinazolinones, pyrazolo- pyridopyrimidinones, benzo[4,5]imidazo[2,1-b]quinazolin-12-
ones, benzo[4,5]imidazo[1,2-a]pyrido[2,3-d]pyrimidin-5-ones, 1,3,4-oxadiazoles and 4-
chromanones as well as adding nucleophiles across polarized vinyl arenes. 
These methods were developed in an economically viable and atom efficient manner thereby 
providing an alternative strategy to access these bioactive motifs without using metals in the 
reaction procedure. Adopting these methods will definitely reduce the chemical waste to a greater 
extent and also simplify the isolation process. Initially, we adopted the nucleophilic aromatic 
substitution reaction (SNAr) strategy to prepare isoquinolin-1(2H)-ones in an excellent yield. 
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Encouraged by this result, we extended the method to prepare pyrazoloquinazolinones, pyrazolo-
pyridopyrimidinones, benzo[4,5]imidazo[2,1-b]quinazolin-12-ones and benzo[4,5]imidazo[1,2-
a]pyrido[2,3-d]pyrimidin-5-ones. 
The SNAr reaction is a nucleophilic aromatic substitution proceeding via an addition-elimination 
mechanism. It has been known for more than 150 years, and its importance can be understood by 
its wide application in organic synthesis and industry.52 In this type of reaction, most commonly a 
halogen on an electron deficient arene is replaced by a nucleophile. For a nucleophilic aromatic 
substitution reaction to occur, electron-withdrawing groups must be positioned ortho or para to 
the halogen. The greater the number of electron-withdrawing substituents, the more easily the 
nucleophilic aromatic substitution takes place (Figure 2.1).  
 
Figure 2.1. General Mechanism for SNAr reaction 
A general mechanism for the SNAr reaction is depicted in Figure 2.1. It is a two-step process. The 
first step is the slow step and involves nucleophilic attack on the carbon bearing the halogen to 
form a resonance-stabilized carbanion intermediate called a Meisenheimer complex. The next 
step is the fast step, the elimination of the halogen to restore aromaticity.53 The order of reactivity 
is fluoride > chloride > bromide > iodide.  
2.2 Results and Discussion 
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2.2.1 Isoquinolin-1(2H)-ones and 1,6-naphthyridin-5(6H)-ones 
The current study was undertaken with the goal of providing an expeditious route to 2,3-dialkyl-
4-methoxycarbonylisoquinolin-1(2H)-ones and 6,7-dialkyl-8-methoxycarbonyl-1,6-naphthyridin-
5(6H)-ones. Several 4-ethoxycarbonylisoquinolin-1(2H)-ones have previously been prepared 
from homophthalic acid54-58 and 2-bromobenzoic acid derivatives.59-62 While the syntheses 
described were reasonably short (2-3 steps), the yields were often quite low (35-50%). These 
compounds are known to have significant potential for the treatment of ulcers,63 inflammation-
based diseases64 and CNS disorders.59, 65 In contrast, 6,7-dialkyl-8-methoxycarbonyl-1,6-
naphthyridin-5(6H)-ones have been reported only once in 40-50% yields by a route that differs 
from the current work,66 and to the best of our knowledge, have not been evaluated for biological 
activity. 
Our synthetic approach is based upon earlier investigations by two groups. Horii and co-workers 
were the first to demonstrate the use of a tandem enamination-cyclization procedure between 
ethyl piperidineacetate and cyclohexanone to produce 1,2,3,4,4a,5,7,8,9,10-decahydro-6H-
benzo[c]quinolizin-6-one as a possible azasteroid precursor.67 Later, the Stille group disclosed a 
related aza-annulation sequence and applied it to the synthesis of several alkaloid targets.68-69 This 
process involved N-acylation of a conjugated enaminoester with acryloyl chloride, followed by 
intramolecular Michael addition of the enamine to the resulting acrylamide. In the current study, 
we have modified this process to utilize an electron-poor fluoroaromatic moiety to serve as the 
acceptor for the second stage of this process. This has led to an efficient synthesis of 2,3-dialkyl-
4-methoxycarbonylisoquinolin-1(2H)-ones and 6,7-dialkyl-8-methoxycarbonyl-1,6-naphthyridin-
5(6H)-ones. Based on the medicinal properties of previously reported derivatives in the 
isoquinoline series, this method could lead to new structures worthy of further development. 
Appropriate cyclization substrates were readily obtained from commercial sources or by standard 
synthetic procedures (Scheme 1). β-Ketoesters 1a-g70 were converted to β-enaminoesters 2a-g by 
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p-TsOH-catalyzed condensation with benzylamine in refluxing benzene with Dean-Stark removal 
of water. N-Methyl-β-enaminoester 2h was prepared by a literature procedure.71 Acids 3 and 6 
were converted to acid chlorides 4 and 7, respectively, using thionyl chloride in boiling benzene, 
while 2-fluorobenzoyl chloride (5) was commercially available.  
 
 
 
 
 
 
 
 
Scheme 2.1. Synthesis of the reaction substrates 
Our cyclization results are summarized in Tables 2.1 and 2.2. The reactions were performed by 
stirring enaminoesters 2a-h (2 equiv) with acid chloride 4 (1 equiv) in purified 1,2-dichloroethane 
(DCE) at 23 oC for 3 h, followed by addition of trimethylamine (TEA, 2 equiv) and heating at 
reflux for 12-18 h. Our experiments revealed that N-acylation of the enaminoester proceeded best 
at room temperature, while the final SNAr ring closure required heating. For substrates having a 
monoactivated aromatic acceptor, such as 5, reactions were performed similarly in purified 1,4-
dioxane72 using a pressure tube with 1,8-diazabicyclo[5.4.0] undec-7-ene (DBU) as the base (2 
equiv, 130 oC, 3 h) for the cyclization. Finally, reactions involving 2-chloronicotinoyl chloride (7) 
were achieved using the enaminoester (3 equiv) in DCE with TEA as the base (2 equiv, 130 oC, 8 
3 (X = NO2) 
 
 
 
4 (X = NO2) 
5 (X = H) 
 
 
 
6 7 
1a-g 
2a (R1 = CH3, R
2 = CH2Ph) 
2b (R1 = C2H5, R
2 = CH2Ph) 
2c (R1 = n-C3H7, R
2 = CH2Ph) 
2d (R1 = n-C5H11, R
2 = CH2Ph) 
2e (R1 = n-C4H7, R
2 = CH2Ph) 
2f (R1 = CH2CH2Ph, R
2 = CH2Ph) 
2g (R1 = i-C3H7, R
2 = CH2Ph) 
 
 
 
1a 2h 
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h). The use of anhydrous, purified solvents was essential, as the enaminoesters were both water 
and acid sensitive. Failure to remove these impurities from DCE and dioxane resulted in 
hydrolysis of the enamine to give benzylamine, which readily added to the SNAr acceptor ring, 
preempting the ring closure. The reaction was facilitated by the use of excess enamine. While 
TEA or DBU were found to be the best reagents for promoting the final cyclization, the use of 
these bases (or elevated temperatures) for the initial acylation had a negative impact on the 
overall yields. Upon completion, the crude reaction mixtures were added to aqueous NaCl and 
subjected to an extractive work-up. Purification was accomplished by chromatography followed 
by recrystallization. 
Some further discussion is warranted regarding the use of excess enaminoester 2 for these 
transformations. In heterocyclizations involving 4 and 5, 2 equiv of this reactant were necessary, 
with the second equivalent neutralizing the HCl produced during the acylation step. For reactions 
of 2-chloronicotinoyl chloride (7), however, it was found that 3 equiv of 2 were required for 
optimum conversion rather than two. This stems from the fact that 7 incorporates an extra 
equivalent of HCl due to the basic nitrogen of the pyridine, and this acid could sabotage the 
reaction sequence at several stages. Protonation at nitrogen significantly increases the C2 
reactivity of 2-chloropyridines toward nucleophiles,73 and thus, attack at this site could compete 
with the acylation process. Additionally, the 2-chloropyridinium cation could serve as a proton 
source [pKa ~ 0.48 (H2O)]74 to deactivate the enaminoester nitrogen or protonate the enamide 
double bond. Hence, it was important to neutralize this salt in addition to the HCl produced 
during enamide formation to decrease the probability of side reactions. This was most effectively 
accomplished by addition of 7 to a cooled solution containing 3 equiv of 2. The alternative use of 
bases, such as TEA or DBU during the acylation stage, was found to lower the overall product 
yields. Inorganic bases were not explored since reaction of these with HCl would produce water, 
which could degrade both reactants. The delocalized enaminoesters have base properties 
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intermediate between 2-chloropyridine and TEA and scavenge the acid without introducing 
additional contaminants. They are easily prepared from inexpensive commercial chemicals and 
do not require purification prior to reaction. Moreover, in applications where the precursor 
ketoester is costly or demands independent synthesis, the required use of surplus 2 is mitigated by 
the fact that much of this material can be recovered as the ketoester and recycled. 
 
Table 2.1 Cyclization results for 2,3-dialkyl-4-methoxycarbonylisoquinolin-(2H)-ones 
 
 
Entry R1 R2 X Conds Pdt Yield (%) 
a CH3 CH2Ph NO2 A 8a 86 
b C2H5 CH2Ph NO2 A 8b 85 
c n-C3H7 CH2Ph NO2 A 8c 77 
d n-C5H11 CH2Ph NO2 A 8d 74 
e 3-butenyl CH2Ph NO2 A 8e 68 
f CH2CH2Ph CH2Ph NO2 A 8f 81 
g i-C3H7 CH2Ph NO2 A 8g 30 
h CH3 CH3 NO2 A 8h 85 
a CH3 CH2Ph H B 9a 57 
b C2H5 CH2Ph H B 9b 52 
c n-C3H7 CH2Ph H B 9c 58 
d n-C5H11 CH2Ph H B 9d 50 
e 3-butenyl CH2Ph H B 9e 60 
f CH2CH2Ph CH2Ph H B 9f 73 
g i-C3H7 CH2Ph H B 9g 30 
2a-h 4 (X = NO2) 
5 (X = H) 
 
8a-h (X = NO2) 
9a-h (X = H) 
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h CH3 CH3 H B 9h 53 
 
 
 
 
Table 2.2 Cyclization results for 6,7-dialkyl-8-methoxycarbonyl-1,6-naphthyridin-5(6H)-ones 
 
 
Entry R1 R2 Pdt 
TEA 
Yield (%) 
DBU 
Yield (%) 
a CH3 CH2Ph 10a 70 59 
b C2H5 CH2Ph 10b 74 62 
c n-C3H7 CH2Ph 10c 76 68 
d n-C5H11 CH2Ph 10d 70 52 
e 3-butenyl CH2Ph 10e 70 61 
f CH2CH2Ph CH2Ph 10f 72 60 
g i-C3H7 CH2Ph 10g 0 0 
h CH3 CH3 10h 84 78 
 
As expected, cyclizations on aromatic acceptors with two electron-withdrawing groups or a 2-
chloropyridine generally proceeded in higher yields and under milder conditions. Monoactivated 
substrates required a stronger base and more robust thermal conditions. The sequence proved 
limited with respect to the steric environment adjacent to the nucleophilic enamine carbon. For 
example, branching at the α-carbon of R1, as in 2g, reduced the yields from mono- and diactivated 
substrates and completely suppressed cyclization for heteroaromatic systems. In these cases, 
2a-h
  
7 10a-h 
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degradation of the acylated enamine, presumably through elimination of the halogen from the 
acceptor ring, competed with cyclization. Substrates having straight-chain alkyl groups at R1, 
however, cyclized in good to excellent yields for all aromatic acceptors investigated, making this 
a viable approach to these highly functionalized heterocycles. Though most of our work was done 
using the N-benzyl-β-enaminoesters (e.g., R2 = benzyl), two reactions with the N-methyl 
derivative 2h were equally successful. Thus, variation of both R1 and R2 can be used to introduce 
substituent diversity to these systems. 
 
Scheme 2.2. Presumed mechanism for the formation of 8a 
A possible mechanism is illustrated in Scheme 2.2 for the reaction of 2a with 4. In the initial step, 
the enaminoester 2a is N-acylated by acid chloride 4 to give 11. This would be followed by attack 
of the N-acyl-β-enaminoester on the aromatic acceptor to generate the fused ring system 12. 
Rearomatization, with loss of fluoride, would then give the 2,3-dialkyl-4-methoxycarbonyl-7-
nitroisoquinolinium-1(4H)-one intermediate 13. In the final step, base (TEA or DBU) would 
remove the acidic proton from the ester-substituted benzylic carbon to convert 13 to the final 
product 8a. 
2.2.2 Conclusion 
In conclusion, we have developed a practical and efficient approach for the synthesis of 2,3-
dialkyl-4-methoxycarbonylisoquinoline-1(2H)-one and 6,7-dialkyl-8-methoxycarbonyl-1,6-
4 2a 8a 
11
  
12 13 
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naphthyridin-5(6H)-ones using a sequential N-acylation-SNAr process. The method involved 
room temperature N-acylation of readily available enaminoesters 2a-h with 2-fluoro-5-
nitrobenzoyl chloride, 2-fluorobenzoyl chloride, and 2-chloronicotinoyl chloride followed by 
heating to promote the final SNAr ring closure. Yields were generally in the 52-86% range. The 
reaction proceeded smoothly for mono- and diactivated aromatic acceptor rings as well as 2-
chloropyridine systems but manifested steric limitations in the ring-forming step when a-
branched alkyl groups were positioned adjacent to the nucleophilic enamine carbon. 
2.2.3 Pyrazoloquinazolinones and pyrazolopyridopyrimidinones 
This work describes the application of an earlier protocol to the synthesis of pyrazolo[1,5-
a]quinazolin-5(4H)-ones and pyrazolo[1,5-a]-pyrido[3,2-e]pyrimidin-5(4H)-ones. Our literature 
search revealed that few methods are available for the synthesis of these heterocycles, and most 
entail multistep procedures. The earliest approach, reported by Michaelis2 involved a four-step 
synthesis of 5H-benzo[d]pyrazolo[5,1-b][1,3]oxazin-5-one followed by heating with aqueous 
ammonia under pressure. Nearly 60 years later, Wright75 reported a second approach from 
substituted 2-hydrazinobenzoic acids and unsaturated nitriles, a method that has been further 
modified to proceed under microwave conditions.76 A third synthesis, designed to give the 2-
amino-4-methyl derivatives, required the preparation of 2-(3-methyl-4-oxo-3,4-
dihydroquinazolin-2-yl)acetonitrile,77-78 followed by a three-step conversion to the target. Thus, a 
need exists to develop a more efficient approach to the synthesis of these systems. 
Our study began by focusing on the reaction of 2-fluorobenzoyl chloride (5) with 5-amino-1H-
pyrazole (14a) to give 15a. This transformation should permit assessment of the viability of this 
approach to the target compounds and optimization of the process. The reaction was initially 
attempted by acylation of the pyrazole (1.3 equiv) with the acid chloride (1 equiv) at 23 oC in the 
presence of 3.0 equiv of triethylamine in 1,2-dichloroethane (DCE). Subsequent heating at 84 oC 
resulted in ca. 15% conversion to the heterocycle with numerous side products. To better control 
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the initial acylation, we performed this step at 10 oC in DMSO containing 3.0 equiv of K2CO3 and 
obtained cleaner formation of the monoacylated product. We then proceeded to optimize the 
conditions for the final SNAr cyclization and found that direct heating of this mixture at 150 oC 
for 30 min gave complete conversion to the pyrazoloquinazolinone.  
Using this procedure, isolation of the heterocycle proved troublesome as it was only sparingly 
soluble in common organic solvents, and DMSO (bp 189 oC) was difficult to remove under 
vacuum. Thus, only 45% of the product was isolated in pure form using this solvent. Other media, 
such as dichloroethane (DCE), acetonitrile (ACN) and tetrahydrofuran (THF) were found to be 
unsatisfactory due to solubility problems and low boiling points. Finally, the entire sequence was 
repeated in DMF (bp 153 oC), the solvent was removed by rotary evaporation, and the yield was 
improved to 81%. Further refinement of the conditions revealed that 2.0 equiv of K2CO3 was 
sufficient to promote product formation, while < 2 equiv dramatically lowered the yield (see 
Table 2.3). Similar results were observed when 2-fluoro-5-nitrobenzoyl chloride and 2-
chloronicotinoyl chloride were used as substrates. 
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Table 2.3. Reaction optimization results for 15a 
 
 
Entry Base Equiv T (oC) Solvent % Yield 
1 TEA 3.0 84 DCE 15 
2 DBU 3.0 84 DCE 20 
3 Na2CO3 3.0 150 DMSO 35 
4 K2CO3 3.0 150 DMSO 45 
5 K2CO3 3.0 81 ACN Trace 
6 K2CO3 3.0 66 THF Trace 
7 K2CO3 3.0 140 DMF 81 
8 K2CO3 2.0 140 DMF 81 
9 K2CO3 1.0 140 DMF Trace 
 
Our results for the synthesis of pyrazolo[1,5-a]quinazolin-5(4H)-ones 15 from reaction of 4, 5 
with 14 are shown in Table 2.4. The initial acylation was performed in DMF using 2 equiv of 
K2CO3 at -10 oC for 15 min. The reaction was then warmed to room temperature and stirred for 
an additional 15 min. The final ring closure was accomplished by heating this mixture at 140 oC, 
in the same flask, for a period of 30–60 min. Work-up consisted of removing the solvent under 
vacuum, slurrying the crude product in water to remove the base, filtering the solid, and washing 
with methanol/ether (2:1). Some cases required chromatographic purification, and this was 
accomplished on a short silica gel column eluted with methanol/chloroform (1:9). Employing this 
standard protocol, yields were consistently between 75–93%, regardless of the level of aromatic 
activation. 
5
  
14a
  
15a
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Our yields for the preparation of pyrazolo[1,5-a]pyrido[3,2-e]pyrimidin-5(4H)-ones 16 from 2-
chloronicotinoyl chloride (7) and 14 are shown in Table 2.5. These reactions are terminated by 
SNAr addition to a 2-chloropyridine moiety, and although the leaving group was less reactive, the 
polarized C=N bond and secondary activation by the ortho amide carbonyl facilitated the final 
ring closure. Only the ester-substituted pyrazole 14e79 failed to give the heterocyclic product in 
good yield. In this case, the reaction produced an inseparable mixture of three products, which 
included the desired ester and the corresponding acid as the major components. In this reaction, 
the ester group underwent facile hydrolysis during workup of the fused 
pyrazolopyridopyrimidinone product, which required more basic conditions for isolation. 
Attempts to remove the acid by extraction, even with mild base, led to additional ester cleavage. 
Apart from this one setback, the yields (66–87%) were similar to those achieved with the above 
fluoroaromatic substrates and the experimental details were essentially the same. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.4. Summary of pyrazolo[1,5-a]quinazolin-5(4H)-ones 15  
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Table 2.5. Pyrazolo[1,5-a]pyrido[3,2-e]pyrimidin-5(4H)-ones 16 from 7 and 14 
Substrate 14 R1 R2 Product % Yield 
4 a H H 15a 82 
 b CH3 H 15b 78 
 c c-C3H5 H 15c 76 
 d 4-CH3Ph H 15d 78 
 e CO2Et H 15e 92 
 f H CN 15f 88 
 g 2-thienyl H 15g 80 
5 a H H 15h 81 
 b CH3 H 15i 75 
 c c-C3H5 H 15j 79 
 d 4-CH3Ph H 15k 77 
 e CO2Et H 15l 89 
 f H CN 15m 93 
4 (X = NO2) 
5 (X = H) 
 
14 
 
15 
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14 R1 R2 Product % Yield 
a H H 16a 66 
b CH3 H 16b 71 
c c-C3H5 H 16c 78 
d 4-CH3Ph H 16d 82 
f H CN 16f 87 
 
The presumed mechanism for the process is illustrated in Scheme 2.3 for the formation of 15h. 
Initial amide formation by the reaction of acid chloride 5 with the 5-amino group of pyrazole 14a 
at -10 oC gave amide 17. This intermediate was isolated in the synthesis of 15h confirming that 
acylation of the C5 amino group is the first step of the sequence. In the second stage of the 
process at 140 oC, N1 of the pyrazole would attack the fluorine-substituted carbon of the aromatic 
ring to give dipolar intermediate 18. Rearomatization of 18 with loss of fluoride would then give 
19, and final deprotonation by the carbonate base would yield product 15h. Interestingly, the 
same product was isolated in identical yield from the reaction of both 5-amino- and 3-amino-1H-
pyrazole-4-carbonitrile with 5. Theoretical and spectroscopic studies have shown that 3- and 5-
substituted pyrazoles are in tautomeric equilibrium in polar aprotic media, and thus, there is 
ample precedent for equilibration of these two structures to give the same final product.80-81 
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14 
 
16 
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Scheme 2.3. Presumed mechanism for 15h 
2.2.4 Conclusion 
In conclusion, we have developed an efficient synthesis of pyrazolo[1,5-a]quinazolin-5(4H)-ones 
and pyrazolo[1,5-a]-pyrido[3,2-e]pyrimidin-5(4H)-ones using a sequential acylation–SNAr 
reaction. The strategy involves reaction of the 1,3-disposed electrophilic sites in the 2-haloaroyl 
chlorides with the similarly disposed nucleophilic sites in the 5-amino-1H-pyrazole reactants to 
construct the central six-membered ring of the fused heterocyclic targets. The reaction is carried 
out in a single flask and the products are isolated with a minimum of purification effort. 
2.2.5 Benzo[4,5]imidazo[2,1-b]quinazolin-12-ones and benzo[4,5]imidazo-[1,2-a]pyrido[2,3-
d]pyrimidin-5-ones 
Benzimidazoles and quinazolinones are important structural units found in biologically active 
compounds. Numerous derivatives of these structures are found individually in drugs used to treat 
a wide variety of medical conditions.82-85 Commercial benzimidazole-based drugs are used as 
antihelmintics, antiulceratives, and antihistimines. Quinazolinones also possess beneficial 
5 
 
14a 
 
17 
 
18 
 
19 
 
15h 
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pharmacological properties and are in use or under investigation as anticancer, antiviral, 
antimicrobial, antihypertensive, anti-inflammatory, and analgesic agents.  
Fused-ring structures incorporating the benzimidazole and quinazolinone systems have also been 
prepared and investigated (Figure 2.2). An early report disclosed that benzo[4,5]imidazo[2,1-b]-
quinazolin-12(5H)-one (20) exhibited potent immunosuppressive activity.86 Additionally, 
derivatives of 20 as well as benzo[4,5]imidazo[1,2-a]quinazolin-5(7H)-one (21) are readily 
intercalated into DNA, and thus, may exhibit antiproliferative activity in human tumor cell    
lines.86-88 Finally, in addition to their potential as anticancer agents, independent studies have also 
investigated these planar heteroaromatic systems as electron transport and emitter materials.89 
 
 
 
Figure 2.2. Benzo[4,5]imidazo[2,1-b]quinazolin-12(5H)-one (1) and benzo[4,5]imidazo[1,2-
a]quinazolin-5(7H)-one (2) antitumor compounds. 
 
To date, syntheses of polycyclic aromatic structures related to 20 have been reported using three 
different strategies. One approach employed an acylation–SNAr sequence between 2-halo-90 or 2-
sulfo-91 substituted benzimidazoles and anthranilic acid derivatives. A second synthesis involved 
the condensation of methyl 2-isothiocyanatobenzoate esters with o-phenylenediamine.88 Two 
related reports outlined a third entry to these systems via a copper-catalyzed Ullman coupling of 
2-bromobenzoic acid with 1-alkyl-2-aminobenzimidazoles87 and a similarly promoted domino 
reaction between a 2-bromo-N-(2-halophenyl)benzamide with cyanamide.92 Synthetic routes to 
compounds having the framework found in 21 have also been reported. Two articles documented 
a sequence involving acylation of 2-aminobenzimidazole with 2-haloaryloyl chlorides, followed 
in a separate step, by cyclization in boiling pyridine or diphenyl ether (20–78%).93-94 Two 
20 
 
21 
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additional disclosures utilized a copper-mediated coupling reaction: one joined 2-
aminobenzimidazole with 2-bromobenzoic acid in refluxing DMF (93%),95 and the other 
promoted displacement of halogen from N-alkyl-2-halobenzamides by N1 of benzimidazole 
under anaerobic conditions in DMSO at 120 oC, and then, upon exposure to air at this same 
temperature, produced oxidative amidation at C2 of the benzimidazole to close the ring (54–
98%).96 The acylation–SNAr approaches to 20 and 21 described relatively few examples, and 
thus, the reaction scope for these two methods was limited. Those catalyzed by copper, showed 
broader applicability, but likely yielded products containing metal impurities, which would 
require removal prior to use as a drug. 
Our strategy was based on two earlier projects, namely synthesis of isoquinolin-1(2H)-ones97 and 
pyrazoloquinazolinones98 involving a one-pot acylation–SNAr sequence that exploited the 1,3-
disposed nucleophilic centers in 2-aminobenzimidazole with the similarly positioned electrophilic 
sites in a 2-haloaroyl chloride to generate the central six-membered ring. Interestingly, two 
regioisomeric products were possible from the current reaction, one derived from initial acylation 
of the amino substituent on the benzimidazole to give structures related to 21 and the other from 
acylation at the saturated benzimidazole nitrogen93,99 to give regioisomers similar to 20. We 
anticipated that treatment of 2-fluoro-5-nitrobenzoyl chloride (4) with 2-aminobenzimidazole 
(22) in the presence of base would proceed by a sequence involving acylation of the amino 
function of 22 followed by an SNAr ring closure to give substituted derivatives of 21. In practice, 
however, product 23a, with the ring system found in 20, was produced. Using N,N-
dimethylformamide (DMF) as the solvent, 4 and 22 were mixed in the presence of different bases 
at -10 oC, and then heated. When complete, the reaction was worked up and purified to give the 
yields of 23a shown in Table 2.6.  
Table 2.6. Reaction optimization results for 23 
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Entry 
Base        
(2 equiv) 
Temp 
(oC) 
Time (h) % Yield 
1 TEA 140 12.0 15 
2 Pyridine 140 12.0 18 
3 DIPEA 140 12.0 26 
4 K2CO3 140 0.5 88 
5 Na2CO3 140 1.0 88 
6 KHCO3 140 1.0 88 
7 NaHCO3 140 1.0 88 
 8 NaHCO3 75 1.0 88 
9 NaHCO3 60 5.0 53 
10 NaHCO3 45 5.0 38 
 
Organic bases (TEA, pyridine, and DIPEA) in DMF at 140 oC failed to give acceptable 
conversions, but sodium carbonate and potassium carbonate, as well as the corresponding 
bicarbonates, promoted complete conversion at 140 oC within 1 h. Since sodium bicarbonate is 
mild as well as inexpensive, we sought to optimize the temperature using this base. Variation of 
this parameter revealed that the reaction proceeded at temperatures as low as 75 oC, but slowed 
dramatically at 45 oC and 60 oC. Thus, our optimized procedure involved treating 2-
4 
 
22 
 
23a 
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aminobenzimidazole (1.2 equiv) with the acid chloride (1.0 equiv) in the presence of NaHCO3 (2 
equiv) in DMF at -10 oC for 30 min, followed by heating to 75 oC for 0.5–1 h. 
Application of these conditions to substrates 4a-h furnished high yields of the target heterocycles 
23a-h, allowing slightly broader reaction scope with respect to substitution on the acid chloride 
than our previous synthesis of pyrazoloquinazolinones. Most reactions proceeded at 75 oC, while 
2,3,4,5,6-pentafluorobenzoyl chloride (4d) gave a near quantitative yield of 23d after 1 h at 23 oC 
(Table 2.7).  The reaction workup involved removal of DMF under vacuum, dilution with 
distilled water and filtration.  The resulting solid was then stirred with ethanol at reflux, cooled 
and filtered.  While the benzimidazoquinazolinone product did not dissolve significantly in hot 
ethanol, soluble impurities were removed by this treatment.  The low solubility of the products in 
common organic solvents rendered chromatographic purification ineffective as a means of 
purification.  Poor mass balances were obtained when this was attempted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.7. Cyclizations to form products 23a-h 
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Substrate X Y Z Pdt Z % Yielda 
4a F CH 5-NO2 23a 2-NO2 88 
4b F CH 5-F 23b 2-F 86 
4c F CH 6-F 23c 1-F 93 
4d F CF 4,5,6-F 23d 1,2,3-F  96b 
4e F CH 4-Me 23e 3-Me 76 
4f F CH 4-Br 23f 3-Br 78 
4g Cl N H 23g H 90 
5 F CH H 23h H 87 
                   aIsolated yield 
                   bReaction was completed in 1 h at 23 oC 
In order to broaden the scope of the reaction, we prepared 2-amino-5,6-dimethylbenzimidazole 
(24) from 4,5-dimethylbenzene-1,2-diamine and cyanogen bromide according to a literature 
procedure.100 Reaction of 4a-g and 5 with 24 using our standard protocol generated the 
corresponding 8,9-dimethylbenzimidazoquinazolinones 25a-h in high yields (Table 2.8). Again, 
the perfluorinated acid chloride afforded excellent conversion to the acylation-SNAr product at 23 
oC.  
 
Previous syntheses of N5- or N6-alkylated benzo[4.5]imidazo-[2,1-b]quinazolin-12-ones were 
reported with unambiguous characterization data,96 though most of these papers did not report 13C 
4a-g and 5 (X, Y, Z – see 
below) 
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NMR spectra.   As the current compounds are not substituted at either of these sites, spectral 
interpretation proved considerably more difficult.  While the 1H NMR spectra were reasonably 
sharp, it was observed that many of the absorptions in the 13C NMR spectra were broadened to a 
point where they could not be observed. It is interesting to note that benzimidazoles normally 
exist as tautomeric structures having partial double bond character between C2–N1 and C2–
N3,101-102 with H exchanged between the two nitrogens. We have observed broadened 13C NMR 
signals resulting from this phenomenon, in a previous syntheses of these compounds.103  
In the current systems, tautomerization involved a proton shift between N6 of the benzimidazole 
moiety and N5 exocyclic to the benzimidazole;  due to its tertiary structure and electron-deficient 
substitution, N11 was not involved in this tautomerization.  The NH proton was often not 
observed in the 1H NMR, presumably due to H-bonding with the solvent, which would shift the 
signal well beyond the normal chemical shift range.104  The broadened signals in the 13C NMR 
spectra for the current products clearly indicated that the bonding situation in these materials was 
not straightforward.  Earlier studies failed to report 13C NMR spectra, which is understandable 
since our attempts to acquire these data were hampered by the tautomeric nature and low 
solubility of the compounds (even at 110 oC in DMSO-d6).  In particular, the aromatic carbons for 
most of the products as well as the methyl carbons of 25a-h were broadened significantly, 
particularly for 23a,c,e and for 25b,c,e,h.  Resolution of this problem was accomplished by 
treatment of these products with acetyl chloride and triethylamine, which selectively acylated N6 
as illustrated below (Table 2.9). An X-ray structure of 6-acetyl-2-nitro-benzo[4,5]imidazo[2,1-
b]quinazolin-12(6H)-one (26a), derived from 23a (Figure 2.3), confirmed the site of reaction. 
 
 
Table 2.8. Cyclizations to form products 25a-h 
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Substrate X Y Z Pdt Z % Yielda 
4a F CH 5-NO2 25a 2-NO2 91 
4b F CH 5-F 25b 2-F 87 
4c F CH 6-F 25c 1-F 95 
4d F CF 4,5,6-F 25d 1,2,3-F  98b 
4e F CH 4-Me 25e 3-Me 80 
4f F CH 4-Br 25f 3-Br 84 
4g Cl N H 25g H 95 
5 F CH H 25h H 83 
               aIsolated Yield 
               bReaction was completed in 1 h at 23 oC 
 
   
 
Figure 2.3. X-ray structure of 26a (CCDC 1424687). 
Most of the acylated derivatives showed improved solubility and gave sharp peaks in the 13C 
NMR spectrum at 75 oC in DMSO-d6.  However, the acetamides of 25c and 25f also proved to be 
24 
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4a-g and 5 
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highly insoluble, and thus, the hexanoyl derivatives were prepared.  The hexanamides presented 
no solubility problems and the spectra were readily acquired in CDCl3 at 23 oC.  As an added 
benefit, these derivatization experiments revealed a facile method for modulating the solubility of 
these compounds. Interestingly, some structures did not show significant signal broadening in the 
13C NMR.  This was noted in products derived from acid chlorides 4d and 4g, which incorporated 
electron deficient fused tetrafluorobenzo 25d and pyrido 25g moieties.  These derivatives gave 
sharp signals in their 13C NMR spectra.  A possible explanation for this observation is that the 
electron-deficient ring draws the double bond away from the benzimidazole ring making 
tautomerization less important.  Furthermore, positioning of the conjugated double bond in the 
six-membered ring exo to the five-membered imidazole ring should also be favorable.  Other 
structures derived from acid chlorides bearing only one electron-withdrawing group (e.g. 4a,b,c) 
were not sufficiently electron deficient to elicit this effect. 
 
Table 2.9. Acylation of N6 to block tautomerization 
 
 Substrate 
R R’ Z Pdt 
% Yield 
23a H Me 2-NO2 26a 94 
23c H Me 2-F 26c 96 
23e H Me 3-Me 26e 92 
25b Me Hex 2-F 27b 85 
23 or 25 
 
26 or 27 
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25c Me Me 1-F 27c 93 
25e Me Hex 3-Me 27e 97 
25h Me Me H 27h 88 
 
The presumed mechanism to convert 4a and 22 to 23a is depicted in Scheme 2.4. Since 
bicarbonate is an insufficiently strong base to deprotonate 2-aminobenzimidazole (22, pKa ca 
16),105-106 it serves to scavenge protons after the various addition-elimination processes take place.  
Following acylation of 22 at N1 by 4a, bicarbonate would deprotonate intermediate 28 to give 
amide 29.  At this stage, the amino nitrogen would attack the fluorinated carbon initiating an 
SNAr addition-elimination to give 30.  Final deprotonation by the second equivalent of base 
would then afford benzimidazoquinazolinone 23a as a mixture of tautomers. 
 
 
 
 
Scheme 2.4. Presumed mechanism for the reaction of 4a and 22 to give 23a. 
2.2.6 Conclusion 
In conclusion, we have developed a one-pot sequential procedure to prepare 
benzo[4,5]imidazo[1,2-a]quinazolin-12-ones and benzo[4.5]imidazo[1,2-a]pyrido[2,3-
4a 22 28 
29 30 
23a 
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d]pyrimidin-5-ones using an acylation–SNAr sequence. The strategy involves the reaction 
between the 1,3-disposed nucleophilic centers in 2-aminobenimidazole and the similarly arranged 
electrophilic sites in the 2-haloaroyl chlorides to construct the central six-membered ring of the 
fused heterocyclic targets. The products are formed in high yields by a procedure that eliminates 
high temperatures, strong bases, and metal catalysts. The 13C NMR spectra of the products exhibit 
broad signals, which suggest that the structures are tautomeric across the N5–C5a–N6 triad. 
Acylation of these products results in exclusive reaction at N6. This locks the double bond into 
the six-membered ring and improves solubility, making NMR characterization more 
straightforward. A presumed mechanism is presented to account for the observed transformation. 
 
 
 
2.2.7 1,3,4-Oxadiazole synthesis promoted by NH4Cl 
The 1,3,4-oxadiazole scaffold has attracted considerable attention in the field of medicinal 
chemistry as depicted in Figure 2.4.107 Due to the broad commercial potential of 1,3,4-
oxadiazoles, numerous methods for their synthesis have been developed over the years. Most 
approaches are either multi-step or involve the cyclization of hydrazides using harsh reagents 
such as phosphorus oxychloride, thionyl chloride, sulfuric acid, zirconium(IV) chloride, 
XtalFluor-E®, Burgess reagent, Deoxo-Fluor®, acid chlorides, Nafion® NR50, or acetic acid, 
under reflux or microwave heating.108 Due to the caustic nature of these reagents, sensitive 
functional groups are often incompatible with these earlier methods. To address this problem, we 
have developed a mild protocol, which involves the formation of 1,3,4-oxadiazoles from 
arylhydrazides and orthoesters promoted by catalytic NH4Cl.  
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Figure 2.4. Drug containing a oxadiazole ring 
In recent years, we have found that NH4Cl is a highly efficient and mild catalyst for the synthesis 
of benzo-fused heterocycles such as benzimidazoles, benzoxazoles, and benzothiazoles,103 and 
also for the preparation of α-aminonitriles using a variant of the Strecker synthesis.109 To extend 
the scope of this catalyst, optimization studies were performed for the current reaction using 
benzhydrazide (1.0 equiv) and triethyl orthoformate (1.1 equiv). The optimized transformation 
occurred using 30 mol% of NH4Cl in refluxing ethanol, which afforded a 96% yield of the 
corresponding oxadiazole in less than 1 h. Lower catalyst loadings gave slow and often 
incomplete reaction, while more catalyst gave no additional rate enhancement. The use of 
absolute EtOH proved essential to achieve maximum conversion for these reactions. Attempts to 
use other solvents (THF, dichloroethane, CH3OH, dioxane, CH3CN, benzene, 10:1 EtOH/H2O or 
1:1 EtOH/H2O) either produced lower yields or required longer reaction times (Fig. 2.5). The 
current procedure represents a considerable improvement over a previously published 
uncatalyzed route that required 18 h and a five-fold excess of the orthoester.110-111 
 
 
31 39a 40a 
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Figure 2.5. Effect of solvent with time in the reaction 
The scope of this reaction was studied by refluxing a series of arylhydrazides with various triethyl 
orthoesters in EtOH using 30 mol% of NH4Cl. Our results are summarized in Table 2.10. The 
mild reaction conditions offered a wide range of functional group tolerance on the arylhydrazide 
including methyl, methoxy, chloro, bromo, and nitro. In most cases, the yields were high, and the 
products were formed cleanly. Solid products were isolated directly from the reaction mixture and 
did not require further purification. Oils required purification by elution through a short column 
of silica gel. The reaction was successful with both electron-releasing and electron-withdrawing 
substituents on the arylhydrazide reactant.  
Table 2.10. Summary of 2- and 2,5-disubstituted 1,3,4-oxadiazoles 
 
 
 
 
Entry R R1 Yield Entry R R1 % Yield 
40a H H 95 43d 3-Br Ph 80 
40b H CH3 93 44a 2-Cl H 28 
48 48 48
24 24 18
6
24
1
35
24
52
70 74 77
30
5
96Time Yield (%)
31-38 39a-d 40-47(a-d) 
31 (R = H); 32 (R = 4-CH3) 
33 (R = 4-OCH3); 34 (R = 3-Br) 
35 (R = 2-Cl); 36 (R = 4-Cl) 
37 (R = 2-NO2); 38 (R = 4-NO2) 
a (R1 = H) 
b (R1 = CH3) 
c (R1 = CH2CH3) 
d (R1 =Ph) 
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40c H CH2CH3 98 44d 2-Cl Ph 97 
40d H Ph 96 45a 4-Cl H 90 
41a 4-CH3 H 88 45b 4-Cl CH3 75 
41b 4-CH3 CH3 53 45c 4-Cl CH2CH3 95 
41c 4-CH3 CH2CH3 95 45d 4-Cl Ph 70 
41d 4-CH3 Ph 96 46a 2-NO2 H 22 
42a 4-OCH3 H 98 46b 2-NO2 CH3 25 
42b 4-OCH3 CH3 90 46c 2-NO2 CH2CH3 38 
42c 4-OCH3 CH2CH3 93 46d 2-NO2 Ph 55 
42d 4-OCH3 Ph 97 47a 4-NO2 H 74 
43a 3-Br H 82 47b 4-NO2 CH3 81 
43b 3-Br CH3 89 47c 4-NO2 CH2CH3 69 
43c 3-Br CH2CH3 86 47d 4-NO2 Ph 92 
 
 
 
Scheme 2.5. Proposed mechanism for the formation of 1,3,4-oxaidazole 40a 
31 
39a 48 
48 49 50 
51 40a 
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The yield of oxadiazole was only decreased when an electron-withdrawing group was positioned 
ortho to the hydrazide carbonyl. This presumably results from an electronic effect, which should 
exert a greater impact on the carbonyl reactivity from this position. Most notably, the presence of 
an electron-withdrawing chloro or nitro at the ortho position of the arylhydrazide resulted in 
lower yields, especially with non-aromatic orthoesters. A proposed mechanism for oxadiazole 
formation is given in Scheme 2.5. Initial protonation and loss of EtOH from 39a would give the 
ether-stabilized carbocation 48. Attack on this species by hydrazide 31 to give 49 would be 
followed by proton exchange and loss of a second molecule of EtOH to give 50. Ring closure to 
generate 51 and elimination of EtOH would then afford oxadiazole 40a. 
2.2.8 Conclusion 
In summary, we have developed an efficient and inexpensive approach to the synthesis of 2-
substituted and 2,5-disubstituted 1,3,4-oxadiazoles using NH4Cl as catalyst. The conditions are 
mild, and thus, compatible with a variety of functional groups. The optimized reaction is 
performed using 30 mol % of NH4Cl in 100% EtOH and is generally complete within 1 h for 
orthoformate, orthoacetate, or orthopropionate, and 2–10 h for orthobenzoate. In most cases, the 
yields are high, and the isolated products require substrate and proceeds smoothly for both non-
aromatic and aromatic orthoesters. Compared with earlier reports, the current reactions proceed in 
shorter time and require considerably less orthoester. 
2.2.9 Nucleophilic addition across polarized vinyl arenes 
The formation of a carbon-nitrogen bond by amine addition 
across a carbon-carbon double bond has been a promising atom 
efficient method since the early 1990’s.112-115 To our 
knowledge, most of the prevailing methods for hydroamination 
utilized transition metals as a catalyst. Rarely observed “anti-Markonikov” selectivity has been 
reported with Rh, Ru, Ti and Cu systems.116-121 Likewise, no reports are available for the anti-
Figure 2.6. Structure of 
CDC25 phosphatases 
inhibitors 
52 
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Markonikov addition to vinyl styrene except the work reported by Dale et al.,122 in 1954, who 
performed the reactionon electron-deficient systems using sodium methoxide in alcohol. This 
method however, is not optimum as it gives low yields and dimerization of the desired product. 
Apart from the necessity to develop better methods for the anti-Markonikov hydroamination of 
electron deficient vinylarenes, the resultant product can be used as a building block to prepare 
CDC25 phosphatases inhibitors such as 52 for cancer treatment.123 
In this project we focused on developing an efficient route for hydroamination and nucleophilic 
addition across electron deficient vinyl arenes under metal free condition. Nucleophiles, such as 
enolates and amines, do not normally react with styrene double bonds. However, when an 
electron withdrawing substituent on the aromatic ring is conjugated with the double bond (at C2 
or C4), the vinyl double bond assumes electrophilic character.  We took advantage of this 
phenomenon and initially tried to perform additions across polarized vinylarenes using enolates 
generated by reaction of malonate esters with 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU). This 
reaction proceeded smoothly, and thus, we sought to optimize the reaction conditions. 
After optimizing the base stoichiometry, we sought to find a better solvent, and of all the solvents 
we tried (Table 2.11), acetonitrile provided the best result.  Reactions in DMF and DMSO 
proceeded faster, but gave problems during product isolation.  We also explored other bases 
besides DBU, including tetramethylguanidine, 4-(dimethylamino)pyridine (DMAP), imidazole, 
diazabicyclo[2.2.2]octane (DABCO), sodium hydride (NaH) and potassium tert-butoxide (t-
BuOK).   These experiments confirmed that DBU was the base of choice for this transformation 
(Table 2.12).  Finally, we optimized the stoichiometry of the nucleophile.  By reducing the 
amount of nucleophile to 1.5 equivalents, the reaction continued to provide good yields; however, 
less than this stochiometry resulted in a dramatic reduction in yield.  The optimized conditions 
required the use of 1.5 equivalent of the nucleophile, 1 equivalent of base, and 1 equivalent of the 
vinylarene. 
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Table 2.11. Solvent optimization for addition to polarized vinylarenes 
 
Entry Solvent Time (h) Yield (%) 
1 DMF 2.0 56 
2 Acetonitrile 4.0 93 
3 DMSO 2.0 48 
4 Ethanol 18 25 
5 THF 10 62 
 
 
Table 2.12. Optimization of base for addition to polarized vinyl arenes 
 
Entry Base Equiv Yield (%) 
1 TMG 1.0 36 
2 DMAP 1.0 28 
3 Imidazole 1.0 45 
4 DBU 1.0 93 
5 DABCO 1.0 80 
6 NaH 1.0 65 
7 t-BuOK 1.0 23 
8 DBU 0.2 26 
9 DBU 0.5 59 
53a 54a 55a 
53a 54a 55a 
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 With the optimized parameters in hand, we attempted to explore the scope of the reaction with 
various nucleophiles and substrates. The optimized conditions worked well for 4-nitrostyrene 
with various active methylene compounds like diethyl malonate (54a), diethyl methylmalonate 
(54b), and ethyl 2-oxocyclopentanecarboxylate (56), giving excellent yields of the products in 4-6 
h.  Active methylene compounds (Table 2.13) also added to 2-nitrostyrene, but yields were 
slightly lower, presumably due to steric hindrance created by the ortho-nitro group.   
 
 
Table 2.13. Reaction using malonate donars 
 
10 DBU 0.7 75 
Acceptor Donor Product Yield (%) 
55 53 
acceptor 
1 equiv 
 
54 
donor 
1.5 equiv 
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Modification of the vinylarene substrates to include 4-cyano- and 4-ethoxycarbonyl-substituted 
aromatic rings (Table 2.13) met with only limited success.  A major problem with these activating 
groups was that they tended to competitively react with the nucleophiles under the conditions of 
the reaction.  In the case of cyano-substituted acceptors, malonate nucleophiles added cleanly, but 
amine nucleophiles failed due to facile polymerization of the substrate.  For the ethoxycarbonyl-
derived arenes, it was not possible to isolate acceptable yields of addition products from any of 
the nucleophiles due to attack at the aromatic ester.  Substitution on the vinyl group was also 
explored, and as expected, steric factors were found to be important in the reaction.  Introduction 
of a methyl group α to the arene (α-vinyl carbon) of the 4-nitrostyrene had little effect on the 
efficiency of addition, while addition of methyl at the site of attack (β-vinyl carbon) in this same 
substrate allowed addition by only simple unsubstituted malonate. 
These conditions were further extended for use in the addition of a cyclic β-ketoester (Table 2.14) 
such as methyl 2-oxocyclopentanecarboxylate (56).  This relatively hindered substrate proceeded 
to react with 1-nitro-4-vinylbenzene (53a, 81%), 1-nitro-4-(prop-1-en-2-yl)benzene (53b, 82%) 
and 1-nitro-2-vinylbenzene (53c, 80%).  In the reaction with 53b, separation of the final mixture 
53a 
(R = 4-NO2, R1 = H) 
54a 
(R2 = H) 
55a 
(R = 4-NO2, R1, R2 = H) 
97 
53a 
(R = 4-NO2, R1 = H) 
54b 
(R2 = Me) 
55b 
(R = 4-NO2, R1, R2 = H) 
93 
53b 
(R = 4-NO2, R1 = Me) 
54a 
(R2 = H) 
55c 
(R = 4-NO2, R1 = H, R2 = Me) 
87 
53b 
(R = 4-NO2, R1 = Me) 
54b 
(R2 = Me) 
55d 
(R = 4-NO2, R1, R2 = Me) 
85 
53c 
(R = 2-NO2, R1 = H) 
54a 
(R2 = H) 
55e 
(R = 2-NO2, R1, R2 = H) 
94 
53c 
(R = 2-NO2, R1 = H) 
54b 
(R2 = Me) 
55f 
(R = 2-NO2, R1 = H, R2 = Me) 
74 
53e 
(R = 4-CN, R1 = H) 
54a 
(R2 = H) 
55g 
(R = 4-CN, R1, R2 = H) 
58 
53e 
(R = 4-CN, R1 = H) 
54b 
(R2 = Me) 
55h 
(4-CN, R1 = H, R2 = Me) 
53 
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yielded two diastereomeric products 57b in nearly a 1:1 ratio.  Separation by preparative TLC 
gave two products:  isomer 1 (39%), an oil, and isomer 2 (43%), a white solid.  A crystal of 
isomer 2 was obtained for X-ray analysis by slow diffusion of pentane into an ether solution of 
the two diastereomers.  Solution of the structure showed that the isomer 2 was racemic methyl 
(R,R)-2-oxo-1-(2-(4-nitrophenyl)propyl)cyclopentanecarboxylate [(±)-R,R-57b] (Figure2.7) 
allowing assignment of isomer 1 as the racemic (±)-R,S-57b.  Note: The unit cell for isomer 2 of 
57b contains one molecule of the R,R (top) and one molecule of the S,S diastereomer (bottom). 
 
 
 
 
 
 
 
 
Table 2.14. Reaction using a cyclic β-keto ester 
 
Acceptor Product Yield (%) 
53a 
(R = 4-NO2, R1 = H) 
57a 
(R = 4-NO2, R1 = H) 
81 
53 
acceptor 
1 equiv 
 
56 
donar 
1.5 equiv 
57 
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We further explored the feasibility of hydroamination of these polarized alkenes with morpholine 
(58), piperidine (59) and benzylamine (60) to give 61-63.  These additions also proceeded in high 
yield, but required longer reaction times than the enolate additions (12-18 h).  Control 
experiments, with and without base, established that DBU was also required for good conversion 
in these reactions.  For each of the amines, reaction only occurred with the 2- and 4-nitrophenyl-
substituted substrates 53a-c (see Table 2.15), as the robust conditions promoted rapid 
polymerization of the cyanophenyl derivative and degradation of the ester in the ethoxycarbonyl 
substrate. Yields were in the 78-95% range.  Attempted addition to the 2- and 4-nitrostyrenes 
bearing a methyl group at the α-carbon gave excellent yields of the addition products (77-84%), 
while substitution at the β-carbon failed to proceed due to steric hindrance at the site of attack. 
 
53b 
(R = 4-NO2, R1 = Me) 
57b 
(R = 4-NO2, R1 = Me) 
 82 
53c 
(R = 2-NO2, R1 = H) 
57c 
(R = 2-NO2, R1 = H) 
80 
53d 
(R = 2-NO2, R1 = Me) 
57d 
(R = 2-NO2, R1 = Me) 
0 
53e 
(R = 4-CN, R1 = H) 
57e 
(R = 4-CN, R1 = H) 
51 
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Figure 2.7. X-ray structure of (±)-R,R-57b 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.15. Reaction with amine donors 
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The presumed mechanism for the reaction of 53a with 54a to give 55a is depicted in Scheme 2.6. 
Deprotonation of 54a using DBU would generate DBU-H+ and carbanion 64. In the presence of 
53a, 64 would add to the side chain double bond to generate adduct 65. Intermediate 65 is 
stabilized in much the same manner as a Meisenheimer complex, but does not have a leaving 
Acceptor Donor Product Yield (%) 
53a 
(4-NO2, R = H) 
58 
 
61a 
(4-NO2, R = H) 
95 
53a 
(4-NO2, R = H) 
59 
 
62a 
(4-NO2, R = H) 
93 
53a 
(4-NO2, R = H) 
60 
 
63a 
(4-NO2, R = H) 
82 
53b 
(4-NO2, R = Me) 
58 
 
61b 
(4-NO2, R = Me) 
86 
53b 
(4-NO2, R = Me) 
59 
 
62b 
(4-NO2, R = Me) 
84 
53b 
(4-NO2, R = Me) 
60 
 
63b 
(4-NO2, R = Me) 
77 
53c 
(2-NO2, R = H) 
58 
 
61c 
(2-NO2, R = H) 
85 
53c 
(2-NO2, R = H) 
59 
 
62c 
(2-NO2, R = H) 
88 
53c 
(2-NO2, R = H) 
60 
 
63c 
(2-NO2, R = H) 
78 
53 
58 
59 
60 
61 
62 
63 53 
53 
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group at the site of attack, which would allow regeneration of the side chain double bond. 
Abstraction of the proton from DBU-H+ (or excess 53a) by 65 would then deliver the required 
single addition product 55a. When the current reaction was performed using 0.2 equiv of DBU in 
DMF at 60 oC, a very poor yield of 55a was obtained and more of the double addition product 67 
was isolated. A likely explanation for this observation is that intramolecular proton transfer from 
the active methylene site to the benzylic anion in 65 is faster than intermolecular proton 
abstraction from the dilute DBU-H+. This would generate 66, which would then add a second 
molecule of 53a and protonate to form 67. Experiments to optimize the stoichiometry of DBU 
indicated that a full equivalent of this base relative to the vinylarene gave the highest conversion 
to the monoadduct. Although intramolecular proton transfer should still be faster, the presence of 
higher concentrations of DBU-H+ along with excess 53a, would make more protons available 
from intermolecular sources to stop the reaction at the single addition stage. Of course, the 
intramolecular proton transfer and double addition would not be an issue for reactions involving 
alkylated malonates such as 54b. 
 
Scheme 2.6. Presumed mechanism for additions to electron-deficient vinylarenes. 
2.2.10 Conclusion 
54a 64 65 
55a 66 
67 
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In conclusion, nucleophilic additions of enolates and amines to electron deficient vinylarenes 
substituted in the ortho or para positions by nitro, cyano, and ethoxycarbonyl have been explored 
and optimized. This reaction proceeded cleanly for nitro compounds 53a and 53d with malonates 
54a and 54b, giving better yields than earlier reports without the need for added metal catalysts. 
The reaction is operationally simple and proceeds to give high yields in refluxing MeCN with 
DBU base after 4–6 h. Additions of the hindered β-ketoester 56 were also successful. For cyano 
compound 53e, only the malonate and ketoester nucleophiles afforded the desired adducts, albeit 
in lower yields than those observed for the nitro compounds. Addition to the nitrostyrene 
substrate 54b with a methyl group at the side chain position was also successful, but substrate 54c 
with a β methyl group was too hindered for additions beyond unsubstituted malonate. The 
hydroamination procedure permitted the addition of primary and secondary amines 61–63 to 
nitrostyrenes 54a, 54b, and 54d without added catalysts in MeCN at reflux for 12–18 h. Other 
acceptor incorporating 4-cyano underwent polymerization or degradation upon attempted 
addition of amines. The targets generated have high potential values for the synthesis of building 
blocks to assemble the backbone of several families of drug candidates. 
2.2.11 Bismuth triflate catalyzed synthesis of 4-chromanones 
 
Efficient methods to produce oxygen heterocycles for use as building blocks in natural product 
and drug synthesis is a worthy endeavor.  Among the heterocyclic scaffolds containing oxygen, 4-
chromanones are widely dispersed in nature and constitute valuable substrates for drug 
synthesis.124-125  For example, 4-chromanones are core structures in the synthesis of anti-
estrogenic compounds used to treat breast cancer.126  Various derivatives of this system are also 
inhibitors of SIRT2, an enzyme involved in age-related neurodegenerative disorders.127  Finally, 
4-chromanones have been used in the synthesis of somatostatin analogues which are currently 
under investigation for the treatment of osteoporosis128 as well as certain stomach tumors.129      
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Previous methods for the synthesis of 4-chromanones have utilized a wide range of reaction 
protocols.  One of the first generated 7-hydroxy-2,2-dimethyl-4-chromanone from highly 
activated resorcinol with 3,3-dimethylacrylic acid in the presence of SbCl3.130 Others have 
involved amine catalyzed condensation of o-hydroxyacetophenones with aliphatic ketones and                  
aldehydes.126-129, 131-133 Further reports have described the use of stoichiometric mercury(II) on 
aryl propargyl ethers,134 addition of cuprates to chromones,135  phosphorus oxychloride/zinc 
chloride with phenols and 3,3-dimethylacrylic acid,136-137 the reaction of carboxylic acids with o-
(trimethylsilyl)aryl triflates promoted by cesium fluoride138 and a one-pot photo-Fries–oxa-
Michael reaction.139  Our approach involves the reaction of phenols bearing additional activating 
groups with 3,3-dimethylacrylic acid or crotonic acid to give a variety of tetra- and trisubstituted 
4-chromanones, respectively. We achieved this, using bismuth(III) triflate to catalyze the one-pot 
conversion by a tandem esterification–Fries rearrangement–oxa-Michael sequence. 
This project originated from our synthetic efforts to convert the phenyl ester of 3,3-
dimethylacrylic acid 68a to 2-chromanone 69a (X = H). Cyclization of the simple phenyl ester is 
reported to give 69a in >70% yield using 1.7 equiv of aluminum chloride,140 and we have 
successfully used this procedure to access drug precursors of interest to our group.  However, 
attempts to perform this reaction with esters of more activated aryl groups such as 68c (X = Me) 
led to the formation of the Fries rearrangement product 1-(2-hydroxy-4-methylphenyl)-3-methyl-
2-buten-1-one (70c, 18%) and significant quantities of 4-chromanone 71c (65%) in addition to 
small amount of 2-chromanone 69c (2%) (see Scheme 2.7).  The 4-chromanone product likely 
arises via a Lewis acid promoted oxa-Michael reaction following the Fries rearrangement.  While 
this may appear to be a reasonable synthesis of 4-chromanones, this reaction with aluminum 
chloride invariably led to mixtures of 69, 70 and 71.  Thus, we sought a more selective route to 4-
chromanone derivatives. Our research group had previously described the use of bismuth(III) 
triflate as a catalyst for Friedel-Crafts cyclizations of tertiary alcohols to produce chromans as 
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well as a variety of other heterocycles.141 Attempting to use the similar strategy with ester 68c 
revealed that the reaction of activated aryl 
 
Scheme 2.7. Friedel-Crafts reaction of aryl ester of 3,3-dimethylacrylic acid 
esters with bismuth(III) triflate afforded >70% of 71c as the exclusive cyclized product, along 
with ca. 10% of the phenol from acid catalyzed cleavage of the ester.  Additional examples 
showed that this process appeared to be broadly applicable to many substrates (see Scheme 2.8).  
 
Scheme 2.8 4-Chromanones from aryl esters of 3,3-dimethylacrylic acid 
68 69 
70c 71c 
69c 
72c 
68 71 
71b, 72% 
71c 
71c, 72% 71d, 67% 
71e, 38% 71f, 62% 71g, 90% 
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In an effort to avoid the extra step of preparing the ester from the relatively expensive 3,3-
dimethylacryloyl chloride, we sought to prepare the 4-chromanones directly from the phenol and 
3,3-dimethylacrylic acid using bismuth(III) triflate. Fortunately, this route proved viable and gave 
fair to excellent yields of 4-chromanones with none of the 2-chromanone products.  Among the 
substrates studied, phenol and 2-methylphenol were the lone disappointments, giving complex 
mixtures of products from which the 4-chromanones could not be isolated in pure form.   
We were also successful in expanding this process to cyclizations with crotonic acid.  However, 
attempts to further expand this reaction for ring closures of trans-cinnamic acid gave intractable 
mixtures with poor yields of the desired products. The results of our study of cyclizations using 
3,3-dimethylacrylic acid and crotonic acid are shown in Schemes 2.9 and 2.10, respectively.   
 
 
 
72 71 
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Scheme 2.9. 4-Chromanones from 3,3-dimethylacrylic acid 
 
 
 
71b, 74% 71c, 68% 71d, 69% 71e, 44% 
71f, 65% 71g, 45% 71h, 25% 
45% 
72 73 
71i, 87% 
45% 
71j, 76% 
45% 
71k, 87% 
45% 
71l, 77% 
45% 
71m, 84% 
45% 
71n, 40% 
45% 
71o, 40% 
45% 
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Scheme 2.10. 4-Chromanones from trans-crotonic acid 
Each reaction was run in toluene at reflux using a 1:1 ratio of phenol to carboxylic acid and 30 
mol% of bismuth(III) triflate.  The mixtures were refluxed for 12-18 h and monitored by TLC.  
When maximum conversions were attained, the reactions were cooled, concentrated under 
vacuum and the crude product, diluted with a small amount of chloroform, was applied to 
preparative thin layer chromatography (PTLC) plates.  Elution 3-4 times with 5% ether in hexane 
(8-10% ether in hexane was used for the methoxy-substituted products) yielded 2-3 bands.  In 
each case, the bright fluorescent blue band was the 4-chromanone, while others contained 
unreacted phenol or the aryl ester of the acid. 
73b, 65% 73c, 52% 73d, 84% 73e, 33% 
73f, 71% 73g, 55% 73h, 42% 
45% 
73i, 72% 
45% 
73j, 36% 
45% 
73k, 80% 
45% 
73l, 75% 
45% 
73m, 52% 
45% 
73n, 36% 
45% 
73o, 52% 
45% 
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The reaction proceeded in moderate to high yields for a broad range of substrates, and the product 
was easily purified by chromatography.  Good yields were achieved with nearly all of the methyl-
substituted derivatives, and in 3-substituted phenols where the two ortho carbons were 
unsubstituted, closure occurred toward the less hindered position.  Only 2-methylphenol failed to 
undergo clean reaction, and this could derive from steric hindrance at the hydroxyl group as well 
as the fact that the single methyl substituent would exert only a minimal activating effect at the 
aromatic carbon that will attack the acylium electrophile during the Fries rearrangement.  Lower 
yields were also observed with 2,5-disubstituted phenols (entries e and f), which were sterically 
hindered and also tended to sublime into the condenser.  Additionally, lower yields were observed 
with 3-chlorophenol (entry m), demonstrating the effect of the deactivating substituent.   
The fluoro-substituted phenol (entry l) was unique in having an electron-withdrawing group while 
still giving a good yield of product. This is typical of fluorine-substituted aromatics which show 
high reactivity in the para position relative to the fluorine.142-143  In 3-fluorophenol, the fluorine is 
para to the position that accepts the acylium ion during the Fries rearrangement, and thus, the 
conversion was better than expected.  Interestingly, 2-naphthol (entry j) and 5,6,7,8-tetrahydro-2-
naphthol (entry k) gave different regioselectivities in the ring closing reaction, with 2-naphthol 
closing at C1 (toward the fused ring) to generate an angular structure, while the tetrahydro 
derivative closed at C3 (away from the fused ring) to form the linear ring structure.  Finally, the 
yields of 4-chromanones were slightly lower for reactions involving crotonic acid, as might be 
expected for a substrate with less stabilization of the acylium ion intermediate.  
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Scheme 2.11. A plausible mechanism for the Bi(OTf)3 catalyzed synthesis of 4-chromanones 
A brief outline of the presumed mechanism is shown for the conversion of 72c to 71c in Scheme 
2.11.  Close monitoring of the reaction by thin layer chromatography indicated that the first 
intermediate in the process is the aryl ester 68c.  While this process produces an equivalent of 
water, which could decompose the catalyst, the boiling toluene solvent serves to remove this by-
product from the reaction by azeotropic distillation into the condenser.  The ester would then 
undergo a Fries rearrangement to give 1-(2-hydroxy-4-methylphenyl)-3-methylbut-2-en-1-one 
(70c).  While this species is a significant product in the aluminum chloride catalyzed reaction, 
strong coordination of the (excess) aluminum chloride with both the phenol and side chain 
oxygen functions prevents cyclization.  However, when 70c is exposed to catalytic bismuth(III) 
triflate, it is rapidly and quantitatively converted to the ring closed product.  Once ring closure 
occurs, proton transfer and tautomerization would lead to the observed 4-chromanone 71c. 
2.2.12 Conclusion 
72c 68c 74 
75 70c 76 
77 78 71c 
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An efficient bismuth(III) catalyzed tandem reaction was developed to prepare 4-chromanones 
from electron rich phenols and 3,3-dimethylacrylic acid or trans-crotonic acid. The procedure is 
convenient to perform, product purification was straightforward, and the target heterocycles are 
isolated in fair to excellent yields. A reasonable selection of substrates was surveyed to define the 
scope of the reaction. Limitations were predictably associated with deactivating groups on the 
aromatic nucleus and steric hindrance toward reattachment of the acyl group to the aromatic ring 
during the Fries rearrangement. Additionally, experiments confirmed that the sequence of events 
during the reaction involved (1) esterification of the acid by the phenol, (2) Fries rearrangement 
of the 2-butenyl acylium fragment to the less hindered ortho position and (3) oxa-Michael ring 
closure of the phenolic OH to the side chain enone of the Fries product.  
2.3 Chemistry  
General Methods: All reactions were run under dry nitrogen in oven-dried glassware. Reactions 
were monitored by thin layer chromatography on silica gel GF plates (Analtech, No. 21521). 
Preparative separations were performed by one of the following methods: (1) preparative thin 
layer chromatography (PTLC) on 20-cm × 20-cm silica gel GF plates (Analtech, No. 02015) or 
(2) column chromatography on silica gel (grade 62, 60–200 mesh) containing UV-active 
phosphor (Sorbent Technologies, No. UV-05) packed into quartz columns. Band elution for all 
chromatographic methods was monitored using a hand-held UV lamp. Melting points were 
uncorrected. FT-IR spectra were run as thin films on NaCl disks or as Nujol mulls. Unless 
otherwise indicated, 1H and 13C NMR spectra were measured in CDCl3 using (CH3)4Si as the 
internal standard; coupling constants (J) are given in Hertz. Low-resolution mass spectra 
(electron impact/direct probe) were obtained at 70 eV. Elemental analyses (±0.4%) were 
performed by Atlantic Microlabs, Inc., Norcross, GA 30071.  All 5-amino-1H-pyrazoles were 
obtained commercially except for ethyl 5-aminopyrazole-3-carboxylate, which was prepared by 
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the method of Skinner and co-workers.79 High-resolution mass spectra (HRMS-ESI) were 
determined using a Thermo LTQ-OrbitrapXL mass spectrometer. 
2.3.1 Isoquinolin-1(2H)-ones and 1,6-naphthyridin-5(6H)-ones 
Representative synthesis of β-enaminoesters 2 
A solution of β-ketoester 1 (10 mmol) in 50 mL of benzene was treated with benzylamine 
(10.5 mmol) and one crystal of p-TsOH. The solution was refluxed for 8 h with Dean–Stark 
removal of H2O. The reaction was cooled and concentrated under vacuum to give the β-
enaminoester as a yellow oil. The Z isomer was strongly favored due to intramolecular hydrogen 
bonding. The product was nearly pure by 1H NMR, but sensitive toward chromatography. It was, 
therefore, used without further purification. 
Methyl (Z)-3-(benzylamino)-2-butenoate (2a). IR: 3292, 1653, 1607 cm−1; 1H NMR 
(300 MHz): δ 8.94 (br s, 1H), 7.36–7.19 (complex m, 5H), 4.54 (s, 1H), 4.42 (d, J = 6.6 Hz, 2H), 
3.63 (s, 3H), 1.90 (s, 3H); 13C NMR (75 MHz): δ 170.8, 161.9, 138.6, 128.7, 127.3, 126.6, 82.7, 
49.9, 46.7, 19.3; ms: m/z 114 (M+−C7H7). 
Methyl (Z)-3-(benzylamino)-2-pentenoate (2b). IR: 3287, 1653, 1606 cm−1; 1H NMR 
(300 MHz): δ 8.96 (br s, 1H), 7.38–7.18 (complex m, 5H), 4.57 (s, 1H), 4.43 (d, J = 6.6 Hz, 2H), 
3.64 (s, 3H), 2.23 (q, J = 7.1 Hz, 2H), 1.12 (q, J = 7.1 Hz, 3H); 13C NMR (75 MHz): δ 171.2, 
167.0, 138.7, 128.7, 127.3, 126.7, 80.7, 50.0, 46.3, 25.1, 12.1; ms: m/z 128 (M+−C7H7). 
Methyl (Z)-3-(benzylamino)-2-hexenoate (2c). IR: 3287, 1655, 1606 cm−1; 1H NMR 
(300 MHz): δ 8.94 (br s, 1H), 7.37–7.21 (complex m, 5H), 4.55 (s, 1H), 4.42 (d, J = 6.6 Hz, 2H), 
3.63 (s, 3H), 2.20 (t, J = 7.7 Hz, 2H), 1.55 (sextet, J = 7.7 Hz, 2H), 0.95 (t, J = 7.7 Hz, 3H); 13C 
NMR (75 MHz): δ 171.1, 165.6, 138.7, 128.7, 127.3, 126.7, 81.8, 49.9, 46.4, 34.2, 21.2, 13.8; 
ms: m/z 142 (M+−C7H7) 
Methyl (Z)-3-(benzylamino)-2-octenoate (2d). IR: 3285, 1657, 1606 cm−1; 1H NMR 
(300 MHz): δ 8.94 (br s, 1H), 7.38–7.22 (complex m, 5H), 4.55 (s, 1H), 4.42 (d, J = 6.6 Hz, 2H), 
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3.63 (s, 3H), 2.18 (t, J = 7.1 Hz, 2H), 1.52 (quintet, J=7.1 Hz, 2H), 1.30 (m, 4H), 0.87 (t, J = 
6.6 Hz, 3H); 13C NMR (75 MHz): δ 171.1, 165.9, 138.7, 128.7, 127.3, 126.7, 81.7, 49.9, 46.4, 
32.2, 31.4, 27.7, 22.3, 13.7; ms: m/z 170 (M+−C7H7). 
Methyl (Z)-3-(benzylamino)-5-phenyl-2-pentenoate (2e). IR: 3285, 1653, 1606 cm−1; 1H NMR 
(300 MHz): δ 8.97 (br s, 1H), 7.38–7.20 (complex m, 8H), 7.13 (d, J = 6.6 Hz, 2H), 4.62 (s, 1H), 
4.37 (d, J = 6.6 Hz, 2H), 3.64 (s, 3H), 2.81 (t, J = 7.7 Hz, 2H), 2.48 (t, J = 7.7 Hz, 2H); 13C NMR 
(75 MHz): δ 171.1, 164.8, 140.4, 138.5, 128.8, 128.5, 128.2, 127.4, 126.7, 126.3, 82.0, 50.0, 46.4, 
34.5, 34.0; ms: m/z 204 (M+−C7H7). 
Methyl (Z)-3-(benzylamino)-2,6-heptadienoate (2f). IR: 3286, 1655, 1610 cm−1; 1H NMR 
(300 MHz): δ 8.95 (br s, 1H), 7.39–7.21 (complex m, 5H), 5.79 (ddt, J = 17.0, 9.3, 4.9 Hz, 1H), 
5.02 (d, J = 17.0 Hz, 1H), 5.00 (d, J = 9.3 Hz, 1H), 4.56 (s, 1H), 4.43 (d, J = 6.6 Hz, 2H), 3.64 (s, 
3H), 2.28 (m, 4H); 13C NMR (75 MHz): δ 171.0, 164.8, 138.6, 136.6, 128.8, 127.4, 126.7, 115.6, 
82.0, 50.0, 46.5, 32.0, 31.5; ms: m/z 154 (M+−C7H7). 
Methyl (Z)-3-(benzylamino)-4-methyl-2-pentenoate (2g). IR: 3281, 1653, 1606 cm−1; 1H NMR 
(300 MHz): δ 9.07 (br s, 1H), 7.38–7.21 (complex m, 5H), 4.61 (s, 1H), 4.45 (d, J = 6.0 Hz, 2H), 
3.64 (s, 3H), 2.66 (septet, J = 6.6 Hz, 1H), 1.10 (d, J = 6.6 Hz, 6H); 13C NMR (75 MHz): δ 171.8, 
171.6, 138.8, 128.7, 127.2, 126.2, 78.1, 50.0, 46.0, 28.5, 21.5; ms: m/z 142 (M+−C7H7). 
Methyl (Z)-3-(methylamino)-2-butenoate (2h). This compound was prepared in 84% yield by a 
literature procedure,72  mp 64–66 °C (lit72 mp 65–67 °C). IR 3310, 1652, 1604 cm−1; 1H NMR 
(300 MHz): δ 8.46 (br s, 1H), 4.47 (s, 1H), 3.61 (s, 3H), 2.91 (d, J = 4.9 Hz, 3H), 1.92 (s, 
3H); 13C NMR (75 MHz): δ 170.9, 162.8, 81.4, 49.8, 29.5, 19.1; ms: m/z 129 (M+). 
2-Fluoro-5-nitrobenzoyl chloride (4). This compound was prepared by refluxing 
acid 3 (10 mmol) with thionyl chloride (12 mmol) in benzene for 8 h. Removal of the solvent 
gave a tan solid, mp 59–60 °C. This material was spectroscopically pure and was used without 
further purification. IR: 1793, 1770, 1626, 1538, 1352 cm−1; 1H NMR (300 MHz): δ 9.02 (dd, J = 
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6.0, 3.0 Hz, 1H), 8.57 (dt, J = 8.8, 3.0 Hz, 1H), 7.44 (t, J = 9.3 Hz, 1H); 13C NMR 
(75 MHz): δ 164.2 (d, J = 276.8 Hz), 161.3 (d, J = 4.9 Hz), 143.9, 131.5 (d, J = 11.5 Hz), 129.5, 
123.0 (d, J = 9.8 Hz), 118.9 (d, J = 23.8 Hz). 
2-Chloronicotinoyl chloride (7). This compound was prepared by refluxing acid 6 (10 mmol) 
with thionyl chloride (12 mmol) in benzene for 8 h. Removal of the solvent gave a tan solid, mp 
39–42 °C (lit.144 mp 39–42 °C). The 1H NMR and 13C NMR spectra matched those reported 
previously144 and the compound was used without further purification 
General cyclization procedure for systems with diactivated aromatic acceptor rings 
A solution of enaminoester 2 (0.98 mmol) in 3 mL of purified 1,2-dichloroethane (DCE)72 was 
cooled to 10 °C and a solution of 5 (100 mg, 0.49 mmol) in 3 mL of DCE was added. The 
solution was stirred at 23 °C for 3 h, then cooled to 10 °C and TEA (0.98 mmol, 99 mg, 
0.136 mL) in 2 mL of DCE was added. The reaction was heated at reflux until complete (12–
18 h). The reaction was cooled and added to saturated aqueous NaCl (10 mL). The organic layer 
was separated, and the aqueous phase was washed with dichloromethane. The combined organic 
extracts were washed with aqueous NaCl, dried (MgSO4), filtered, and concentrated under 
vacuum. The crude product was purified by PTLC eluted with 1:1 ethyl acetate/hexanes 
containing 1% TEA. The following compounds were prepared by this method. 
2-Benzyl-4-methoxycarbonyl-3-methyl-7-nitroisoquinolin-1(2H)-one (8a). Yield: 146 mg 
(0.42 mmol, 85%) as a tan solid, mp 192–194 °C; IR: 1733, 1632, 1614, 1523, 1342 cm−1; 1H 
NMR (300 MHz): δ 9.13 (d, J = 2.7 Hz, 1H), 8.27 (dd, J = 9.9, 2.7 Hz, 1H), 7.44–7.31 (complex 
m, 4H), 7.07 (d, J = 6.6 Hz, 2H), 5.50 (s, 2H), 3.96 (s, 3H), 2.51 (s, 3H); 13C NMR 
(75 MHz): δ 173.1, 167.0, 151.2, 144.2, 143.4, 133.6, 129.6, 128.4, 126.7, 125.8, 125.0, 122.9, 
119.6, 118.1, 52.7, 51.4, 18.8; ms: m/z 261 (M+−C7H7). Anal. Calcd for C19H16N2O5: C, 64.77; H, 
4.55; N, 7.95. Found: C, 64.90; H, 4.58; N, 7.74. 
113 
 
2-Benzyl-3-ethyl-4-methoxycarbonyl-7-nitroisoquinolin-1(2H)-one (8b). Yield: 154 mg 
(0.42 mmol, 86%) as a tan solid, mp 128–130 °C; IR: 1730, 1630, 1613, 1523, 1354 cm−1; 1H 
NMR (300 MHz): δ 9.22 (d, J = 2.7 Hz, 1H), 8.28 (dd, J = 9.3, 2.7 Hz, 1H), 7.48–7.30 (complex 
m, 4H), 7.07 (d, J = 6.0 Hz, 2H), 5.52 (s, 2H), 3.97 (s, 3H), 2.78 (q, J = 7.7 Hz, 2H), 1.40 (t, J = 
7.7 Hz, 3H); 13C NMR (75 MHz): δ 173.6, 167.0, 155.5, 144.2, 143.5, 134.0, 129.6, 128.5, 126.7, 
126.3, 125.1, 123.3, 119.4, 118.2, 52.7, 50.7, 25.5, 13.7; ms: m/z 275 (M+−C7H7). Anal. Calcd for 
C20H18N2O5: C, 65.57; H, 4.92; N, 7.65. Found: C, 65.68; H, 4.90; N, 7.53. 
2-Benzyl-4-methoxycarbonyl-7-nitro-3-propylisoquinolin-1(2H)-one (8c). Yield: 152 mg 
(0.40 mmol, 82%) as a tan solid, mp 120–121 °C; IR: 1730, 1628, 1614, 1525, 1353 cm−1; 1H 
NMR (300 MHz): δ 9.22 (d, J = 2.7 Hz, 1H), 8.27 (dd, J = 9.3, 2.7 Hz, 1H), 7.45 (d, J = 9.3 Hz, 
1H), 7.44–7.32 (complex m, 3H), 7.07 (d, J = 6.6 Hz, 2H), 5.50 (s, 2H), 3.97 (s, 3H), 2.72 (t, J = 
7.7 Hz, 2H), 1.80 (sextet, J = 7.7 Hz, 2H), 1.04 (t, J = 7.7 Hz, 3H); 13C NMR (75 MHz): δ 173.5, 
167.1, 154.5, 144.2, 143.5, 134.0, 129.6, 128.5, 126.7, 126.3, 125.1, 123.2, 119.6, 118.3, 52.7, 
50.8, 34.0, 23.0, 14.3; ms: m/z 289 (M+−C7H7). Anal. Calcd for C21H20N2O5: C, 66.32; H, 5.26; N, 
7.37. Found: C, 66.52; H, 5.59; N, 7.19.  
2-Benzyl-4-methoxycarbonyl-7-nitro-3-pentylisoquinolin-1(2H)-one (8d). Yield: 148 mg 
(0.36 mmol, 74%) as a tan solid, mp 122–123 °C; IR: 1733, 1628, 1613, 1523, 1343 cm−1; 1H 
NMR (300 MHz): δ 9.18 (d, J = 2.7 Hz, 1H), 8.26 (dd, J = 9.3, 2.7 Hz, 1H), 7.49 (d, J = 9.3 Hz, 
1H), 7.41–7.30 (complex m, 3H), 7.08 (d, J = 6.6 Hz, 2H), 5.54 (s, 2H), 3.95 (s, 3H), 2.73 (t, J = 
7.7 Hz, 2H), 1.77 (quintet, J = 7.7 Hz, 2H), 1.34 (m, 4H), 0.88 (t, J = 6.6 Hz, 3H); 13C NMR 
(75 MHz): δ 173.4, 167.0, 154.7, 144.1, 143.3, 134.0, 129.4, 128.3, 126.5, 126.1, 125.0, 123.0, 
119.4, 118.4, 52.5, 50.7, 31.9, 31.6, 28.9, 21.8, 13.6; ms: m/z 317 (M+−C7H7). Anal. Calcd for 
C23H24N2O5: C, 67.65; H, 5.88; N, 6.86. Found: C, 67.91; H, 5.93; N, 6.51. 
2-Benzyl-3-(3-butenyl)-4-methoxycarbonyl-7-nitroisoquinolin-1(2H)-one (8e). Yield: 130 mg 
(0.33 mmol, 68%) as a yellow solid, mp 114–116 °C; IR: 1730, 1633, 1614, 1524, 1344 cm−1; 1H 
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NMR (300 MHz): δ 9.23 (d, J = 2.7 Hz, 1H), 8.29 (dd, J = 9.3, 2.7 1H), 7.45 (d, J = 9.3 Hz, 1H), 
7.44–7.31 (complex m, 3H), 7.07 (d, J = 6.6 Hz, 2H), 5.82 (ddt, J = 17.0, 9.9, 6.6 Hz, 1H), 5.50 
(s, 2H), 5.07 (d, J = 17.0 Hz, 1H), 5.06 (d, J = 9.9 Hz, 1H), 3.96 (s, 3H), 2.86 (t, J = 7.7 Hz, 2H), 
2.50 (q, J = 7.7 Hz, 2H); 13C NMR (75 MHz): δ 173.4, 166.9, 153.9, 144.2, 143.5, 135.1, 133.9, 
129.5, 128.5, 126.7, 126.2, 125.1, 123.2, 119.7, 118.4, 116.7, 52.7, 50.9, 33.0, 31.3; ms: m/z 301 
(M+−C7H7). Anal. Calcd for C22H20N2O5: C, 67.35; H, 5.10; N, 7.14. Found: C, 67.46; H, 5.12; N, 
7.07.  
2-Benzyl-4-methoxycarbonyl-7-nitro-3-(2-phenylethyl)isoquinolin-1(2H)-one (8f). Yield: 
175 mg (0.40 mmol, 81%) as a tan solid, mp 188–189 °C; IR: 1729, 1628, 1613, 1522, 
1343 cm−1; 1H NMR (300 MHz): δ 9.28 (d, J = 2.7 Hz, 1H), 8.32 (dd, J = 9.3, 2.7 Hz, 1H), 7.43 
(d, J = 9.3 Hz, 1H), 7.42–7.23 (complex m, 6H), 7.12 (d, J = 6.0 Hz, 2H), 7.05 (d, J = 6.0 Hz, 
2H), 5.40 (s, 2H), 4.00 (s, 3H), 3.05 (s, 4H); 13C NMR (75 MHz): δ 173.6, 167.1, 153.7, 144.2, 
143.8, 139.1, 133.9, 129.7, 128.9, 128.7, 128.1, 127.1, 126.9, 126.5, 125.1, 123.5, 119.8, 118.2, 
52.9, 50.9, 35.6, 33.9; ms: m/z 351 (M+−C7H7). Anal. Calcd for C26H22N2O5: C, 70.59; H, 4.98; N, 
6.33. Found: C, 70.66; H, 5.01; N, 6.25. 
2-Benzyl-3-isopropyl-4-methoxycarbonyl-7-nitroisoquinolin-1(2H)-one (8g). Yield: 56 mg 
(0.15 mmol, 30%) as a tan solid, mp 170–172 °C; IR: 1730, 1625, 1610, 1524, 1344 cm−1; 1H 
NMR (300 MHz): δ 9.22 (d, J = 2.7 Hz, 1H), 8.27 (dd, J = 9.3, 2.7 Hz, 1H), 7.45–7.31 (complex 
m, 4H), 7.10 (d, J = 6.6 Hz, 2H), 5.52 (s, 2H), 3.96 (s, 3H), 3.20 (septet, J = 7.1 Hz, 1H), 1.42 
(d, J = 7.1 Hz, 6H); 13C NMR (75 MHz): δ 174.6, 167.3, 158.1, 144.8, 143.4, 134.3, 129.6, 
128.46, 128.43, 126.6, 125.6, 124.9, 123.0, 118.5, 52.6, 51.6, 31.8, 29.6, 20.6; ms: m/z 289 
(M+−C7H7). Anal. Calcd for C21H20N2O5: C, 66.32; H, 5.26; N, 7.37. Found: C, 66.45; H, 5.30; N, 
7.23.  
2,3-Dimethyl-4-methoxycarbonyl-7-nitroisoquinolin-1(2H)-one (8h). Yield: 115 mg 
(0.42 mmol, 85%) as a yellow solid, mp 298–300 °C (darkens); IR: 1725, 1626, 1611, 1523, 
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1340 cm−1; 1H NMR (300 MHz, DMSO-d6): δ 8.85 (d, J = 2.7 Hz, 1H), 8.49 (dd, J = 9.3, 2.7 Hz, 
1H), 8.08 (d, J = 9.3 Hz, 1H), 3.83 (s, 3H), 3.82 (s, 3H), 2.50 (s, 3H); 13C NMR (75 MHz, 
DMSO-d6): δ 172.0, 167.0, 151.9, 144.6, 142.8, 126.4, 124.8, 121.4, 119.3, 118.7, 52.3, 35.7, 
19.3; ms: m/z 276 (M+). Anal. Calcd for C13H12N2O5: C, 56.52; H, 4.35; N, 10.14. Found: C, 
56.57; H, 4.35; N, 10.08. 
General cyclization procedure for systems with monoactivated aromatic acceptor rings 
A 15-mL, screw-top, pressure vessel (ChemGlass, No CG-1880-01) was charged with 
enaminoester 2 (2.52 mmol) and 2 mL of purified 1,4-dioxane. The solution was cooled to 15 °C, 
and a solution of 2-fluorobenzoyl chloride (6) (200 mg, 1.26 mmol) in 2 mL of dioxane was 
added. The reaction was stirred at 23 °C for 3 h, then cooled to 15 °C and DBU (2.52 mmol, 
383 mg, 0.376 mL) in 1 mL of dioxane was added. The reaction was sealed under nitrogen, and 
heated to 130 °C for 3 h. The reaction was cooled and concentrated under vacuum. The residue 
was dissolved in dichloromethane, washed with water and aqueous NaCl, dried (MgSO4), filtered, 
and concentrated under vacuum. The resulting product was purified on a 20 cm × 2 cm silica gel 
column eluted with increasing concentrations of ethyl acetate in hexanes. The following 
compounds were prepared: 
2-Benzyl-4-methoxycarbonyl-3-methylisoquinolin-1(2H)-one (9a). Yield: 220 mg (0.72 mmol, 
57%) as a white solid, mp 113–115 °C; IR: 1727, 1618, 1602 cm−1; 1H NMR (300 MHz): δ 8.46 
(dd, J = 8.2, 1.6 Hz, 1H), 7.53 (td, J = 7.1, 1.6 Hz, 1H), 7.42–7.24 (complex m, 5H), 7.08 (d, J = 
6.6 Hz, 2H), 5.44 (s, 2H), 3.96 (s, 3H), 2.43 (s, 3H); 13C NMR (75 MHz): δ 174.2, 168.2, 149.8, 
140.8, 134.6, 132.7, 129.2, 127.9, 126.7, 126.3, 125.1, 124.0, 118.2, 116.2, 52.4, 50.6, 18.6; 
ms: m/z 216 (M+−C7H7). Anal. Calcd for C19H17NO3: C, 74.27; H, 5.54; N, 4.56. Found: C, 74.19; 
H, 5.55; N, 4.51. 
2-Benzyl-3-ethyl-4-methoxycarbonylisoquinolin-1(2H)-one (9b). Yield: 210 mg (0.66 mmol, 
52%) as a white solid, mp 108-109 oC; IR: 1727, 1618, 1600 cm-1; 1H NMR (300 MHz): δ 8.46 
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(d, J = 8.2 Hz, 1H), 7.51 (t, J = 7.1 Hz, 1H), 7.40-7.25 (complex m, 5H), 7.07 (d, J = 7.1 Hz, 2H), 
5.46 (s, 2H), 3.96 (s, 3H), 2.76 (q, J = 7.1 Hz, 2H), 1.37 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz): 
δ 174.7, 168.2, 154.3, 140.8, 135.1, 132.7, 129.3, 128.0, 126.9, 126.6, 125.2, 124.0, 117.9, 116.5, 
52.5, 50.0, 25.3, 13.8; ms: m/z 230 (M+-C7H7). Anal. Calcd for C20H19NO3: C, 74.77; H, 5.92; N, 
4.36. Found: C, 74.91; H, 5.94; N, 4.27. 
2-Benzyl-4-methoxycarbonyl-3-propylisoquinolin-1(2H)-one (9c). Yield: 245 mg (0.73 mmol, 
58%) as a white solid, mp 168-169 oC; IR: 1727, 1619, 1600 cm-1; 1H NMR (300 MHz): δ 8.46 
(d, J  = 8.2 Hz, 1H), 7.51 (t, J  = 6.6 Hz, 1H), 7.40-7.25 (complex m, 5H), 7.07 (d, J  = 7.1 Hz, 
2H), 5.44 (s, 2H), 3.96 (s, 3H), 2.69 (t, J  = 7.7 Hz, 2H), 1.79 (sextet, J  = 7.7 Hz, 2H), 1.01 (t, J  
= 7.1 Hz, 3H); 13C NMR (75 MHz): δ 174.6, 168.2, 153.3, 140.8, 135.1, 132.7, 129.3, 128.1, 
127.0, 126.7, 125.3, 124.1, 118.2, 116.5, 52.5, 50.2, 33.9, 23.1, 14.3; ms: m/z 244 (M+-C7H7). 
Anal. Calcd for C21H21NO3: C, 75.22; H, 6.27; N, 4.18. Found: C, 75.31; H, 6.30; N, 4.05. 
2-Benzyl-4-methoxycarbonyl-3-pentylisoquinolin-1(2H)-one (9d). Yield: 229 mg (0.63 mmol, 
50%) as a white solid, mp 92-93 oC; IR: 1727, 1619, 1600 cm-1; 1H NMR (300 MHz): δ 8.47 (d, J  
= 7.7 Hz, 1H), 7.52 (t, J  = 7.1 Hz, 1H), 7.41-7.27 (complex m, 5H), 7.07 (d, J  = 6.6 Hz, 2H), 
5.44 (s, 2H), 3.96 (s, 3H), 2.69 (t, J  = 7.7 Hz, 2H), 1.75 (quintet, J  = 7.1 Hz, 2H), 1.60 (m, 4H), 
0.88 (t, J  = 7.1 Hz, 3H); 13C NMR (75 MHz): δ 174.6, 168.2, 153.5, 140.8, 135.1, 132.7, 129.3, 
128.1, 127.0, 126.7, 125.3, 124.1, 118.2, 116.5, 52.5, 50.2, 31.9, 31.8, 29.2, 22.1, 13.8; ms: m/z 
272 (M+-C7H7). Anal. Calcd for C23H25NO3: C, 76.03; H, 6.89; N, 3.86. Found: C, 75.97; H, 6.93; 
N, 3.69.  
2-Benzyl-3-(3-butenyl)-4-methoxycarbonylisoquinolin-1(2H)-one (9e). Yield: 262 mg (0.76 
mmol, 60%) as a white solid, mp 106-107 oC; IR: 1726, 1618, 1601 cm-1 ; 1H NMR (300 MHz): δ 
8.48 (dd, J  = 6.6, 1.6 Hz, 1H), 7.53 (t, J  = 7.1 Hz, 1H), 7.40-7.28 (complex m, 5H), 7.07 (d, J  = 
6.6 Hz, 2H), 5.82 (ddt, J  = 17.0, 10.4, 6.6 Hz, 1H), 5.42 (s, 2H), 5.06 (d, J  = 17.0 Hz, 1H), 5.05 
(d, J  = 10.4 Hz, 1H), 3.96 (s, 3H), 2.83 (t, J  = 6.6 Hz, 2H), 2.49 (q, J  = 6.6 Hz, 2H); 13C NMR 
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(75 MHz): δ 174.6, 168.1, 152.6, 140.8, 135.7, 135.0, 132.8, 129.4, 128.1, 127.0, 126.7, 125.3, 
124.2, 118.2, 116.5, 116.4, 52.5, 50.3, 33.3, 31.2; ms: m/z 256 (M+). Anal. Calcd for C22H21NO3: 
C, 76.08; H, 6.05; N, 4.03. Found: C, 76.01; H, 6.08; N, 3.98. 
2-Benzyl-4-methoxycarbonyl-3-(2-phenylethyl)isoquinolin-1(2H)-one (9f). Yield: 365 mg 
(0.92 mmol, 73%) as a white solid, mp 154-156 oC; IR: 1724, 1616, 1600 cm-1 ; 1H NMR (300 
MHz): δ 8.48 (dd, J  = 6.6, 1.1 Hz, 1H), 7.53 (t, J  = 8.2 Hz, 1H), 7.40-7.19 (complex m, 9H), 
7.12 (d, J  = 6.6 Hz, 2H), 7.06 (d, J  = 6.6 Hz, 2H), 5.40 (s, 2H), 3.98 (s, 3H), 3.03 (s, 3H); 13C 
NMR (75 MHz): δ 174.6, 168.2, 152.5, 140.9, 138.5, 135.0, 132.8, 129.4, 128.8, 128.1, 127.0, 
126.8, 126.7, 125.3, 124.2, 118.3, 116.5, 52.6, 50.2, 35.6, 33.9 (one aromatic C was unresolved); 
ms: m/z 306 (M+-C7H7). Anal. Calcd for C26H23NO3: C, 78.59; H, 5.79; N, 3.53. Found: C, 78.55; 
H, 5.80; N, 3.49.  
2-Benzyl-3-isopropyl-4-methoxycarbonylisoquinolin-1(2H)-one (9g). Yield: 126 mg (0.38 
mmol, 30%) as a white solid, mp 145-147 oC; IR: 1729, 1616, 1602 cm-1; 1H NMR (300 MHz): δ 
8.43 (dd, J  = 7.7, 1.1 Hz, 1H), 7.52 (td, J  = 7.7, 1.1 Hz, 1H), 7.42-7.23 (complex m, 5H), 7.10 
(d, J  = 6.6 Hz, 2H), 5.47 (s, 2H), 3.95 (s, 3H), 3.19 (septet, J  = 6.6 Hz, 1H), 1.40 (d, J  = 6.6 Hz, 
6H); 13C NMR (75 MHz): δ 175.6, 168.5, 156.7, 141.4, 135.5, 132.7, 129.3, 128.0, 126.7, 126.1, 
125.1, 123.9, 116.7, 52.4, 51.0, 31.7, 20.7 (1 aromatic C unresolved); ms: m/z 244 (M+). Anal. 
Calcd for C21H21NO3: C, 75.22; H, 6.27; N, 4.18. Found: C, 75.28; H, 6.24; N, 4.16.  
2,3-Dimethyl-4-methoxycarbonylisoquinolin-1(2H)-one (9h). Yield: 154 mg (0.66 mmol, 
53%) as a white solid, mp 156-157 oC; IR: 1721, 1610, 1601 cm-1; 1H NMR (300 MHz): δ 8.41 
(dd, J  = 8.2, 1.6 Hz, 1H), 7.64 (td, J  = 8.2, 1.6 Hz, 1H), 7.47 (d, J  = 8.8 Hz, 1H), 7.36 (t, J  = 
7.1 Hz, 1H), 3.94 (s, 3H), 3.74 (s, 3H), 2.50 (s, 3H); 13C NMR (75 MHz): δ 174.2, 168.4, 149.6, 
141.1, 132.6, 126.9, 126.3, 124.0, 118.1, 115.3, 52.5, 34.7, 19.4; ms: m/z 231 (M+). Anal. Calcd 
for C13H13NO3: C, 67.53; H, 5.63; N, 6.06. Found: C, 67.66; H, 5.65; N, 5.99. 
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General cyclization procedure for systems with 2-chloropyridine systems. These reactions 
were run as above using enaminoester 2 (3.42 mmol) and 7 (200 mg, 1.14 mmol) in purified 
DCE. The cyclization was completed by adding TEA (2.28 mmol, 230 mg, 0.317 mL) and 
heating at 130 oC for 8 h in a pressure tube. In each case, work-up and purification by PTLC, 
eluted with 1:1 ethyl acetate/hexanes containing 1% TEA, afforded the final product. [Note: DBU 
(2.28 mmol) was also used in the cyclization step, but the yields were lower.] The following 
compounds were prepared by this method.  
6-Benzyl-8-methoxycarbonyl-7-methyl-1,6-naphthyridin-5(6H)-one (10a). Yield: 246 mg 
(0.80 mmol, 70%) as a tan solid, mp 143-145 oC; IR: 1727, 1617, 1600 cm-1; 1H NMR (400 
MHz): δ 8.76 (dd, J  =  8.0, 2.0 Hz, 1H), 8.70 (dd, J  = 4.5, 2.0 Hz, 1H), 7.38 (dd, J  = 7.8, 4.5 Hz, 
1H), 7.35-7.24 (complex m, 3H), 7.04 (d, J  = 6.6 Hz, 2H), 5.89 (br s, 2H), 3.94 (s, 3H), 2.47 (s, 
3H); 13C NMR (100 MHz): δ 174.5, 167.7, 152.6, 151.4, 150.4, 136.2, 136.1, 129.0, 127.6, 125.8, 
120.8, 120.4, 119.1, 52.6, 48.0, 18.7; ms: m/z 217 (M+-C7H7). Anal. Calcd for C18H16N2O3: C, 
70.13; H, 5.19; N, 9.09. Found: C, 70.18; H, 5.20; N, 9.04.  
6-Benzyl-7-ethyl-8-methoxycarbonyl-1,6-naphthyridin-5(6H)-one (10b). Yield: 272 mg (0.84 
mmol, 74%) as a tan solid, mp 156-158 oC; IR: 1727, 1617, 1600 cm-1 ; 1H NMR (400 MHz): δ 
8.74 (dd, J  = 7.8, 2.0 Hz, 1H), 8.67 (dd, J  = 4.5, 2.0 Hz, 1H), 7.35 (dd, J  = 8.0, 4.5 Hz, 1H), 
7.32-7.22 (complex m, 3H), 7.01 (d, J  = 6.8 Hz, 2H), 5.79 (br s, 2H), 3.94 (s, 3H), 2.77 (q, J  = 
7.6 Hz, 2H), 1.34 (t, J  = 7.6 Hz, 3H); 13C NMR (100 MHz): δ 174.7, 167.5, 156.0, 152.5, 150.3, 
136.6, 136.0, 128.9, 127.5, 125.5, 120.8, 120.3, 118.7, 52.5, 47.4, 25.1, 13.8; ms: m/z 231 (M+-
C7H7). Anal. Calcd for C19H18N2O3: C, 70.81; H, 5.59; N, 8.70. Found: C, 70.88; H, 5.61; N, 8.57.  
6-Benzyl-8-methoxycarbonyl-7-propyl-1,6-naphthyridin-5(6H)-one (10c). Yield: 291 mg 
(0.87 mmol, 76%) as a tan solid, mp 162-163 oC; IR: 1727, 1617, 1600 cm-1; 1H NMR (400 
MHz): δ 8.74 (dd, J  = 8.0, 2.0 Hz, 1H), 8.67 (dd, J  = 4.5, 2.0 Hz, 1H), 7.35 (dd, J  = 7.8, 4.5 Hz, 
1H), 7.36-7.26 (complex m, 3H), 7.02 (d, J  = 6.8 Hz, 2H), 5.87 (br s, 2H), 3.94 (s, 3H), 2.70 (t, J  
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= 8.2 Hz, 2H), 1.74 (sextet, J  = 7.4 Hz, 2H), 1.01 (t, J  = 7.2 Hz, 3H); 13C NMR (100 MHz): δ 
174.7, 167.6, 154.9, 152.5, 150.3, 136.7, 136.1, 128.9, 127.6, 125.7, 120.9, 120.3, 118.9, 52.5, 
47.6, 33.7, 23.2, 14.4; ms: m/z 245 (M+-C7H7). Anal. Calcd for C20H20N2O3: C, 71.43; H, 5.95; N, 
8.33. Found: C, 71.39; H, 5.92; N, 8.29. 
6-Benzyl-8-methoxycarbonyl-7-pentyl-1,6-naphthyridin-5(6H)-one (10d). Yield: 290 mg 
(0.80 mmol, 70%) as a tan solid, mp 165-166 oC; IR: 1728, 1619, 1605 cm-1; 1H NMR (400 
MHz): δ 8.74 (dd, J  = 8.0, 4.5 Hz, 1H), 8.67 (dd, J  = 4.5, 2.0 Hz, 1H), 7.35 (dd, J  = 8.0, 4.5 Hz, 
1H), 7.33-7.23 (complex m, 3H), 7.02 (d, J  = 6.8 Hz, 2H), 5.88 (br s, 2H), 3.93 (s, 3H), 2.71 (t, J  
= 8.2 Hz, 2H), 1.71 (quintet, J  = 7.4 Hz, 2H), 1.38 (m, 4H), 0.89 (t, J  = 7.0 Hz, 3H); 13C NMR 
(100 MHz): δ 174.6, 167.6, 155.1, 152.5, 150.3, 136.6, 136.0, 128.9, 127.5, 125.6, 120.8, 120.3, 
118.8, 52.4, 47.6, 31.8, 31.6 29.2, 22.0, 13.8; ms: m/z 273 (M+-C7H7). Anal. Calcd for 
C22H24N2O3: C, 72.53; H, 6.59; N, 7.69. Found: C, 72.61; H, 6.59; N, 7.63.  
6-Benzyl-7-(3-butenyl)-8-methoxycarbonyl-1,6-naphthyridin-5(6H)-one (10e). Yield: 278 mg 
(0.80 mmol, 70%) as a tan solid, mp 135-136 oC; IR: 1727, 1617, 1600 cm-1; 1H NMR (400 
MHz): δ 8.75 (d, J  = 7.8 Hz, 1H), 8.69 (d, J  = 4.3 Hz, 1H), 7.37 (dd, J  = 7.8, 4.5 Hz, 1H), 7.34-
7.23 (complex m, 3H), 7.02 (d, J  = 6.8 Hz, 2H), 5.89 (br s, 2H), 5.81 (ddt, J  = 16.8, 10.1, 6.4 
Hz, 1H), 5.06 (d, J  = 16.6 Hz, 1H), 5.05 (d, J  = 10.3 Hz, 1H), 3.94 (s, 3H), 2.84 (t, J  = 8.0 Hz, 
2H), 2.44 (q, J  = 7.6 Hz, 2H); 13C NMR (100 MHz): δ 174.7, 167.5, 154.3, 152.6, 150.4, 136.6, 
136.2, 135.7, 129.0, 127.6, 125.7, 120.9, 120.4, 119.1, 116.3, 52.5, 47.7, 33.3, 31.0; ms: m/z 257 
(M+-C7H7). Anal. Calcd for C21H20N2O3: C, 72.41; H, 5.75; N, 8.05. Found: C, 72.29; H, 5.77; N, 
7.99. 
6-Benzyl-8-methoxycarbonyl-7-(2-phenylethyl)-1,6-naphthyridin-5(6H)-one (10f). Yield: 327 
mg (0.82 mmol, 72%) as a tan solid, mp 141-142 oC; IR: 1726, 1620, 1601 cm-1; 1H NMR (400 
MHz): δ 8.77 (d, J  = 7.8 Hz, 1H), 8.70 (d, J  = 4.5 Hz, 1H), 7.39 (dd, J  = 7.8, 4.5 Hz, 1H), 7.34-
7.21 (complex m, 6H), 7.12 (d, J  = 7.2 Hz, 2H), 7.01 (d, J  = 7.0 Hz, 2H), 5.87 (br s, 2H), 3.96 
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(s, 3H), 3.04 (m, 2H), 2.97 (m, 2H); 13C NMR (100 MHz): δ 174.8, 167.6, 154.2, 152.6, 150.4, 
139.6, 136.6, 136.2, 129.0, 128.8, 128.1, 127.7, 126.8, 125.7, 121.0, 120.5, 119.1, 52.6, 47.7, 
35.7, 33.8; ms: m/z 307 (M+-C7H7). Anal. Calcd for C25H22N2O3: C, 75.38; H, 5.53; N, 7.04. 
Found: C, 75.41; H, 5.50; N, 6.97. 
6-Benzyl-7-isopropyl-8-methoxycarbonyl-1,6-naphthyridin-5(6H)-one (10g). No naphthyri-
dinone product was formed in this reaction.  
6,7-Dimethyl-8-methoxycarbonyl-1,6-naphthyridin-5(6H)-one (10h). Yield: 222 mg (0.96 
mmol, 84%) as a tan solid, mp 189-191 C; IR: 1727, 1617, 1600 cm-1; 1H NMR (400 MHz): δ 
8.71 (dd, J  = 4.5, 2.1 Hz, 1H), 8.68 (dd, J  = 8.0, 2.1 Hz, 1H), 7.33 (dd, J  = 7.8, 4.5 Hz, 1H), 
3.92 (s, 3H), 3.94 (s, 3H), 2.57 (s, 3H); 13C NMR (100 MHz): δ 174.2, 167.8, 152.1, 151.4, 150.2, 
136.0, 120.9, 120.0, 118.5, 52.5, 32.4, 19.2; ms: m/z 232 (M+). Anal. Calcd for C12H12N2O3: C, 
62.07; H, 5.17; N, 12.07. Found: C, 62.21; H, 5.21; N, 11.94. 
2.3.2 Pyrazoloquinazolinones and pyrazolopyridopyrimidinones 
Representative procedure for the pyrazolo[1,5-a]quinazolin-5(4H)-one synthesis: To a 
cooled (-10 °C) mixture containing 5-amino-1H-pyrazole (0.65 mmol) and potassium carbonate 
(1.00 mmol) in 3.0 mL of anhydrous DMF was added dropwise a solution of the acid chloride 
(0.50 mmol) in 2.0 mL of DMF.  The reaction was stirred at -10 oC for 15 minutes, and then 
gradually warmed to room temperature.  After stirring at room temperature for 15 minutes, TLC 
indicated that acylation of the amino group was complete.   The reaction was then immersed in a 
preheated oil bath at 140-145 °C until the ring closure was complete (30 min-1h).  The reaction 
mass was cooled to room temperature and concentrated to dryness under vacuum.  The crude 
product was slurried in deionized water, filtered, and the resulting solid was washed with 
methanol:ether (2:1).  Alternatively, some cases required column chromatography, which was 
done on silica using methanol:dichloromethane (1:9) as the eluent [ethanol:dichloromethane (1:9) 
was used for the product having the ethyl ester]. 
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7-Nitropyrazolo[1,5-a]quinazolin-5(4H)-one (15a). Yield: 94 mg (0.41 mmol, 82%) as a yellow 
solid, mp > 300 °C; IR (Nujol mull): 3149, 1711 cm-1; 1H NMR (400 MHz, DMSO-d6): δ 13.0 (br 
s, 1H), 8.94 (d, J = 2.9 Hz, 1H), 8.49 (dd, J = 9.6, 2.8 Hz, 1H), 8.07 (d, J = 1.8 Hz, 1H), 7.53 (d, J 
= 9.6 Hz, 1H), 6.26 (d, J = 1.8 Hz, 1H); 13C NMR (100 MHz, DMSO-d6): δ 155.5, 146.1, 144.6, 
142.8, 140.8, 129.0, 125.2, 118.4, 111.7, 89.8; MS: m/z 230 (M+).  Anal. Calcd for C10H6N4O3: C, 
52.17; H, 2.61; N, 24.35.  Found: C, 52.04; H, 2.54; N, 24.47. 
2-Methyl-7-nitropyrazolo[1,5-a]quinazolin-5(4H)-one (15b). Yield: 95 mg (0.39 mmol, 78%) 
as a orange solid, mp > 300 °C; IR (Nujol mull): 3154, 1650 cm-1; 1H NMR (400 MHz, DMSO-
d6): δ 8.92 (s, 1H), 7.99 (d, J = 9.4 Hz, 1H), 7.14 (d, J = 9.5 Hz, 1H), 5.84 (s, 1H), 2.30 (s, 3H) 
(NH not observed); 13C NMR (100 MHz, DMSO-d6): δ 157.0, 154.2, 153.6, 153.2, 135.8, 126.6, 
125.4, 124.7, 110.6, 92.5, 15.1; MS: m/z 244 (M+).  Anal. Calcd for C11H8N4O3: C, 54.10; H, 
3.28; N, 22.95.  Found: C, 54.01; H, 3.24; N, 23.02. 
 2-Cyclopropyl-7-nitropyrazolo[1,5-a]quinazolin-5(4H)-one (15c). Yield: 102 mg (0.38 mmol, 
76%) as a red solid, mp > 300 °C; IR (Nujol mull): 3213, 1665 cm-1; 1H NMR (400 MHz, 
DMSO-d6): δ 8.77 (s, 1H), 8.37 (d, J = 8.8 Hz, 1H), 7.93 (d, J = 9.1 Hz, 1H), 5.24 (s, 1H), 1.89 
(m, 1H), 0.90 (dm, J = 10.8 Hz, 2H), 0.75 (dm, J = 5.3 Hz, 2H) (NH not observed); 13C NMR 
(100 MHz, DMSO-d6): δ 163.8, 160.0, 153.6, 142.2, 141.6, 126.3, 124.8, 118.6, 114.5, 86.8, 10.5, 
8.6; MS: m/z 270 (M+).  Anal. Calcd for C13H10N4O3: C, 57.78; H, 3.70; N, 20.74.  Found: C, 
57.69; H, 3.63; N, 20.84. 
 2-(4-Methylphenyl)-7-nitropyrazolo[1,5-a]quinazolin-5(4H)-one (15d). Yield: 125 mg (0.39 
mmol, 78%) as a yellow solid, mp > 300 °C; IR (Nujol mull): 3579, 1687 cm-1; 1H NMR (400 
MHz, DMSO-d6): δ 8.81 (s, 1H), 8.54 (d, J = 9.0 Hz, 1H), 8.20 (d, J = 9.0 Hz, 1H), 7.85 (d, J = 
7.6 Hz, 2H), 7.27 (d, J = 7.8 Hz, 2H), 6.21 (s, 1H), 2.36 (s, 3H) (NH not observed); 13C NMR 
(100 MHz, DMSO-d6): δ 160.9, 154.7, 143.4, 141.6, 138.5, 130.5, 129.7, 129.6, 128.1, 126.2, 
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124.6, 118.3, 115.6, 87.4, 21.4; MS: m/z 320 (M+). Anal. Calcd for C17H12N4O3: C, 63.75; H, 
3.75; N, 17.50.  Found: C, 63.67; H, 3.71; N, 17.62. 
Ethyl 7-nitro-5-oxo-4,5-dihydropyrazolo[1,5-a]quinazoline-2-carboxylate (15e).  Yield:  139 
mg (0.46 mmol, 92%) as a maroon powder, mp >300 oC; IR: 3149, 1716, 1656 cm-1; 1H NMR 
(400 MHz, DMSO-d6): δ 8.98 (s, 1H), 8.09 (d, J = 9.3 Hz, 1H), 7.28 (d, J = 9.5 Hz, 1H), 6.45 (s, 
1H), 4.35 (q, J = 7.1 Hz, 2H), 1.36 (t, J = 7.1 Hz, 3H) (NH not observed); 13C NMR (100 MHz, 
DMSO-d6): δ 163.4, 157.7, 153.5, 153.4, 147.1, 136.8, 126.5, 126.1, 125.2, 110.6, 94.2, 60.9, 
14.7; MS: m/z 302 (M+).  Anal. Calcd for C13H10N4O5: C, 51.66; H, 3.31; N, 18.54.  Found: C, 
51.84; H, 3.37; N, 18.39. 
7-Nitro-5-oxo-4,5-dihydropyrazolo[1,5-a]quinazoline-3-carbonitrile (15f).  Yield: 112 mg 
(0.44 mmol, 88%) as a yellow solid, mp > 300 °C; IR (Nujol mull): 3370, 2217, 1662 cm-1; 1H 
NMR (400 MHz, DMSO-d6): δ 8.97 (s, 1H), 8.30 (s, 1H), 8.23 (d, J = 9.1 Hz, 1H), 7.47 (d, J = 
9.3 Hz, 1H) (NH not observed); 13C NMR (100 MHz, DMSO-d6): δ 156.9, 155.2, 153.9, 146.9, 
138.9, 126.4, 126.3, 125.4, 116.3, 112.7, 75.8; MS: m/z 255 (M+). Anal. Calcd for C11H5N5O3: C, 
51.76; H, 1.96; N, 27.45.  Found: C, 51.64; H, 1.94; N, 27.63. 
7-Nitro-2-(thiophen-2-yl)pyrazolo[1,5-a]quinazolin-5(4H)-one (15g). Yield: 125 mg (0.40 
mmol, 80%) as a yellow solid, mp > 300 °C; IR (Nujol mull): 3572, 1671 cm-1; 1H NMR (400 
MHz, DMSO-d6): δ 8.81 (s, 1H), 8.46 (dd, J = 8.8, 2.2 Hz, 1H), 8.08 (d, J = 9.0 Hz, 1H), 7.55 (d, 
J = 4.4 Hz, 2H), 7.14 (t, J = 4.4 Hz, 1H), 6.01 (s, 1H) (NH not observed); 13C NMR (100 MHz, 
DMSO-d6): δ 163.0, 152.7, 150.3, 143.0, 141.4, 137.4, 128.2, 126.9, 126.3, 125.8, 124.7, 118.9, 
115.2, 87.5; MS: m/z 312 (M+).  Anal. Calcd for C14H8N4O3S: C, 53.85; H, 2.56; N, 17.95.  
Found: C, 53.78; H, 2.51; N, 18.05. 
Pyrazolo[1,5-a]quinazolin-5(4H)-one (15h). Yield: 75 mg (0.40 mmol, 81%) as a white solid, 
mp 270-271 °C; IR (Nujol mull): 3138, 1690 cm-1; 1H NMR(400 MHz, DMSO-d6): δ 12.2 (s, 
1H), 8.15 (d, J = 8.0 Hz, 1H), 8.09 (d, J = 8.2 Hz, 1H), 7.89 (t, J = 8.0 Hz, 1H), 7.80 (s, 1H), 7.50 
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(t, J = 7.8 Hz, 1H), 5.92 (s, 1H); 13C NMR (100 MHz, DMSO-d6): δ 158.9, 142.6, 139.0, 137.9, 
135.5, 128.7, 125.8, 116.6, 114.8, 89.0;  MS: m/z 185 (M+).  Anal. Calcd for C10H7N3O: C, 64.86; 
H, 3.78; N, 22.70.  Found: C, 64.88; H, 3.77; N, 22.66.   
2-Methylpyrazolo[1,5-a]quinazolin-5(4H)-one (15i).  Yield: 75 mg (0.37 mmol, 75%) as a 
white solid, mp 287-288 °C (lit75 mp 288-289 °C); IR (Nujol mull): 3175, 1669 cm-1; 1H NMR 
(400 MHz, DMSO-d6): δ 12.1 (s, 1H), 8.12 (d, J = 8.1 Hz, 1H), 7.61 (t, J = 7.7 Hz, 1H), 7.32 (d, J 
= 8.5 Hz, 1H), 7.11 (t, J = 7.5 Hz, 1H), 5.82 (s, 1H), 2.31 (s, 3H); 13C NMR (100 MHz, DMSO-
d6): δ 156.3, 154.1, 146.0, 143.0, 133.8, 127.7, 120.1, 118.7, 111.9, 87.4, 14.9; MS: m/z 199 (M+).  
Anal. Calcd for C11H9N3O: C, 66.33; H, 4.54; N, 21.11.  Found: C, 66.30; H, 4.54; N, 21.07.   
2-Cyclopropylpyrazolo[1,5-a]quinazolin-5(4H)-one (15j).  Yield: 89 mg (0.39 mmol, 79%) as 
a white solid, mp 298-299 °C; IR (Nujol mull): 3179, 1694 cm-1; 1H NMR (400 MHz, DMSO-d6): 
δ 12.1 (s, 1H), 8.16 (d, J = 8.0 Hz, 1H), 7.73 (t, J = 7.7 Hz, 1H), 7.37 (d, J = 8.4 Hz, 1H), 7.24 (t, 
J = 7.6 Hz, 1H), 5.82 (s, 1H), 2.03 (m, 1H), 1.00 (d, J = 7.9 Hz, 2H), 0.85 (d, J = 5.2 Hz, 2H); 13C 
NMR (100 MHz, DMSO-d6): δ 161.0, 155.6, 143.0, 140.0, 134.9, 128.0, 121.6, 116.3, 112.0, 
84.1, 10.3, 9.2; MS: m/z 225 (M+).  Anal. Calcd for C13H11N3O: C, 69.33; H, 4.89; N, 18.67.  
Found: C, 69.27; H, 4.91; N, 18.59.   
2-(4-Methylphenyl)pyrazolo[1,5-a]quinazolin-5(4H)-one (15k). Yield: 105 mg (0.38 mmol, 
77%) as a white solid, mp >300 °C; IR (Nujol mull): 3177, 1684 cm-1; 1H NMR (400 MHz, 
DMSO-d6): δ 12.3 (s, 1H), 8.22 (d, J = 7.9 Hz, 1H), 7.94 (d, J = 7.8 Hz, 2H), 7.77 (t, J = 7.8 Hz, 
1H), 7.43 (d, J = 8.4 Hz, 1H), 7.32 (d, J = 7.9 Hz, 2H), 7.28 (t, J = 7.7 Hz, 1H), 6.55 (s, 1H), 2.38 
(s, 3H); 13C NMR (100 MHz, DMSO-d6): δ 156.0, 155.4, 143.7, 140.2, 139.2, 135.1, 130.0, 
129.8, 128.0, 126.8, 121.8, 116.5, 112.2, 84.5, 21.4; MS: m/z 275 (M+). Anal. Calcd for 
C17H13N3O: C, 74.18; H, 4.73; N, 15.27.  Found: C, 74.13; H, 4.78; N, 15.18.   
Ethyl 5-oxo-4,5-dihydropyrazolo[1,5-a]quinazoline-2-carboxylate (15l).  Yield 116 mg (0.45 
mmol, 90%) as a white solid, mp 282-283 oC; IR (Nujol mull): 3129, 1718, 1692 cm-1; 1H NMR 
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(400 MHz, DMSO-d6): δ 12.4 (s, 1H), 8.17 (apparent t, J = 8.3 Hz, 2H), 7.94 (t, J = 7.6 Hz, 1H), 
7.59 (t, J = 7.6 Hz, 1H), 6.27 (s, 1H), 4.35 (q, J = 7.1 Hz, 2H), 1.34 (t, J = 7.1 Hz, 3H); 13C NMR 
(100 MHz, DMSO-d6): δ 161.8, 158.6, 144.9, 139.9, 137.4, 135.7, 128.7, 127.1, 117.8, 115.4, 
90.7, 61.2, 14.6; MS: m/z 257 (M+).  Anal. Calcd for C13H11N3O3: C, 64.10; H, 4.28; N, 16.34.  
Found: C, 64.04; H, 4.25; N, 16.19. 
5-Oxo-4,5-dihydropyrazolo[1,5-a]quinazoline-3-carbonitrile (15m). Yield: 97 mg (0.46 mmol, 
93%) as a white solid, mp >300 °C; IR (Nujol mull): 3093, 2213, 1699 cm-1; 1H NMR (400 MHz, 
DMSO-d6): δ 8.06 (d, J = 7.8 Hz, 1H), 7.97 (s, 1H), 7.93 (d, J = 8.1 Hz, 1H), 7.68 (t, J = 7.6 Hz, 
1H), 7.37 (t, J = 7.5 Hz, 1H) (NH not observed); 13C NMR (100 MHz, DMSO-d6): δ 166.1, 154.5, 
143.8, 137.6, 132.1, 128.4, 124.5, 119.1, 117.0, 113.9, 74.1; MS: m/z 210 (M+).  Anal. Calcd for 
C11H6N4O: C, 62.86; H, 2.86; N, 26.67.  Found: C, 62.79; H, 2.81; N, 26.65. 
Pyrazolo[1,5-a]pyrido[3,2-e]pyrimidin-5(4H)-one (16a). Yield: 61 mg (0.33 mmol, 66%) as a 
yellow solid, mp >300 °C; IR (Nujol mull): 3509, 1664 cm-1; 1H NMR (400 MHz, DMSO-d6): δ 
8.55 (dd, J = 4.5, 1.7 Hz, 1H), 8.33 (dd, J = 7.6, 1.7 Hz, 1H), 7.55 (s, 1H), 7.31 (dd, J = 7.7, 4.7 
Hz, 1H), 5.50 (s, 1H) (NH not observed); 13C NMR (100 MHz, DMSO-d6): δ 163.7, 152.2, 149.7, 
147.5, 142.0, 136.2, 118.9, 113.5, 88.9; MS: m/z 186 (M+).  Anal. Calcd for C9H6N4O: C, 58.06; 
H, 3.23; N, 30.11.  Found: C, 57.94; H, 3.19; N, 30.19. 
2-Methylpyrazolo[1,5-a]pyrido[3,2-e]pyrimidin-5(4H)-one (16b).  Yield: 71 mg (0.35 mmol, 
71%) as a yellow solid, mp >300 °C; IR (Nujol mull): 3071, 1683 cm-1; 1H NMR (400 MHz, 
DMSO-d6): δ 8.53 (dd, J = 4.3, 2.2 Hz, 1H), 8.34 (dd, J = 8.0, 2.2 Hz, 1H), 6.76 (dd  J = 7.8, 4.2 
Hz, 1H), 5.66 (s, 1H), 2.29 (s, 3H) (NH not observed); 13C NMR (100 MHz, DMSO-d6): δ 158.0, 
157.9, 154.2, 153.8, 153.6, 136.3, 112.2, 106.3, 89.4, 15.3; MS: m/z 200 (M+).  Anal. Calcd for 
C10H8N4O: C, 60.00; H, 4.00; N, 28.00.  Found: C, 59.93; H, 3.97; N, 28.06.  
2-Cyclopropylpyrazolo[1,5-a]pyrido[3,2-e]pyrimidin-5(4H)-one (16c).  Yield: 88 mg (0.39 
mmol, 78%) as a yellow solid, mp >300 °C; IR (Nujol mull): 3120, 1695 cm-1; 1H NMR (400 
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MHz, DMSO-d6): δ 12.6 (s, 1H), 8.72 (d, J = 4.4 Hz, 1H), 8.54 (d, J = 7.7 Hz, 1H), 7.30 (dd, J = 
7.8, 4.7 Hz, 1H), 5.82 (s, 1H), 2.04 (m, 1H), 1.00 (m, 2H), 0.85 (m, 2H); 13C NMR (100 MHz, 
DMSO-d6): δ 160.9, 154.9, 154.7, 149.8, 142.2, 137.3, 117.5, 107.1, 84.9, 9.7, 8.7; MS: m/z 226 
(M+). Anal. Calcd for C12H10N4O: C, 63.72; H, 4.42; N, 24.78.  Found: C, 63.68; H, 4.39; N, 
24.85.  
2-(4-Methylphenyl)pyrazolo[1,5-a]pyrido[3,2-e]pyrimidin-5(4H)-one (16d).  Yield: 113 mg 
(0.41 mmol, 82%) as a yellow solid, mp >300 °C; IR (Nujol mull): 3118, 1668 cm-1; 1H NMR 
(400 MHz, DMSO-d6): δ 8.57 (dd, J = 4.0, 2.3 Hz, 1H), 8.38 (dd, J = 8.3, 2.3 Hz, 1H), 7.88 (d, J 
= 7.8 Hz, 2H), 7.26 (d, J = 7.8 Hz, 2H), 6.79 (dd, J = 7.8, 4.2 Hz, 1H), 6.27 (s, 1H), 2.36 (s, 3H) 
(NH not observed); 13C NMR (100 MHz, DMSO-d6) δ 158.0, 157.9, 154.6, 154.4, 154.2, 137.7, 
136.4, 132.2, 129.5, 126.4, 112.5, 106.7, 86.8, 21.4; MS: m/z 276 (M+). Anal. Calcd for 
C16H12N4O: C, 69.56; H, 4.35; N, 20.29.  Found: C, 69.53; H, 4.34; N, 20.25. 
5-Oxo-4,5-dihydropyrazolo[1,5-a]pyrido[3,2-e]pyrimidine-3-carbonitrile (16f). Yield: 92 mg 
(0.44 mmol, 87%) as a yellow solid, mp >300 °C; IR (Nujol mull): 3445, 2221, 1673 cm-1; 1H 
NMR (400 MHz, DMSO-d6): δ 8.68 (d, J = 4.6 Hz, 1H), 8.41 (d, J = 7.7 Hz, 1H), 8.02 (s, 1H), 
7.47 (dd, J = 7.0, 5.4 Hz, 1H) (NH not observed); 13C NMR (100 MHz, DMSO-d6): δ 165.9, 
156.4, 152.0, 147.9, 144.6, 137.7, 121.5, 116.7, 114.5, 74.6; MS: m/z 211 (M+). Anal. Calcd for 
C10H5N5O: C, 56.87; H, 2.37; N, 33.18.  Found: C, 56.89; H, 2.36; N, 33.11.  
2.3.3 Benzo[4,5]imidazo[2,1-b]quinazolin-12-ones  and  benzo[4,5]imidazo[1,2-a]-  
         pyrido[2,3-d]pyrimidin-5-ones 
Representative procedure for the synthesis of benzo[4,5]imidazo[2,1-b]quinazolin-12-ones  
and  benzo[4,5]imidazo[1,2-a]-pyrido[2,3-d]pyrimidin-5-ones:  
To a stirred reaction mixture of NaHCO3 (2.14 mmol, 2.0 equiv) and benzimidazole (1.28 
mmol, 1.2 equiv) in DMF (6 mL) was added dropwise the acid chloride (1.07 mmol, 1.0 equiv) 
in DMF (4.0 mL) over a period of 30 min at –10 °C. The resulting reaction mass was allowed 
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to warm to room temperature, maintained for 30 min, and immersed in a preheated oil bath (75-
80 °C). The reaction was monitored by TLC (5% MeOH in CHCl3). Upon completion, the 
DMF was removed under vacuum at 65-70 °C, the residue was made into a slurry in water, and 
was then filtered. The resulting solid was stirred with ethanol at reflux temperature for 15 min, 
cooled and filtered. 
2-Nitrobenzo[4,5]imidazo[2,1-b]quinazolin-12-one (23a): Yield: 88% (264 mg, 0.94 mmol) 
as a crimson red solid, mp > 300 °C; IR: 3151, 1655, 1548, 1345 cm-1; 1H NMR (DMSO-d6, 
400 MHz): δ 8.95 (d, J = 1.7 Hz, 1H), 8.39 (d, J = 7.9 Hz, 1H), 8.21 (dd, J = 9.3, 1.7 Hz, 1H), 
7.49 (d, J = 7.9 Hz, 1H), 7.36 (d, J = 9.3 Hz, 1H and t, J = 7.9 Hz, 1H), 7.12 (t, J = 7.7 Hz, 1H) 
(NH not observed); 13C NMR (DMSO-d6, 100 MHz, 110 oC): δ 158.8, 149.1, 143.6, 141.4, 
133.5 (br), 128.4, 126.8, 126.7, 125.6, (br), 124.3, 122.6, 115.7, 115.3, 113.5 (br); Anal. Calcd 
for C14H8N4O3: C, 60.00; H, 2.88; N, 19.99.  Found: C, 60.18; H, 2.75; N, 19.79. 
2-Fluorobenzo[4,5]imidazo[2,1-b]quinazolin-12-one (23b):  Yield: 86% (233 mg, 0.92 
mmol) as a yellow solid, mp > 300 °C; IR: 3176, 1668 cm-1; 1H NMR (DMSO-d6, 400 MHz): δ 
8.29 (s, 1H), 8.00 (d, J = 8.0 Hz, 1H), 7.83 (d, J = 8.0 Hz, 1H), 7.52 (t, J = 8.0 Hz, 1H), 7.34 (d, 
J = 8.0 Hz, 1H), 7.14 (t, J = 8.1 Hz, 2H), 7.01 (t, J = 8.0 Hz, 1H) (NH not observed); 13C NMR 
(DMSO-d6, 100 MHz, 110 oC): δ 166.5, 158.2 (d, J = 241.4 Hz), 157.2, 145.3, 135.0, 130.0, 
122.6, 121.7 (d, J = 6.1 Hz), 119.1 (d, J = 23.2 Hz), 118.5, 116.4 (2C, d, J = 7.1 Hz, and s), 
113.8 (d, J = 23.2 Hz), 111.5; Anal. Calcd for C14H8FN3O: C, 66.40; H, 3.18; N, 16.59.  Found: 
C, 66.47; H, 3.21; N, 16.41.  
1-Fluorobenzo[4,5]imidazo[2,1-b]quinazolin-12-one (23c): Yield: 93% (252 mg, 1.0 mmol) 
as a yellow solid, mp > 300 °C; IR: 3160, 1643 cm-1; 1H NMR (DMSO-d6, 400 MHz): δ 8.41 
(d, J = 7.9 Hz, 1H), 7.55 (q, J = 7.5 Hz, 1H), 7.43 (d, J = 7.9 Hz, 1H), 7.35 (t, J = 7.6 Hz, 1H), 
7.23 (d, J = 8.5 Hz, 1H), 7.14 (t, J = 7.7 Hz, 1H), 6.88 (dd, J = 9.8, 7.2 Hz, 1H) (NH not 
observed); 13C NMR (DMSO-d6, 100 MHz, 110 oC): δ  162.4 (d, J = 261.6 Hz), 157.7, 152.3, 
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151.5, 139.7, 133.7 (d, J = 12.1 Hz), 128.1, 125.4, 120.2 (d, J = 4.0 Hz), 119.5, 115.3, 113.7, 
105.7 (d, J = 21.2 Hz), 104.3 (d, J = 7.1 Hz); Anal. Calcd for C14H8FN3O: C, 66.40; H, 3.18; N, 
16.59.  Found: C, 66.46; H, 3.16; N, 16.52.  
1,2,3,4-Tetrafluorobenzo[4,5]imidazo[2,1-b]quinazolin-12-one (23d): Yield: 96% (316 mg, 
1.03 mmol) as a yellow solid, mp > 300 °C; IR: 3154, 1651 cm-1; 1H NMR (DMSO-d6, 400 
MHz): δ 8.38 (d, J = 8.0 Hz, 1H), 7.42 (d, J = 8.0 Hz, 1H), 7.28 (t, J = 8.0 Hz, 1H), 7.04 (t, J = 
8.0 Hz, 1H) (NH not observed); 13C NMR (DMSO-d6, 100 MHz, 110 oC): δ 163.9, 157.6, 
154.9, 146.0 (dm, J = 253.5 Hz), 145.3, 142.4 (dm, J = 254.5 Hz), 140.4 (dd, J = 9.1, 5.1 Hz), 
139.7 (dm, J = 253.0 Hz), 131.0 (dt, J = 239.4, 16.2 Hz), 128.5, 124.8, 117.9, 115.0, 118.0; 
Anal. Calcd for C14H5F4N3O: C, 54.74; H, 1.64; N, 13.68.  Found: C, 54.82; H, 1.68; N, 13.57.  
3-Methylbenzo[4,5]imidazo[2,1-b]quinazolin-12-one(23e): Yield: 76% (203 mg, 0.81 mmol) 
as a white solid, mp > 300 °C; IR: 3159, 1657 cm-1; 1H NMR (DMSO-d6, 400 MHz): δ 12.5 (br 
s, 1H), 8.39 (d, J = 7.9 Hz, 1H), 8.11 (d, J = 8.1 Hz, 1H), 7.45 (d, J = 8.0 Hz, 1H), 7.42 (t, J = 
7.9 Hz, 1H), 7.28 (m, 2H), 7.15 (d, J = 8.1 Hz, 1H), 2.45 (s, 3H); 13C NMR (DMSO-d6, 100 
MHz, 110 oC): δ 158.2, 146.7, 144.7 (2C, 1 sharp, 1 br), 136.8 (br), 126.8, 126.1, 125.0, 123.2, 
120.4, 119.8 (br), 114.2, 112.8 (br), 111.6, 21.0 ; Anal. Calcd for C15H11N3O: C, 72.28; H, 4.45; 
N, 16.86; Found: C, 72.49; H, 4.48; N, 16.73.  
3-Bromobenzo[4,5]imidazo[2,1-b]quinazolin-12-one (23f): Yield: 78% (262 mg, 0.84 mmol) 
as a white solid, mp > 300 °C; IR: 3158, 1662 cm-1; 1H NMR (DMSO-d6, 400 MHz): δ 12.7 (s, 
1H), 8.41 (d, J = 8.2 Hz, 1H), 8.14 (d, J = 8.2 Hz, 1H), 7.72 (s, 1H), 7.47 (m, 3H), 7.31 (m, 
1H); 13C NMR (DMSO-d6, 100 MHz, 110 oC): δ 158.1, 147.0, 128.0, 127.5, 126.0, 125.3, 
124.5, 120.9, 114.5, 113.9 (br), 111.3 (br) (all C not resolvable); Anal. Calcd for C14H8BrN3O: 
C, 53.53; H, 2.57; N, 13.38; Found: C, 53.59; H, 2.55; N, 13.27. 
Benzo[4,5]imidazo[1,2-a]pyrido[2,3-d]pyrimidin-5-one (23g): Yield: 90% (227 mg, 0.96 
mmol) as a yellow solid, mp > 300 °C; IR: 3178, 1644 cm-1; 1H NMR (DMSO-d6, 400 MHz): δ 
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8.63 (s, 1H), 8.40 (d, J = 7.7 Hz, 1H), 8.35 (d, J = 7.8 Hz, 1H), 7.37 (d, J = 7.9 Hz, 1H), 7.25 (t, 
J = 7.8 Hz, 1H), 6.99 (t, J = 7.9 Hz, 1H), 6.89 (d, J = 7.9 Hz, 1H) (NH not observed); 13C NMR 
(DMSO-d6, 100 MHz, 110 oC): δ 161.6, 160.8, 156.1, 152.2, 146.0, 135.9, 128.8, 124.5, 117.2, 
115.2, 114.6, 113.3, 107.6; Anal. Calcd for C13H8N4O: C, 66.10; H, 3.41; N, 23.72; Found: C, 
66.24; H, 3.46; N, 23.49. 
Benzo[4,5]imidazo[2,1-b]quinazolin-12-one (23h): Yield: 87% (219 mg, 0.93 mmol) as a 
white solid, mp > 300 °C; IR: 3170, 1653 cm-1; 1H NMR (DMSO-d6, 400 MHz): δ 12.69 (br s, 
1H), 8.41 (d, J = 7.9 Hz, 1H), 8.23 (d, J = 8.0 Hz, 1H), 7.92 (t, J =  8.0 Hz, 1H), 7.51 (m, 2H), 
7.43 (t, J = 8.3 Hz, 1H), 7.31 (m, 2H); 13C NMR (DMSO-d6, 100 MHz, 110 oC): δ 159.5, 147.5, 
145.9 (br), 136.2, (br), 135.1, 127.7, 127.2, 126.2, 122.6, 121.8 (br), 121.5, 115.4, 115.1, 113.5 
(br);  Anal. Calcd for C14H9N3O: C, 71.48; H, 3.86; N, 17.86.  Found: C, 71.37: H, 3.81; N, 
17.76.  
8,9-Dimethyl-2-nitrobenzo[4,5]imidazo[2,1-b]quinazolin-12-one (25a): Yield: 91% (300 
mg, 0.97 mmol) as a red solid, mp > 300 °C; IR: 3161, 1647 cm-1; 1H NMR (DMSO-d6, 400 
MHz): δ 8.92 (d, J = 1.8 Hz, 1H), 8.17 (s, 1H), 8.11 (dd, J = 8.0, 1.8 Hz, 1H), 7.27 (s, 1H), 7.24 
(d, J = 8.0 Hz, 1H), 2.34 (s, 3H), 2.30 (s, 3H) (NH not observed); 13C NMR (DMSO-d6, 100 
MHz, 110 oC): δ 160.5, 156.2, 155.2, 143.5, 136.3, 132.9, 127.0 (2C, 1 sharp and 1 br), 125.8 
(br), 125.0 (br), 117.0 (br), 115.7 (br), 114.9 (br), 111.6, 20.7 (br), 20.2 (br); Anal. Calcd for 
C16H12N4O3: C, 62.33; H, 3.92; N, 18.17; Found: C, 62.42; H, 3.96; N, 18.05.  
2-Fluoro-8,9-dimethylbenzo[4,5]imidazo[2,1-b]quinazolin-12-one (25b): Yield: 87%, (261 
mg, 0.93 mmol) as a yellow solid, mp > 300 °C; IR: 3141, 1675 cm-1; 1H NMR (DMSO-d6, 400 
MHz): δ 12.3 (br s, 1H), 8.22 (s, 1H), 7.88 (dd, J = 9.1, 2.3 Hz, 1H), 7.66 (td, J = 9.0, 2.3 Hz, 
1H), 7.57 (dd, J = 8.9, 5.0 Hz, 1H), 7.23 (s, 1H), 2.36 (s, 3H), 2.33 (s, 3H); 13C NMR (DMSO-
d6, 100 MHz, 110 oC): δ 163.1, 157.8, 155.4, 146.7, 146.4, 144.2, 133.7, 128.4, 125.0, 124.1, 
121.6, 115.1, 111.4, 109.4, 18.7 (br), 18.4 (br), (the spectrum was not sufficiently resolved to 
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observe 13C-19F couplings); Anal. Calcd for C16H12FN3O: C, 68.32; H, 4.30; N, 14.94. Found: 
C, 68.59; H, 4.29; N, 14.78. 
1-Fluoro-8,9-dimethylbenzo[4,5]imidazo[2,1-b]quinazolin-12-one (25c): Yield: 95% (286 
mg, 1.01 mmol) as a yellow solid, mp > 300 °C; IR: 3182, 1682 cm-1; 1H NMR (DMSO-d6, 400 
MHz): δ 8.19 (s, 1H), 7.56 (q, J = 7.6 Hz, 1H), 7.22 (d, J = 7.8 Hz, 1H), 7.21 (s, 1H), 6.81 (dd, 
J = 11.7, 7.9 Hz, 1H), 2.34 (s, 3H), 2.33 (s, 3H), (the NH was not observed); 13C NMR 
(DMSO-d6, 100 MHz, 110 oC): δ 162.5 (d, J = 260.6 Hz), 157.1, 154.4, 152.1, 150.5, 136.3, 
134.0 (br), 133.1, 128.0, 126.2, 120.1 (br), 115.6 (br), 113.8 (br), 106.0 (br), 20.1(br), 19.6 (br) 
(the spectrum was not sufficiently resolved to observe 13C-19F couplings); Anal. Calcd for 
C16H12FN3O: C, 68.32; H, 4.30; N, 14.94. Found: C, 68.44; H, 4.38; N, 14.89. 
1,2,3,4-Tetrafluoro-8,9-dimethylbenzo[4,5]imidazo[2,1-b]quinazolin-12-one (25d): Yield: 
98% (351 mg, 1.05 mmol) as a yellow solid, mp > 300 °C; IR: 3183, 1667 cm-1; 1H NMR 
(DMSO-d6, 400 MHz): δ (ppm) 8.17 (s, 1H), 7.21 (s, 1H), 2.33 (s, 6H), (the NH was not 
observed); 13C NMR (DMSO-d6, 100 MHz, 110 oC): δ 161.7, 156.4, 153.6, 145.0 (dm, J = 
258.6 Hz), 142.7, 141.3 (dm, J = 258.6 Hz), 139.3 (dd, J = 9.1, 5.1 Hz), 138.5 (dm J = 250.5 
Hz), 131.7, 129.7 (dt, J = 236.3 Hz), 125.8, 124.7, 115.4, 114.6, 19.7, 19.3; Anal. Calcd for 
C16H9F4N3O: C, 57.32; H, 2.71; N, 12.53. Found: C, 57.51; H, 2.74; N, 12.51. 
3,8,9-Trimethylbenzo[4,5]imidazo[2,1-b]quinazolin-12-one (25e): Yield: 80% (237 mg, 0.86 
mmol) as a white solid, mp > 300 °C; IR: 3142, 1669 cm-1; 1H NMR (DMSO-d6, 400 MHz): δ 
8.20 (s, 1H), 8.11 (d, J = 8.2 Hz, 1H), 7.34 (s, 1H), 7.29 (s, 1H), 7.18 (d, J = 8.2 Hz, 1H), 2.46 
(s, 3H), 2.37 (s, 3H), 2.33 (s, 3H), (the NH was not observed); 13C NMR (DMSO-d6, 100 MHz, 
110 oC): δ 158.4, 146.4 (br), 142.9 (br), 135.3 (br), 131.4 (br), 131.2, 127.6 (br), 126.8 (br), 
125.2, 120.0 (br), 116.2 (br), 115.5 (br), 113.5 (br), 112.9, 21.9 (br), 20.3 (2C, br); Anal. Calcd 
for C17H15N3O: C, 73.63; H, 5.45; N, 15.15. Found: C, 73.57; H, 5.48; N, 15.02. 
3-Bromo-8,9-dimethylbenzo[4,5]imidazo[2,1-b]quinazolin-12-one  (25f): Yield: 84% (307 mg, 
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0.89 mmol) as a white solid, mp > 300 °C; IR: 3158, 1679 cm-1; 1H NMR (DMSO-d6, 400 MHz): 
δ 12.5 (br s, 1H), 8.19 (s, 1H), 8.10 (d, J = 8.6 Hz, 1H), 7.69 (s, 1H), 7.42 (d, J = 8.5 Hz, 1H), 
7.22 (s, 1H), 2.34 (s, 6H); 13C NMR (DMSO-d6, 100 MHz, 110 oC): δ 158.9, 149.5, 148.2, 134.9, 
132.0, 130.0, 129.0 (br), 128.2, 125.3 (2C, 1 sharp and 1 br), 116.5 (br), 115.6 (br), 115.0, 112.9 
(br), 20.1, 19.6; Anal. Calcd for C16H12BrN3O: C, 56.16; H, 3.53; N, 12.28. Found: C, 56.29; H, 
3.53; N, 12.25. 
8,9-Dimethylbenzo[4,5]imidazo[1,2-a]pyrido[2,3-d]pyrimidin-5-one (25g):  Yield: 95% (268 
mg, 1.0 mmol) as a yellow solid, mp > 300 °C; IR: 3179, 1651 cm-1; 1H NMR (DMSO-d6, 400 
MHz): δ 8.59 (d, J = 4.5 Hz, 1H), 8.36 (d, J = 7.4 Hz, 1H), 8.14 (s, 1H), 7.17 (s, 1H), 6.84 (dd, J 
= 7.5, 4.5 Hz, 1H), 2.33 (s, 3H), 2.29 (s, 3H), (the NH was not observed); 13C NMR (DMSO-d6, 
100 MHz, 110 oC): δ 161.3, 160.6, 155.6, 155.0, 144.0, 136.0, 132.4, 127.0, 125.1, 116.1, 115.3, 
113.1, 107.6, 20.8, 20.4; Anal. Calcd for C15H12N4O: C, 68.17; H, 4.58; N, 21.20. Found: C, 
68.31; H, 4.45; N, 21.07. 
8,9-Dimethylbenzo[4,5]imidazo[2,1-b]quinazolin-12-one (25h): Yield: 83% (234 mg, 0.88 
mmol) as a white solid, mp > 300 °C; IR: 3142, 1677 cm-1; 1H NMR (DMSO-d6, 400 MHz): δ 
12.4 (br s, 1H), 8.23 (s, 1H and d, J = 7.9 Hz, 1H), 7.76 (t, J = 7.7 Hz, 1H), 7.51 (d, J = 8.2 Hz, 
1H), 7.31 (t, J = 7.6 Hz, 1H), 7.26 (s, 1H), 2.36 (s, 3H), 2.35 (s, 3H); 13C NMR (DMSO-d6, 100 
MHz, 110 oC): δ 159.3, 147.6, 147.3, 146.9, 134.5, 129.6, 127.4, 126.3, 125.8, 122.4, 122.1, 
115.9, 115.5, 113.1, 20.4, 19.4; Anal. Calcd for C16H13N3O: C, 72.99; H, 4.98; N, 15.96; Found: 
C, 73.14; H, 5.04; N, 15.79. 
Representative procedure for the N-acylation of benzo[4,5]imidazo[2,1-b]quinazolin-12-
ones: 
To a stirred solution of TEA (0.63 mmol) in 5.0 mL of DMSO was added 5 or 7 (0.25 mmol), and 
the mixture was stirred for 10 min. The acid chloride (0.33 mmol) was added drop-wise to the 
resulting suspension at 20 °C, and the reaction was stirred for 1 h.  Upon completion of the 
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reaction (monitored by TLC), water (2.0 mL) was added, the mixture was stirred for 10 min and 
the solid was filtered.  The filter cake was washed with water and ether and the product was dried 
under vacuum at 50 °C for 6-12 h.  The N-acetyl derivatives were prepared for 23a, 23b, 23e, 25c 
and 25h.  For 25b and 25e, the acetyl derivatives were still insoluble, and thus the hexanoyl 
derivatives were prepared. 
6-Acetyl-2-nitrobenzo[4,5]imidazo[2,1-b]quinazolin-12(6H)-one (26a): Yield: 94% (76 mg, 
0.235  mmol) as a yellow solid, mp > 300 °C; IR: 1725, 1698, 1603, 1517, 1336 cm-1; 1H NMR 
(DMSO-d6, 400 MHz): δ 9.03 (dd, J = 2.7, 0.8 Hz, 1H), 8.61-8.57 (complex, 2H), 8.40 (m, 1H), 
7.91 (dd, J = 9.1, 0.8 Hz, 1H), 7.58 (m, 2H), 3.09 (s, 3H); 13C NMR (DMSO-d6, 100 MHz, 75 
oC): δ 170.4, 158.9, 158.4, 151.9, 147.6, 144.2, 129.4, 129.0, 128.5, 127.6, 125.9, 123.1, 118.0, 
116.2, 115.6, 27.5; Anal. Calcd for C16H10N4O4: C, 59.63; H, 3.13; N, 17.38; Found: C, 59.38; H, 
2.98; N, 17.35. 
6-Acetyl-1-fluorobenzo[4,5]imidazo[2,1-b]quinazolin-12(6H)-one (26c): Yield: 96% (71 mg, 
0.24 mmol) as a brown solid, mp > 300 °C; IR: 1702, 1685, 1640, 1619, 1376 cm-1; 1H NMR 
(DMSO-d6, 400 MHz): δ 8.54 (d, J = 7.4 Hz, 1H), 8.38 (d, J = 7.6 Hz, 1H), 7.84 (q, J = 7.4 Hz, 
1H), 7.58-7.47 (m, 3H), 7.26 (t, J = 9.6 Hz, 1H), 3.00 (s, 3H); 13C NMR (DMSO-d6, 100 MHz, 75 
oC): δ 169.5, 160.9 (d, J = 263.6 Hz), 155.4, 148.9, 145.2, 134.9 (d, J = 11.1 Hz), 128.5, 126.3, 
126.2, 124.7, 122.2, 115.3, 114.7, 111.0 (d, J = 20.2 Hz), 107.3 (d, J = 6.1 Hz), 26.6; Anal. Calcd 
for C16H10FN3O2: C, 65.08; H, 3.41; N, 14.23. Found: C, 65.23; H, 3.44; N, 14.09. 
6-Acetyl-3-methylbenzo[4,5]imidazo[2,1-b]quinazolin-12(6H)-one (26e): Yield: 92% (67 mg, 
0.23 mmol) as a brown solid, mp > 300 °C; IR: 1717, 1694, 1637, 1616, 1374 cm-1; 1H NMR 
(DMSO-d6, 400 MHz): δ 8.68 (d, J = 8.0 Hz, 1H), 8.49 (d, J = 8.0 Hz, 1H), 8.31 (d, J = 8.2 Hz, 
1H), 7.52 (s, 1H), 7.45 (m, 2H), 7.30 (d, J = 8.3 Hz, 1H), 3.12 (s, 3H), 2.54 (s, 3H); 13C NMR 
(DMSO-d6, 100 MHz, 75 oC): δ 170.1, 159.3, 147.4, 145.9, 144.7, 128.8, 127.1, 126.7 (2C), 
126.5, 125.3, 116.2, 115.9, 115.7, 27.7, 22.0 (1 aromatic C unresolved); Anal. Calcd for 
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C17H13N3O2: C, 70.09; H, 4.50; N, 14.42; Found: C, 70.18; H, 4.48; N, 14.34. 
2-Fluoro-6-hexanoyl-8,9-dimethylbenzo[4,5]imidazo[2,1-b]quinazolin-12(6H)-one (27b): 
Yield: 85% (75 mg, 0.21 mmol) as a white solid, mp 190-191 °C; IR (CHCl3): 1702, 1634, 1385 
cm-1; 1H NMR (CDCl3, 400 MHz): δ 8.43 (s, 1H), 8.29 (s, 1H), 8.03 (dd, J = 8.3, 2.4 Hz, 1H), 
7.70 (dd, J = 8.1, 5.4 Hz, 1H), 7.51 (m, 1H), 3.55 (t, J = 7.4 Hz, 2H), 2.40 (s, 3H), 2.39 (s, 3H), 
1.88 (quintet, J = 7.3 Hz, 2H), 1.57-1.40 (m, 4H), 0.95 (t, J = 7.0 Hz, 3H); 13C NMR (CDCl3, 100 
MHz, 25 oC): δ 173.3, 159.8 (d, J = 255.8 Hz), 158.6, 144.1 (d, J = 22.2 Hz), 136.0, 134.1, 128.8 
(d, J = 8.1 Hz), 127.1, 124.4, 123.4, 123.1, 119.1 (d, J = 8.1 Hz), 117.0, 116.3, 111.5 (d, J = 24.2 
Hz), 39.0, 31.5, 24.2, 22.6, 20.5, 20.1, 14.0; Anal. Calcd for C22H22FN3O2: C, 69.64; H, 5.84; N, 
11.07; Found: C, 69.46; H, 5.52; N, 11.23. 
6-Acetyl-1-fluoro-8,9-dimethylbenzo[4,5]imidazo[2,1-b]quinazolin-12(6H)-one (27c): Yield: 
93% (75 mg, 0.232 mmol) as a brown solid, mp > 300 °C; IR: 1707, 1642, 1618, 1377 cm-1; 1H 
NMR (DMSO-d6, 400 MHz): δ 8.21 (s, 1H), 8.05 (s, 1H), 7.75 (q, J = 7.4 Hz, 1H), 7.43 (d, J = 
8.2 Hz, 1H), 7.16 (dd, J = 11.2, 7.9 Hz, 1H), 2.95 (s, 3H), 2.29 (s, 3H), 2.28 (s, 3H); 13C NMR 
(DMSO-d6, 100 MHz, 75 oC): δ 169.2, 16.8 (d, J = 264.6 Hz), 155.0, 148.8, 145.0, 134.6 (d, J = 
10.1 Hz), 134.5, 132.8, 126.4, 124.1, 122.1, 115.8, 115.1, 110.8 (d, J = 21.2 Hz), 107.2 (d, J = 7.1 
Hz), 26.4, 19.5, 19.2; Anal. Calcd for C18H14FN3O2: C, 66.87; H, 4.36; N, 13.00; Found: C, 66.91; 
H, 4.43; N, 12.86. 
6-Hexanoyl-3,8,9-trimethylbenzo[4,5]imidazo[2,1-b]quinazolin-12(6H)-one (27e): Yield: 97% 
(91 mg, 0.242 mmol) as a white solid, mp 198-199 °C; IR (CHCl3): 1699, 1634, 1615, 1382 cm-1; 
1H NMR (CDCl3, 400 MHz): δ 8.39 (s, 1H), 8.24 (d, J = 8.2 Hz, 1H), 8.23 (s, 1H), 7.44 (s, 1H), 
7.23 (d, J = 8.2 Hz, 1H), 3.53 (t, J = 7.3 Hz, 2H), 2.39 (s, 3H), 2.36 (s, 3H), 2.35 (s, 3H), 1.87 
(quintet, J = 7.3 Hz, 2H), 1.56-1.40 (m, 4H), 0.97 (t, J = 7.1 Hz, 3H); 13C NMR (CDCl3, 100 
MHz, 25 oC): δ 173.4, 159.1, 147.4, 145.6, 144.6, 135.4, 133.8, 127.0, 126.7, 126.6, 126.3, 124.7, 
116.9, 116.2, 115.8, 39.0, 31.5, 24.2, 22.6, 22.0, 20.4, 20.1, 14.1; Anal. Calcd for C23H25N3O2: C, 
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73.57; H, 6.65; N, 11.19; Found: C, 73.41; H, 6.56; N, 11.23. 
6-Acetyl-8,9-dimethylbenzo[4,5]imidazo[2,1-b]quinazolin-12(6H)-one (27h): Yield: 88% (67 
mg, 0.22 mmol) as a white solid, mp > 300 °C; IR: 1700, 1638, 1606, 1381 cm-1; 1H NMR 
(DMSO-d6, 400 MHz): δ 8.33 (s, 1H), 8.28 (d, J = 8.0 Hz, 1H), 8.16 (s, 1H), 7.85 (t, J = 7.7 Hz, 
1H), 7.69 (d, J = 8.1 Hz, 1H), 7.50 (t, J = 7.5 Hz, 1H), 3.03 (s, 3H), 2.36 (s, 3H), 2.34 (s, 3H); 13C 
NMR (DMSO-d6, 100 MHz, 75 oC): δ 170.1, 158.9, 147.5, 145.4, 135.2, 135.1, 133.6, 127.5, 
126.9, 126.7, 125.4, 125.0, 118.3, 116.7, 115.9, 27.3, 20.4, 20.1; Anal. Calcd for C18H15N3O2: C, 
70.81; H, 4.95; N, 13.76; Found: C, 70.88; H, 4.93; N, 13.69. 
2.3.4 1,3,4-oxadiazoles promoted by NH4Cl 
Representative procedure for the 1,3,4-oxadiazoles synthesis: To a solution of the hydrazide 
(0.73 mmol) in 10 mL of anhydrous ethanol, added triethyl orthoester (0.81 mmol) and 
ammonium chloride (0.219 mmol).  The solution was stirred and heated to reflux until the 
reaction was complete (0.5-18 h). The mixture was cooled to room temperature and concentrated 
under vacuum.  The crude product was made into slurry in a mixture of hexanes and ether (3:1), 
which was filtered and washed with deionized water or purified by column chromatography. 
2-Phenyl-1,3,4-oxadiazole (40a). Yield: 101 mg (0.69 mmol, 95%) as a colorless liquid. IR: 
3140, 1600, 1033 cm-1; 1H NMR (400 MHz): δ 8.47 (s, 1H), 8.11-8.08 (m, 2H), 7.59-7.51 (m, 
3H); 13C NMR (100 MHz) δ 164.7, 152.7, 132.0, 129.1, 127.1, 123.5; MS: m/z 146 (M+).  Anal. 
Calcd for C8H6N2O: C, 65.75; H, 4.14; N, 19.17.  Found: C, 65.76; H, 4.18; N, 19.03.        
5-Methyl-2-phenyl-1,3,4-oxadiazole (40b). Yield: 107 mg (0.67 mmol, 93%) as a white solid, 
mp 63-64 °C (lit145 mp 65-67 °C).  IR: 3033, 1577, 1070 cm-1; 1H NMR (400 MHz): δ 8.04-8.02 
(m, 2H), 7.53-7.47 (m, 3H), 2.62 (s, 3H); 13C NMR (100 MHz) δ 164.87, 163.6, 131.5, 129.0, 
126.7, 124.0, 11.1; MS: m/z 160 (M+).  
5-Ethyl-2-phenyl-1,3,4-oxadiazole (40c). Yield: 125 mg (0.72 mmol, 98%) as a colorless liquid. 
IR: 3052, 1573, 1070 cm-1; 1H NMR (400 MHz): δ 8.06-8.02 (m, 2H), 7.55-7.47 (m, 3H), 2.96 (q, 
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J = 7.6 Hz, 2H), 1.45 (t, J = 7.6 Hz, 3H); 13C NMR (100 MHz) δ 167.8, 164.7, 131.5, 129.0, 
126.8, 124.1, 19.2, 10.9; MS: m/z 174 (M+).  Anal. Calcd for C10H10N2O: C, 68.95; H, 5.79; N, 
16.08.  Found: C, 68.99; H, 5.77; N, 15.94. 
2,5-Diphenyl-1,3,4-oxadiazole (40d). Yield: 155 mg (0.70 mmol, 96%) as a tan solid, mp 137-
138 °C (lit146 mp 136-138 °C).  IR: 3062, 1548, 1042 cm-1; 1H NMR (400 MHz): δ 8.17-8.14 (m, 
4H), 7.58-7.51 (m, 6H); 13C NMR (100 MHz) δ 169.0, 164.6, 131.7, 129.1, 126.9, 123.9; MS: m/z 
222 (M+).  
2-(p-Tolyl)-1,3,4-oxadiazole (41a). Yield: 102 mg (0.64 mmol, 88%) as a white solid, mp 86-87 
°C (lit147 mp 86.9 °C).  IR: 3124, 1611, 1070 cm-1; 1H NMR (400 MHz): δ 8.44 (s, 1H), 7.97 (d, J 
= 7.9 Hz, 2H), 7.33 (d, J = 7.9 Hz, 2H), 2.44 (s, 3H); 13C NMR (100 MHz) δ 164.9, 152.4, 142.6, 
129.8, 127.1, 120.7; MS: m/z 160 (M+).  
5-Methyl-2-(p-tolyl)-1,3,4-oxadiazole (41b). Yield: 67 mg (0.39 mmol, 53%) as a white solid, 
mp 96-97 °C.  IR: 3015, 1595, 1097 cm-1; 1H NMR (400 MHz): δ 7.91 (d, J = 8.2 Hz, 2H), 7.30 
(d, J = 8.0 Hz, 2H), 2.61 (s, 3H), 2.42 (s, 4H); 13C NMR (100 MHz) δ 165.0, 163.3, 142.0, 129.7, 
126.7, 121.2 21.6, 11.1. MS: m/z 174 (M+).  Anal. Calcd for C10H10N2O: C, 68.95; H, 5.79; N, 
16.08.  Found: C, 68.91; H, 5.81; N, 15.97. 
5-Ethyl-2-(p-tolyl)-1,3,4-oxadiazole (41c). Yield: 131 mg (0.69 mmol, 95%) as a colorless 
liquid. IR: 2991, 1569, 1068 cm-1; 1H NMR (400 MHz): δ 7.92 (d, J = 8.2 Hz, 2H), 7.30 (d, J = 
8.0 Hz, 2H), 2.95 (q, J = 7.6 Hz, 2H), 2.42 (s, 3H), 1.44 (t, J = 7.6 Hz, 3H); 13C NMR (100 MHz) 
δ 167.5, 164.8, 141.9, 129.7, 126.7, 121.3, 21.6, 19.2, 10.9; MS: m/z 188 (M+).  Anal. Calcd for 
C11H12N2O: C, 70.19; H, 6.43; N, 14.88.  Found: C, 70.08; H, 6.46; N, 14.72. 
5-Phenyl-2-(p-tolyl)-1,3,4-oxadiazole (41d). Yield: 165 mg (0.7 mmol, 96%) as a white solid, 
mp 122-123 °C (lit146 mp 121-122 °C).  IR: 3058, 1616, 1072 cm-1; 1H NMR (400 MHz): δ 8.18-
8.10 (m, 2H), 8.05 (d, J = 8.2 Hz, 2H), 7.56-7.49 (m, 3H), 7.34 (d, J = 7.9 Hz, 2H), 2.45 (s, 3H); 
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13C NMR (100 MHz) δ 164.7, 164.3, 142.3, 131.6, 129.8, 129.0, 126.9, 124.0, 121.1, 21.7; MS: 
m/z 236 (M+).  
2-(4-Methoxyphenyl)-1,3,4-oxadiazole (42a). Yield: 128 mg (0.73 mmol, 100%) as a white 
solid, mp 61-62 °C (lit148 mp 63 °C).  IR: 3133, 1613, 1095 cm-1; 1H NMR (400 MHz): δ 8.41 (s, 
1H), 8.04 (d, J = 8.9 Hz, 2H), 7.04 (d, J = 8.9 Hz, 2H), 3.89 (s, 3H); 13C NMR (100 MHz) δ 
164.7, 162.5, 152.2, 128.9, 116.0, 114.6, 55.5; MS: m/z 176 (M+).    
2-(4-Methoxyphenyl)-5-methyl-1,3,4-oxadiazole (42b). Yield: 125 mg (0.66 mmol, 90%) as a 
white solid, mp 84-85 °C.  IR: 3045, 1600, 1026 cm-1; 1H NMR (400 MHz): δ 7.98 (d, J = 8.9 Hz, 
2H), 7.01 (d, J = 8.9 Hz, 2H), 3.88 (s, 3H), 2.60 (s, 3H); 13C NMR (100 MHz) δ 164.8, 163.1, 162.2, 
128.5, 116.6, 114.4, 55.4, 11.1; MS: m/z 190 (M+).  Anal. Calcd for C10H10N2O2: C, 63.15; H, 5.30; 
N, 14.73.  Found: C, 63.22; H, 5.31; N, 14.66. 
5-Ethyl-2-(4-methoxyphenyl)-1,3,4-oxadiazole (42c). Yield: 139 mg (0.68 mmol, 93%) as a 
white solid, mp 53-54 °C.  IR: 2982, 1614, 1025 cm-1; 1H NMR (400 MHz): δ 7.99 (d, J = 8.8 Hz, 
2H), 7.01 (d, J = 8.8 Hz, 2H), 2.94 (q, J = 7.6 Hz, 2H), 1.43 (t, J = 7.6 Hz, 3H); 13C NMR (100 
MHz) δ 167.3, 164.6, 162.1, 128.5, 116.7, 114.4, 55.4, 19.2, 10.9; MS: m/z 204 (M+).  Anal. 
Calcd for C11H12N2O2: C, 64.69; H, 5.92; N, 13.72.  Found: C, 64.72; H, 5.94; N, 13.63. 
2-(4-Methoxyphenyl)-5-phenyl-1,3,4-oxadiazole (42d). Yield: 179 mg (0.71 mmol, 97%) as a 
white solid, mp 150-151 °C (lit146 mp 149-150 °C).  IR: 3007, 1614, 1017 cm-1; 1H NMR (400 
MHz): δ 8.14 – 8.11 (m, 2H), 8.10 (d, J = 8.9 Hz, 2H), 7.57-7.50 (m, 3H), 7.07 (d, J = 8.8 Hz, 
2H), 3.90 (s, 3H); 13C NMR (100 MHz) δ 164.5, 164.1, 162.3, 131.5, 129.0, 128.7, 126.8, 124.1, 
116.5, 114.5, 55.5. MS: m/z 252 (M+).  
2-(3-Bromophenyl)-1,3,4-oxadiazole (43a). Yield: 135 mg (0.6 mmol, 82%) as tan solid, mp 79- 
80 °C (lit147 mp 80.1 °C).  IR: 2927, 1595, 1066 cm-1; 1H NMR (400 MHz): δ 8.49 (s, 1H), 8.25 (t, 
J = 1.8 Hz, 1H), 8.04 (dt, J = 7.8, 1.3 Hz, 1H), 7.70 (ddd, J = 8.1, 2.1, 1.1 Hz, 1H), 7.41 (t, J = 7.9 
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Hz, 1H); 13C NMR (100 MHz) δ 163.5, 152.8, 135.0, 130.7, 130.0, 125.7, 125.3, 123.1; MS: m/z 
224, 226 (M+).  
2-(3-Bromophenyl)-5-methyl-1,3,4-oxadiazole (43b). Yield: 155 mg (0.65 mmol, 89%) as a 
white solid, mp 69-70 °C.  IR: 3066, 1572, 1066 cm-1; 1H NMR (400 MHz): δ 8.19 (t, J = 1.8 Hz, 
1H), 7.99 (dt, J = 8.2 Hz, 1.2 Hz, 1H), 7.66 (ddd, J = 8.1, 2.0, 1.1 Hz, 1H), 7.38 (t, J = 7.9 Hz, 
1H), 2.63 (s, 3H); 13C (100 MHz) δ 164.0, 163.6, 134.5, 130.6, 129.6, 125.8, 125.2, 123.1, 11.1; 
MS: m/z 238, 240 (M+). Anal. Calcd for C9H7BrN2O: C, 45.22; H, 2.95; N, 11.72.  Found: C, 
45.34; H, 2.98; N, 11.60. 
2-(3-Bromophenyl)-5-ethyl-1,3,4-oxadiazole (43c). Yield: 159 mg (0.63 mmol, 86%) as a 
yellow solid, mp 51-52 °C.  IR: 3060, 1571, 1066 cm-1; 1H NMR (400 MHz): δ 8.19 (t, J = 1.8 
Hz, 1H), 7.99 (ddd, J = 7.8, 1.7, 1.0 Hz, 1H), 7.65 (ddd, J = 8.1, 2.0, 1.0 Hz, 1H), 7.38 (t, J = 7.9 
Hz, 1H), 2.97 (q, J = 7.6 Hz, 2H), 1.45 (t, J = 7.6 Hz, 3H); 13C NMR (100 MHz) δ 168.1, 163.4, 
134.4, 130.6, 129.6, 125.9, 125.3, 123.0, 19.2, 10.8. MS: m/z 252, 254 (M+). Anal. Calcd for 
C10H9BrN2O: C, 47.46; H, 3.58; N, 11.07.  Found: C, 47.58; H, 3.52; N, 11.12. 
2-(3-Bromophenyl)-5-phenyl-1,3,4-oxadiazole (43d). Yield: 174 mg (0.58 mmol, 80%), mp 
115-116 °C.  IR: 3068, 1565, 1058 cm-1; 1H NMR (400 MHz): δ 8.29 (t, J = 1.8 Hz, 1H), 8.18-
8.13 (m, 2H), 8.10 (dt, J = 7.8 Hz, 1H), 7.69 (ddd, J = 8.0, 2.0, 1.0 Hz, 1H), 7.61-7.52 (m, 3H), 
7.43 (t, J = 7.9 Hz, 1H); 13C NMR (100 MHz) δ 164.9, 163.3, 134.7, 132.0, 130.7, 129.7, 129.1, 
127.0, 125.8, 125.5, 123.7, 123.1; MS: m/z 300,302 (M+). Anal. Calcd for C14H9BrN2O: C, 55.81; 
H, 3.01; N, 9.30.  Found: C, 55.76; H, 3.08; N, 9.17. 
2-(2-Chlorophenyl)-1,3,4-oxadiazole (44a). Yield: 36 mg (0.2 mmol, 28%) as a viscous oil.  IR: 
3125, 1596, 1090 cm-1; 1H NMR (400 MHz): δ 8.56 (s, 1H), 8.01 (dd, J = 7.8, 1.7 Hz, 1H), 7.58 
(dd, J = 8.1, 1.3 Hz, 1H), 7.50 (td, J = 7.7, 1.7 Hz, 1H), 7.43 (td, J = 7.6, 1.4 Hz, 1H); 13C NMR 
(100 MHz) δ 163.2, 153.0, 133.3, 132.7, 131.3, 131.3, 127.1, 122.8; MS: m/z 180, 182 (M+).  
Anal. Calcd for C8H5ClN2O: C, 53.21; H, 2.79; N, 15.51.  Found:  C, 53.15; H, 2.86; N, 15.33. 
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2-(2-Chlorophenyl)-5-phenyl-1,3,4-oxadiazole (44d). Yield: 189 mg (0.71 mmol, 97%) as a 
yellow solid, mp 99-100 °C (lit149 mp 99-101 °C).  IR: 3065, 1590, 1072 cm-1; 1H NMR (400 
MHz): δ 8.16 (dd, J = 7.5, 2.1 Hz, 2H), 8.12 (dd, J = 7.7, 1.9 Hz, 1H), 7.61-7.52 (m, 4H), 7.49 
(td, J = 7.8, 2.0 Hz, 1H), 7.46 (dt, J = 7.6 Hz, 1.3 Hz, 1H); 13C NMR (100 MHz) δ 162.1, 163.1, 
133.1, 132.4, 131.9, 131.3, 131.3, 129.1, 127.1, 127.1, 123.8, 123.2; MS: m/z 256, 258 (M+).  
2-(4-Chlorophenyl)-1,3,4-oxadiazole (45a). Yield: 119 mg (0.66 mmol, 90%) as a white solid, 
mp 134-135 °C.  IR: 3099, 1608, 1103 cm-1; 1H NMR (400 MHz): δ 8.48 (s, 1H), 8.03 (d, J = 8.6 
Hz, 2H), 7.52 (d, J = 8.6 Hz, 2H); 13C (100 MHz) δ 164.0, 152.7, 138.4, 129.6, 128.4, 122.0. MS: 
m/z 180, 182 (M+).    
2-(4-Chlorophenyl)-5-methyl-1,3,4-oxadiazole (45b). Yield: 105 mg (0.54 mmol, 75%) as a 
yellow solid, mp 107-108 °C. IR: 3076, 1585, 1087 cm-1; 1H NMR (400 MHz): δ 7.97 (d, J = 8.6 
Hz, 2H), 7.49 (d, J = 8.6 Hz, 2H), 2.62 (s, 3H); 13C NMR (100 MHz) δ 164.1, 163.8, 137.8, 
129.4, 128.0, 122.5, 11.1; MS: m/z 194, 196 (M+). 
2-(4-Chlorophenyl)-5-ethyl-1,3,4-oxadiazole (45c). Yield: 144 mg (0.69 mmol, 95%) as a white 
solid, mp 92-94 °C (lit110 mp 93-94 °C).  IR: 3095, 1585, 1083 cm-1; 1H NMR (400 MHz): δ 7.98 
(d, J = 8.6 Hz, 2H), 7.48 (d, J = 8.6 Hz, 2H), 2.96 (q, J = 7.6 Hz, 2H), 1.44 (t, J = 7.6 Hz, 3H); 
13C NMR (100 MHz) δ 167.9, 163.9, 137.7, 129.4, 128.0, 122.6, 19.2, 10.8; MS: m/z 208, 210 
(M+).  
2-(4-Chlorophenyl)-5-phenyl-1,3,4-oxadiazole (45d). Yield: 130 mg (0.51 mmol, 70%) as a 
white solid, mp 161-162 °C (lit110 mp 160-162 °C).  IR: 3072, 1552, 1093 cm-1; 1H NMR (400 
MHz): δ 8.14 (dd, J = 7.7, 1.7 Hz, 2H), 8.09 (d, J = 8.6 Hz, 2H), 7.59-7.50 (m, 5H); 13C NMR 
(100 MHz) δ 164.7, 163.7, 138.0, 131.9, 129.5, 129.1, 128.2, 127.0, 123.7, 122.4; MS: m/z 256, 
258 (M+).  
2-(2-Nitrophenyl)-1,3,4-oxadiazole (46a). Yield: 31 mg (0.16 mmol, 22%) as a yellow solid, mp 
102-104 °C.  IR: 3103, 1560, 1122 cm-1; 1H NMR (400 MHz): δ 8.54 (s, 1H), 8.09 (dd, J = 7.2, 
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2.1 Hz, 1H), 7.99 (dd, J = 7.0, 2.1 Hz, 1H), 7.83-7.75 (m, 2H); 13C NMR (100 MHz) δ 161.7, 
153.7, 148.2, 133.3, 132.8, 131.9, 124.8, 118.5; MS: m/z 191 (M+).  Anal. Calcd for C8H5N3O3: C, 
50.27; H, 2.64; N, 21.98.  Found:  C, 50.31; H, 2.68; N, 21.89. 
5-Methyl-2-(2-nitrophenyl)-1,3,4-oxadiazole (46b). Yield: 37 mg (0.18 mmol, 25%) as a 
yellow solid, mp 91-92 °C (lit150 mp 94-95 °C). IR: 3090, 1575, 1108 cm-1; 1H NMR (400 MHz): 
δ 8.03 (d, J = 7.7 Hz, 1H), 7.97 (d, J = 7.3 Hz, 1H), 7.75 (quintet, J = 7.5 Hz, 2H), 2.61 (s, 3H); 
13C NMR (100 MHz) δ 164.9, 161.7, 148.1, 133.1, 132.4, 131.7, 124.7, 118.9, 11.03; MS: m/z 
205 (M+).  Anal. Calcd for C9H7N3O3: C, 52.69; H, 3.44; N, 20.48.  Found:  C, 52.76; H, 3.45; N, 
20.33. 
5-Ethyl-2-(2-nitrophenyl)-1,3,4-oxadiazole (46c). Yield: 60 mg (0.28 mmol, 38%) as a 
colorless liquid. IR: 3070, 1570, 1063 cm-1; 1H NMR (400 MHz): δ 8.03 (dd, J = 7.6, 1.7 Hz, 1H), 
7.98 (dd, J= 7.3, 1.8 Hz, 1H), 7.80-7.70 (m, 2H), 2.95 (q, J = 7.6 Hz, 2H), 1.42 (t, J = 7.6 Hz, 
3H); 13C NMR (100 MHz) δ 169.1, 161.5, 148.1, 133.1, 132.3, 131.7, 124.7, 119.0, 19.1, 10.7; 
MS: m/z 219 (M+). Anal. Calcd for C10H9N3O3: C, 54.79; H, 4.14; N, 21.90.  Found:  C, 54.76; H, 
4.16; N, 21.78. 
2-(2-Nitrophenyl)-5-phenyl-1,3,4-oxadiazole (46d). Yield: 107 mg (0.40 mmol, 55%) as a 
yellow solid, mp 120-121 °C (lit150 mp 120.5 °C).  IR: 3081, 1525, 1064 cm-1; 1H NMR (400 
MHz): δ 8.11-8.04 (m, 4H), 7.82-7.74 (m, 2H), 7.59-7.51 (m, 3H); 13C NMR (100 MHz) δ 161.8, 
157.3, 144.3, 129.1, 128.6, 128.2, 127.7, 125.2, 123.2, 120.7, 119.4, 114.7; MS: m/z 267 (M+). 
2-(4-Nitrophenyl)-1,3,4-oxadiazole (47a). Yield: 103 mg (0.54 mmol, 74%) as a yellow solid, 
mp 154-155 °C (lit151 mp 156-157 °C).  IR: 3106, 1555, 1049 cm-1; 1H NMR (400 MHz): δ 8.57 
(s, 1H 8.42 (d, J = 8.9 Hz, 2H), 8.32 (d, J = 8.9 Hz, 2H); 13C NMR (100 MHz) δ 163.1, 153.4, 
149.8, 128.9, 128.1, 124.5; MS: m/z 191 (M+).  
5-Methyl-2-(4-nitrophenyl)-1,3,4-oxadiazole (47b). Yield: 121.0 mg (0.59 mmol, 81%) as a 
ellow solid, mp 164-165 °C (lit144 mp 169-170 °C).  IR: 3068, 1581, 1071 cm-1; 1H NMR (400 
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MHz): δ 8.39 (d, J = 8.8 Hz, 2H), 8.24 (d, J = 8.8 Hz, 2H), 2.68 (s, 3H); 13C NMR (100 MHz) δ 
164.8, 163.2, 149.5, 129.5, 127.6, 124.4, 11.2; MS: m/z 205 (M+).  
5-Ethyl-2-(4-nitrophenyl)-1,3,4-oxadiazole (47c). Yield: 110mg (0.50 mmol, 69%) as a yellow 
solid, mp 128-129 °C.  IR: 2923, 1566, 1109 cm-1; 1H NMR (400 MHz): δ 8.37 (d, J = 8.6 Hz, 
2H), 8.24 (d, J = 8.7 Hz, 2H), 3.01 (q, J = 7.6 Hz, 2H), 1.48 (t, J = 7.6 Hz, 3H); 13C NMR (100 
MHz) δ 168.9, 163.0, 149.5, 129.6, 127.7, 124.3, 19.2, 10.8; MS: m/z 219 (M+).  Anal. Calcd for 
C10H9N3O3: C, 54.79; H, 4.14; N, 19.17.  Found:  C, 54.80; H, 4.14; N, 19.13. 
2-(4-Nitrophenyl)-5-phenyl-1,3,4-oxadiazole (47d). Yield: 126 mg (0.47 mmol, 65%) as a 
yellow solid, mp 207-208 °C.  IR:  3067, 1554, 1095 cm-1; 1H NMR (400 MHz): δ 8.44 (d, J = 
8.9 Hz, 2H), 8.38 (d, J = 8.9 Hz, 2H), 8.20-8.15 (m, 2H), 7.75-7.48 (m, 3H); 13C NMR (100 
MHz) δ 165.0, 162.3, 148.9, 131.7, 128.8, 128.7, 127.2, 123.8, 122.7; MS: m/z 219 (M+).  Anal. 
Calcd for C14H9N3O3: C, 62.92; H, 3.39; N, 15.72.  Found:  C, 63.01; H, 3.43; N, 15.60. 
2.3.5 Nucleophilic addition to polarized vinylarenes 
Representative procedure for the addition reaction: To a stirred solution of the nucleophile 
(active methylene compound or amine, 1.0 mmol) in 10 mL of acetonitrile was added 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU, 0.67 mmol) and the appropriate vinylarene (0.67 mmol). 
The solution was stirred and heated at reflux until the reaction was complete (4-6 h for malonate, 
12-18 h for amines). The reaction mass was cooled to room temperature and concentrated under 
vacuum. The resulting crude product was purified by column chromatography, eluted with 
increasing concentrations of ether in hexanes, to give the pure compound.  The two isomers of 
57b were separated by silica gel GF preparative TLC (Analtech, No. 02015) using 10% ether in 
hexanes.   
Diethyl 2-(4-nitrophenethyl)malonate (55a). Yield: 201 mg (0.65 mmol, 97%) as a colorless 
oil; IR: 1730, 1519, 1346, 854 cm-1; 1H NMR (400 MHz): δ 8.17 (d, J = 8.6 Hz, 2H), 7.38 (d, J = 
8.5 Hz, 2H), 4.27 (qd, J = 4.6, 2.5 Hz, 4H), 3.35 (t, J = 7.4 Hz, 1H), 2.80 (t, J = 7.4 Hz, 2H), 2.27 
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(q, J = 6.0 Hz, 2H), 1.30 (t, J = 7.1 Hz, 6H); 13C NMR (100 MHz): δ 168.9, 148.5, 146.7, 129.3, 
123.8, 61.6, 51.1, 33.2, 29.8, 14.1; MS (ESI): m/z 310 (M+ + 1).  Anal. Calcd for C15H19NO6: C, 
58.25; H, 6.19; N, 4.53.  Found: C, 58.01; H, 6.31; N, 4.32.   
(±)-Diethyl 2-methyl-2-(4-nitrophenethyl)malonate (55b). Yield: 201 mg (0.62 mmol, 93%) as 
a colorless oil; IR: 1729, 1520, 1346, 855 cm-1; 1H NMR (400 MHz): δ 8.17 (d, J = 8.6 Hz, 2H), 
7.38 (d, J = 8.6 Hz, 2H), 4.23 (q, J = 7.1 Hz, 4H), 2.73-2.68 (m, 2H), 2.19-2.14 (m, 2H), 1.51 (s, 
3H), 1.29 (t, J = 7.1 Hz, 6H); 13C NMR (100 MHz): δ 171.9, 149.4, 146.5, 129.2, 123.7, 61.4, 
53.5, 37.1, 30.9, 20.1, 14.1; MS (ESI): m/z 324 (M+ + 1).  Anal. Calcd for C16H21NO6: C, 59.43; 
H, 6.55; N, 4.33.  Found: C, 59.56; H, 6.21; N, 4.22 
(±)-Diethyl 2-(2-(4-nitrophenyl)propyl)malonate (55c). Yield: 188 mg (0.58 mmol, 87%) as a 
colorless oil;  IR: 1746, 1732, 1524, 1346, 855 cm-1; 1H NMR (400 MHz): δ 8.17 (d, J = 8.2 Hz, 
2H), 7.34 (d, J = 8.2 Hz, 2H), 4.20 (q, J = 7.2 Hz, 2H), 4.11 (q, J = 7.0 Hz, 2H), 3.13 (t, J = 7.8 
Hz, 1H), 2.88 (septet, J = 7.5 Hz, 1H), 2.28-2.14 (m, 2H), 1.31 (d, J = 7.0 Hz, 3H), 1.27 (t, J = 
7.0 Hz, 3H), 1.22 (t, J = 7.0 Hz, 3H); 13C NMR (100 MHz): δ 169.1, 169.0, 153.3, 146.8, 128.0, 
123.9, 61.6, 50.1, 37.8, 36.5, 22.0, 14.1, 14.0; MS (ESI): m/z 324 (M+ + 1).  Anal. Calcd for 
C16H21NO6: C, 59.43; H, 6.55; N, 4.33.  Found: C, 59.61; H, 6.38; N, 4.18. 
(±)-Diethyl 2-methyl-2-(2-(4-nitrophenyl)propyl)malonate (55d). Yield: 192 mg (0.57 mmol, 
85%) as a colorless oil;  IR: 1729, 1521, 1346, 855 cm-1; 1H NMR (400 MHz): δ 8.14 (d, J = 8.1 
Hz, 2H), 7.35 (d, J = 8.1 Hz, 2H), 4.11 (q, J = 7.1 Hz, 2H), 3.96-3.88 (m, 1H), 3.78-3.70 (m, 1H), 
3.00-2.91 (m, 1H), 2.40-2.35 (m, 1H), 2.27-2.22 (m, 1H), 1.35 (s, 3H), 1.26 (d, J = 6.9 Hz, 6H), 
1.22 (t, J = 7.4 Hz, 3H), 1.11 (t, J = 7.4 Hz, 3H); 13C NMR (100 MHz): δ 172.1, 171.7, 154.8, 
146.5, 128.2, 123.6, 61.4, 61.1, 53.2, 42.5, 36.3, 24.5, 20.3, 14.0, 13.8; MS: m/z 338 (M+ + 1).  
Anal. Calcd for C17H23NO6: C, 60.52; H, 6.87; N, 4.15.  Found: C, 60.27; H, 6.75; N, 3.98. 
Diethyl 2-(2-nitrophenethyl)malonate (55e). Yield: 195 mg (0.63 mmol, 94%) as a colorless 
oil; IR: 1730, 1527, 1347 cm-1; 1H NMR (400 MHz): δ 7.93 (d, J = 8.0 Hz, 1H), 7.59-7.50 (m, 
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3H), 7.38 (d, J = 7.8 Hz, 2H), 4.33-4.11 (m, 4H), 3.41 (t, J = 7.4 Hz, 1H), 3.07-2.82 (m, 3H), 
2.40-2.12 (m, 3H), 1.40-1.17 (m, 6H); 13C NMR (100 MHz): δ 169.0, 149.2, 135.9, 133.1, 132.1, 
127.5, 124.9, 61.6, 51.6, 30.5, 29.5, 14.1; MS (ESI): m/z 310 (M+ + 1).  Anal. Calcd for 
C15H19NO6: C, 58.25; H, 6.19; N, 4.53.  Found: C, 58.32; H, 6.05; N, 4.18 
(±)-Diethyl 2-methyl-2-(2-nitrophenethyl)malonate (55f). Yield: 162 mg (0.5 mmol, 74%) as a 
colorless oil; IR: 1729, 1527, 1349, 742 cm-1; 1H NMR (400 MHz): δ 7.92 (dd, J = 8.0, 1.2 Hz, 
2H), 7.55 (td, J = 8.0, 1.2 Hz, 2H), 4.25 (q, J = 7.1 Hz, 4H), 2.86 (distorted t, J = 8.5 Hz, 2H), 
2.19 (distorted t, J = 8.5 Hz, 2H), 1.53 (s, 3H), 1.29 (t, J = 7.1 Hz, 6H); 13C NMR (100 MHz): δ 
172.0, 149.2, 136.6, 133.1, 132.2, 127.3, 124.8, 61.4, 53.5, 36.7, 28.3, 19.8, 14.1; MS (ESI): m/z 
324 (M+ + 1).  Anal. Calcd for C16H21NO6: C, 59.43; H, 6.55; N, 4.33.  Found: C, 59.13; H, 6.28; 
N, 4.13.  
Diethyl 2-(4-cyanophenethyl)malonate (55h).  Yield:  113 mg (0.39 mmol, 58%); as a colorless 
oil; IR: 2228, 1751, 1731 cm-1; 1H NMR (400 MHz): δ 7.60 (d, J = 7.9 Hz, 2H), 7.30 (d, J = 7.9 
Hz, 2H), 4.23 (m, 4H), 3.35 (t, J = 7.4 Hz, 1H), 2.73 (t, J = 7.2 Hz, 2H), 2.22 (q, J = 7.7 Hz, 2H), 
1.28 (t, J = 7.1 Hz, 6H); 13C NMR (100 MHz): δ 169.0, 146.3, 132.3, 129.3, 118.9, 110.2, 61.6, 
51.1, 33.4, 29.7, 14.1; MS: m/z 290 (M+ + 1).  Anal. Calcd for C16H19NO4: C, 66.42; H, 6.62; N, 
4.84.  Found: C: 66.53; H, 6.67; N, 4.61. 
(±)-Diethyl 2-(4-cyanophenethyl)-2-methylmalonate (55i).  Yield: 109 mg (0.36 mmol, 53%) 
as a colorless oil; IR: 2228, 1730 cm-1; 1H NMR (400 MHz): δ 7.58 (d, J = 8.0 Hz, 2H), 7.30 (d, J 
= 8.0 Hz, 2H), 4.20 (q, J = 7.1 Hz, 4H), 2.65 (m, 2H), 2.14 (m, 2H), 1.49 (s, 3H), 1.26 (t, J = 7.1 
Hz, 6H); 13C NMR (100 MHz): δ 171.9, 147.2, 132.3, 129.2, 119.0, 110.0, 61.4, 53.5, 37.0, 31.1, 
20.0, 14.1; MS (ESI): m/z 304 (M+ + 1).  Anal. Calcd for C17H21NO4:  C, 67.31; H, 6.98; N, 4.62.  
Found: C: 67.41; H, 6.91; N, 4.53. 
(±)-Methyl 1-(4-nitrophenethyl)-2-oxocyclopentane-1-carboxylate (57a). Yield: 157 mg (0.54 
mmol, 81%) as a colorless oil; IR: 1748, 1724, 1518, 1346, 855 cm-1; 1H NMR (400 MHz): δ 8.14 
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(d, J = 8.6 Hz, 2H), 7.34 (d, J = 8.6 Hz, 2H), 3.75 (s, 3H), 2.82 (td, J = 12.0, 4.9 Hz, 1H), 2.66 
(td, J = 12.0, 4.9 Hz, 1H), 2.60 (m, 1H), 2.47 (m, 1H), 2.36-2.18 (complex, 2H), 2.12-1.85 
(complex, 4H); 13C NMR (100 MHz): δ 214.2, 171.2, 149.2, 146.6, 129.2, 123.7, 60.0, 52.7, 37.9, 
35.2, 33.4, 31.2, 19.7; MS (ESI): m/z 292 (M+ + 1).  Anal. Calcd for C15H17NO5: C, 61.85; H, 
5.88; N, 4.81.  Found: C, 61.76; H, 5.42; N, 4.70. 
Methyl (±)-R,S-1-(2-(4-nitrophenyl)propyl)-2-oxocyclopentane-1-carboxylate [(±)-R,S-57b]. 
Isomer A; Yield: 79.4 mg (0.26 mmol, 39%) as a colorless oil; IR: 1753, 1722, 1519, 1346, 855 
cm-1; 1H NMR (400 MHz): δ 8.15 (d, J = 8.1 Hz, 2H), 7.35 (d, J = 8.1 Hz, 2H), 3.66 (s, 3H), 3.01 
(m, 1H), 2.45 (dd, J = 14.4 4.8 Hz, 1H), 2.34 (m, 1H), 2.23 (m, 1H), 2.12 (m, 1H), 1.84 (m, 3H), 
1.42 (m, 1H), 1.26 (d, J = 6.8 Hz, 3H); 13C NMR (100 MHz): δ 213.8, 170.6, 154.5, 146.6, 128.2, 
123.7, 60.6, 52.6, 42.1, 37.2, 33.5, 23.5, 19.5 (1 aliphatic carbon unresolved); MS (ESI): m/z 306 
(M+ + 1).  Anal. Calcd for C16H19NO5: C, 62.94; H, 6.27; N, 4.59.  Found: C, 62.68; H, 6.39; N, 
4.65. 
Methyl (±)-R,R-1-(2-(4-nitrophenyl)propyl)-2-oxocyclopentane-1-carboxylate [(±)-R,R-57b]. 
Isomer B; Yield: 85.5 mg (0.28 mmol, 43%) as a white solid, mp 51-52 °C; IR: 1752, 1723, 1519, 
1346, 855 cm-1; 1H NMR (400 MHz): δ 8.14 (d, J = 8.2 Hz, 2H), 7.35 (d, J = 8.2 Hz, 2H), 3.33 (s, 
3H), 2.94 (m, 1H), 2.67 (m, 1H), 2.54 (dd, J = 14.4, 8.7 Hz, 1H), 2.38 (m, 1H), 2.24 (m, 1H), 
1.95 (m, 2H), 1.81 (m, 2H), 1.27 (d, J = 7.2 Hz, 3H); 13C NMR (100 MHz): δ 213.7, 169.8, 153.9, 
146.5, 128.2, 123.6, 60.5, 52.3, 42.0, 37.4, 37.2, 33.0, 23.8, 19.5; MS (ESI): m/z 306 (M+ + 1).  
Anal. Calcd for C16H19NO5: C, 62.94; H, 6.27; N, 4.59.  Found: C, 62.75; H, 6.07; N, 4.35. 
(±)-Methyl 1-(2-nitrophenethyl)-2-oxocyclopentane-1-carboxylate (57c). Yield: 157 mg (0.54 
mmol, 80%) as a colorless oil; IR: 1748, 1723, 1525, 1347, 744 cm-1; 1H NMR (400 MHz): δ 7.91 
(dd, J = 8.2, 1.4 Hz, 1H), 7.53 (td, J = 7.6, 1.4 Hz, 1H), 7.40 (dd, J = 8.2, 1.4 Hz, 1H), 7.36 (td, J 
= 7.6, 1.4 Hz, 1H), 3.75 (s, 3H), 2.89 (m, 2H), 2.62 (m, 1H), 2.45 (m, 1H), 2.39-2.23 (complex, 
2H), 2.13-1.98 (complex, 3H), 1.90 (ddd, J = 13.6, 11.8, 5.5 Hz, 1H); 13C NMR (100 MHz): δ 
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214.4, 171.2, 149.1, 136.5, 133.3, 132.4, 127.4, 124.8, 60.3, 52.7, 37.8, 34.8, 32.7, 28.8, 19.7; MS 
(ESI): m/z 292 (M+ + 1).  Anal. Calcd for C15H17NO5: C, 61.85; H, 5.88; N, 4.81.  Found: C, 
61.48; H, 5.68; N, 4.49. 
(±)-Methyl 1-(4-cyanophenethyl)-2-oxocyclopentane-1-carboxylate (57e).  Yield: 92 mg  (0.34 
mmol, 51%); IR: 2228, 1747, 1735 cm-1; 1H NMR (400 MHz): δ 7.57 (d, J = 8.0 Hz, 2H), 7.29 (d, 
J = 8.0 Hz, 2H), 3.72 (s, 3H), 2.76 (td, J = 13.1, 5.0 Hz, 1H), 2.60 (m, 2H), 2.47 (m, 1H), 2.36-
2.16 (complex, 2H), 2.12-1.80 (complex, 4H); 13C NMR (100 MHz): δ 214.3, 171.2, 147.0, 
132.3, 129.2, 119.0, 110.0, 60.1, 52.7, 37.9, 35.2, 33.4, 31.4, 19.7; MS (ESI): m/z 272 (M+ + 1).  
Anal. Calcd for C16H17NO3:  C, 70.83; H, 6.32; N, 5.16.  Found: C: 70.88; H, 6.30; N, 5.19. 
4-(4-Nitrophenethyl)morpholine (61a). Yield: 151 mg (0.64 mmol, 95%) as a colorless oil; IR: 
1517, 1345, 1116, 858 cm-1; 1H NMR (400 MHz): δ 8.15 (d, J = 8.4 Hz, 2H), 7.37 (d, J = 8.4 Hz, 
2H), 3.73 (t, J = 4.6 Hz, 4H), 2.91 (t, J = 7.5 Hz, 2H), 2.64 (t, J = 7.5 Hz, 2H), 2.52 (t, J = 4.6 Hz,  
4H); 13C NMR (100 MHz): δ 148.2, 146.5, 129.5, 123.7, 123.6, 66.9, 59.8, 53.6, 33.1; MS (ESI): 
m/z 237 (M+ + 1).  Anal. Calcd for C12H16N2O3: C, 61.00; H, 6.83; N, 11.86.  Found: C, 60.85; H, 
6.74; N, 11.65. 
(±)-4-(2-(4-Nitrophenyl)propyl)morpholine (61b). Yield: 145 mg (0.58 mmol, 86%) as a 
colorless oil; IR: 1523, 1345, 1117, 855 cm-1; 1H NMR (400 MHz): δ 8.14 (d, J = 8.4 Hz, 2H), 
7.36 (d, J = 8.4 Hz, 2H), 3.64 (t, J = 4.8 Hz, 4H), 3.07 (sextet, J = 7.2 Hz, 1H), 2.48 (m, 2H), 2.42 
(t, J = 4.8 Hz, 4H), 1.31 (d, J = 6.9 Hz, 3H); 13C NMR (100 MHz): δ 153.8, 146.5, 128.0, 123.6, 
66.9, 65.8, 53.9, 37.3, 19.8; MS (ESI): m/z 251 (M+ + 1).  Anal. Calcd for C13H18N2O3: C, 62.38; 
H, 7.25; N, 11.19.  Found: C, 62.28; H, 7.05; N, 11.31. 
4-(2-Nitrophenethyl)morpholine (61c). Yield: 134 mg (0.57 mmol, 85%) as a colorless oil; IR: 
1524, 1353, 1116, 742 cm-1; 1H NMR (400 MHz): δ 7.90 (dd, J = 8.2, 0.9 Hz, 1H), 7.51 (td, J = 
7.4, 0.9 Hz, 1H), 7.37 (d, J = 8.2 Hz, 1H), 7.35 (obscured td, J ≈ 7.4, 1.0 Hz, 1H), 3.72 (t, J = 4.6 
Hz, 4H), 3.10 (distorted t, J = 8.0 Hz, 2H), 2.64 (distorted t, J = 8.0 Hz, 2H), 2.53 (t, J = 4.6 Hz, 
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4H); 13C NMR (100 MHz): δ 149.7, 135.3, 132.9, 132.4, 127.3, 124.7, 67.0, 59.5, 53.6, 30.3; MS 
(ESI): m/z 237 (M+ + 1).  Anal. Calcd for C12H16N2O3: C, 61.00; H, 6.83; N, 11.86.  Found: C, 
61.12; H, 6.75; N, 11.92. 
1-(4-Nitrophenethyl)piperidine (62a). Yield: 146 mg (0.62 mmol, 93%) as a colorless oil; IR: 
1524, 1353, 1116, 742 cm-1; 1H NMR (400 MHz): δ 8.14 (d, J = 8.4 Hz, 2H), 7.36 (d, J = 8.4 Hz, 
2H), 2.91 (distorted t, J = 7.5 Hz, 2H), 2.58 (distorted t, J = 7.5 Hz, 2H), 2.46 (t, J = 5.2 Hz, 4H), 
1.61 (quintet, J = 5.7 Hz, 4H), 1.46 (quintet, J = 5.9 Hz, 2H); 13C NMR (100 MHz): δ 148.8, 
146.4, 129.5, 123.6, 60.4, 54.5, 33.6, 26.0, 24.4; MS (ESI): m/z 235 (M+ + 1).  Anal. Calcd for 
C13H18N2O2: C, 66.64; H, 7.74; N, 11.96.  Found: C, 66.51; H, 7.52; N, 11.69.  
(±)-1-(2-(4-Nitrophenyl)propyl)piperidine (62b). Yield: 140 mg (0.56 mmol, 84%) as a 
colorless oil; IR: 1519, 856 cm-1; 1H NMR (400 MHz): δ 8.15 (d, J = 8.1 Hz, 2H), 7.36 (d, J = 8.1 
Hz, 2H), 3.07 (sextet, J = 7.2 Hz, 1H), 2.43 (d, J = 7.4 Hz, 2H), 2.35-2.32 (m, 4H), 1.53-1.47 (m, 
4H), 1.41-1.37 (m, 2H), 1.27 (d, J = 7.5 Hz, 3H); 13C NMR (100 MHz): δ 154.5, 146.4, 128.1, 
123.5, 66.3, 55.0, 37.7, 26.0, 24.4, 19.9; MS (ESI): m/z 249 (M+ + 1).  Anal. Calcd for 
C14H20N2O2: C, 67.72; H, 8.12; N, 11.28.  Found: C, 68.13; H, 8.02; N, 11.70. 
1-(2-Nitrophenethyl)piperidine (62c). Yield: 138 mg (0.59 mmol, 88%) as a colorless oil; IR: 
1525, 1350, 860 cm-1; 1H NMR (400 MHz): δ 7.89 (dd, J = 8.1, 0.9 Hz, 1H), 7.51 (td, J = 7.5, 1.0 
Hz, 1H), 7.38 (dd, J = 8.1, 0.9 Hz, 1H), 7.34 (td, J = 7.5, 1.0 Hz, 1H), 3.11 (distorted t, J = 7.7 
Hz, 2H), 2.62 (distorted t, J = 7.7 Hz, 2H), 2.49 (m, 4H), 1.60 (quintet, J = 5.6 Hz, 4H), 1.44 
(quintet, J = 5.8 Hz, 2H); 13C NMR (100 MHz): δ 149.6, 135.7, 132.9, 132.5, 127.1, 124.6, 59.9, 
54.4, 30.4, 26.0, 24.4; MS (ESI): m/z 235 (M+ + 1).  Anal. Calcd for C13H18N2O2: C, 66.64; H, 
7.74; N, 11.96.  Found: C, 66.51; H, 7.79; N, 11.83.  
N-Benzyl-2-(4-nitrophenyl)ethan-1-amine (63a). Yield: 141 mg (0.55 mmol, 82%) as a red oil; 
IR: 3310, 1516, 1345, 855 cm-1; 1H NMR (400 MHz): δ 8.15 (d, J = 8.5 Hz, 2H), 7.36 (d, J = 8.5 
Hz, 2H), 7.36-7.25 (complex, 5H), 3.81 (s, 2H), 2.93 (t, J = 3.8 Hz, 4H), 1.68 (br s, 1H); 13C 
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NMR (100 MHz): δ 148.0, 146.6, 139.8, 129.5, 128.5, 128.1, 127.1, 123.7, 53.8, 49.8, 36.3; MS 
(ESI): m/z 255 (M+ + 1).  Anal. Calcd for C15H16N2O2: C, 70.29; H, 6.29; N, 10.93.  Found: C, 
70.15; H, 6.70; N, 11.08.  
(±)-N-Benzyl-2-(4-nitrophenyl)propan-1-amine (63b). Yield: 139 mg (0.52 mmol, 77%) as a 
yellow oil; IR: 3356, 1516, 1344, 854 cm-1; 1H NMR (400 MHz): δ 8.16 (d, J = 8.4 Hz, 2H), 7.35 
(d, J = 8.4 Hz, 2H), 7.32-7.28 (m, 2H), 7.26-7.22 (m, 3H), 3.76 (d, J = 4.21 Hz, 2H), 3.06 (septet, 
J = 7.0 Hz, 1H), 2.82 (d, J = 7.1 Hz, 2H), 1.43 (br s, 1H), 1.28 (d, J = 7.0 Hz, 3H); 13C NMR (100 
MHz): δ 153.4, 146.6, 140.1, 128.4, 128.1, 128.0, 127.0, 123.8, 55.8, 53.8, 40.4, 19.7; MS (ESI): 
m/z 271 (M+ + 1).  Anal. Calcd for C16H18N2O2: C, 71.09; H, 6.71; N, 10.36.  Found: C, 71.38; H, 
6.58; N, 10.47. 
N-Benzyl-2-(2-nitrophenyl)ethan-1-amine (63c). Yield: 134 mg (0.52 mmol, 78%) as a brown 
oil; IR: 3346, 1524, 1347, 740 cm-1; 1H NMR (400 MHz): δ 7.90 (d, J = 8.1 Hz, 1H), 7.51 (t, J = 
8.0 Hz, 1H), 7.36 (apparent d, J = 8.1 Hz, 1H), 7.36-7.20 (complex, 6H), 3.82 (s, 2H), 3.11 (t, J = 
7.4 Hz, 2H), 2.94 (t, J = 7.3 Hz, 2H), 1.50 (br s, 1H); 13C NMR (100 MHz): δ 149.6, 140.2, 135.2, 
132.9, 132.3, 128.4, 128.1, 127.3, 127.0, 124.8, 53.7, 49.7, 33.6; MS (ESI): m/z 257 (M+ + 1).  
Anal. Calcd for C15H16N2O2: C, 70.29; H, 6.29; N, 10.93.  Found: C, 70.18; H, 6.42; N, 10.79.  
2.3.6 Bismuth triflate catalyzed synthesis of 4-chromanone 
Representative procedure for the preparation of aryl 3,3-dimethylacrylates (68). The general 
procedure of Dawson and co-workers was followed.33 To an oil free suspension of sodium 
hydride (0.60 g, 25.0 mmol) in 10 mL of anhydrous THF, a solution of the phenol (23.1 mmol) in 
30 mL of THF was added over a 5-min period with stirring at 0 oC (ice bath). The solution was 
stirred for 10 min and treated with a solution of 3-methyl-2-butenoyl chloride (2.78 g, 23.3 mmol) 
in 15 mL of dry THF over a 5-min period at 0 oC. The reaction was then allowed to warm to room 
temperature over a 3-h period. The white suspension was transferred to separatory funnel 
containing water (75 mL) and acetic acid (0.5 mL) and was gently shaken. The mixture was 
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extracted with ether (2 × 50 mL) and the extract was washed with saturated aq NaCl (3 × 50 mL), 
dried (MgSO4), and concentrated to give a light yellow oil. The product was purified on a 40-cm 
× 2.5-cm silica gel column eluted with 10% ether in hexanes to give the pure ester.  
Phenyl 3-methyl-2-butenoate (68a).  Yield:  3.61 g (20.6 mmol, 89%) as a colorless oil.  IR: 
1738, 1653 cm-1; 1H NMR (400 MHz, CDCl3): δ 7.38 (t, J = 7.9 Hz, 2H), 7.20 (t, J = 7.8 Hz, 1H), 
7.10 (d, J = 8.0 Hz, 2H), 5.91 (m, 1H), 2.22 (d, J = 1.8 Hz, 3H), 1.96 (d, J = 1.8 Hz, 3H); 13C 
NMR (100 MHz, CDCl3): δ 164.9, 159.9, 150.7, 129.3, 125.5, 121.8, 115.3, 27.6, 20.5; HRMS 
(ESI) m/z Calcd for [C11H12O2 + H]+: 177.0916; found: 177.0910.  
4-Methylphenyl 3-methyl-2-butenoate (68b):  Yield: 4.30 g (22.6 mmol, 98%) as a colorless 
oil; IR: 1738, 1650 cm-1; 1H NMR (400 MHz, CDCl3): δ 7.16 (d, J = 8.0 Hz, 2H), 6.97 (d, J = 8.0 
Hz, 2H), 5.90 (s, 1H), 2.33 (s, 3H), 2.22 (s, 3H), 1.97 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 
165.1, 159.6, 148.4, 135.1, 129.8, 121.5, 115.3, 27.6, 20.9, 20.5; HRMS (ESI) m/z Calcd for 
[C12H14O2 + H]+: 191.1072; found: 191.1073. 
3-Methylphenyl 3-methyl-2-butenoate (68c).  Yield:  4.25 g (22.4 mmol, 97%) as a colorless 
oil; IR: 1739, 1647 cm-1; 1H NMR (400 MHz, CDCl3): δ 7.24 (t, J = 7.7 Hz, 1H), 7.02 (d, J = 7.7 
Hz, 1H), 6.91 (s, 1H), 6.89 (d, J = 7.7 Hz, 1H), 5.90 (s, 1H), 2.35 (s, 3H), 2.23 (s, 3H), 1.97 (s, 
3H); 13C NMR (100 MHz, CDCl3): δ 165.1, 159.7, 150.6, 139.5, 129.1, 126.3, 122.4, 118.8, 
115.3, 27.7, 21.3, 20.5; HRMS (ESI) m/z Calcd for [C12H14O2 + H]+: 191.1072; found: 191.1062. 
3,5-Dimethylphenyl 3-methyl-2-butenoate (68d): Yield: 4.23 g (20.7 mmol, 89%) as a colorless 
oil; IR: 1734, 1650 cm-1; 1H NMR (400 MHz, CDCl3): δ 6.84 (s, 1H), 6.97 (s, 2H), 5.89 (s, 1H), 
2.30 (s, 6H), 2.22 (s, 3H), 1.97 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 165.2, 159.5, 150.6, 
139.1, 127.3, 119.4, 115.3, 27.6, 21.2, 20.4; HRMS (ESI) m/z Calcd for [C13H16O2 + H]+:  
205.1229; found: 205.1222.    
2-Isopropyl-5-methylphenyl 3-methyl-2-butenoate (68e):  Yield: 5.19 g (22.3 mmol, 96%) as a 
colorless oil; IR: 1738, 1650 cm-1; 1H NMR (400 MHz, CDCl3): δ 7.19 (d, J = 7.9 Hz, 1H), 7.00 
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(d, J = 7.9 Hz, 1H), 6.83 (s, 1H), 5.95 (apparent sextet, J = 1.3 Hz, 1H), 2.99 (d septet, J = 6.8, 
1.3 Hz, 1H), 2.32 (s, 3H), 2.23 (s, 3H), 1.99 (s, 3H), 1.19 (dd, J = 8.0, 1.9 Hz, 6H); 13C NMR 
(100 MHz, CDCl3): δ 165.2, 159.5, 147.8, 137.2, 136.4, 126.8, 126.3, 123.0, 115.2, 27.6, 27.1, 
23.1, 20.8, 20.5; HRMS (ESI) m/z Calcd for [C15H20O2 + H]+:  233.1542; found: 233.1548. 
3-Fluorophenyl 3-methyl-2-butenoate (68f):  Yield: 4.07 g (21.0 mmol, 90%) as a colorless oil; 
IR: 1739, 1648, 1123 cm-1; 1H NMR (400 MHz, CDCl3): δ 7.34 (AB pattern, J = 7.8 Hz, 1H), 
6.95-6.84 (complex, 3H), 5.89 (s, 1H), 2.23 (s, 3H), 1.99 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 
164.4, 162.9 (d, J = 247.0 Hz), 160.8, 151.6 (d, J = 10.8 Hz), 130.0 (d, J  = 9.5 Hz), 117.6 (d, J  = 
3.3 Hz), 114.8, 112.5 (d, J  = 21.0 Hz), 109.9 (d, J  = 24.1 Hz), 27.7, 20.6; HRMS (ESI) m/z 
Calcd for [C11H11FO2 + H]+:  195.0821; found: 195.0825. 
3-Methoxyphenyl 3-methyl-2-butenoate (68g):  Yield: 4.61 g (22.4 mmol, 96%) as a colorless 
oil; IR: 2838, 1740, 1648 cm-1; 1H NMR (400 MHz, CDCl3): δ 7.26 (t, J = 8.2 Hz, 1H), 6.77 (ddd, 
J = 8.2, 2.3, 0.7 Hz, 1H), 6.70 (ddd, J = 8.0, 2.3, 0.7 Hz, 1H), 6.66 (t, J = 2.3 Hz, 1H), 5.91 (s, 
1H), 3.79 (s, 3H), 2.23 (s, 3H), 1.98 (s, 3H); 13C NMR 100 MHz, CDCl3): δ 164.8, 160.4, 160.0, 
151.7, 129.7, 115.2, 114.1, 111.4, 107.7, 55.4, 27.6, 20.5; HRMS (ESI) m/z Calcd for [C12H14O3 + 
H]+: 207.1021; found: 207.1017. 
Reaction of 3-methylphenyl 3-methyl-2-butenoate (68c) with aluminum chloride.   A 250-
mL three-necked round-bottomed flask equipped with a stir bar, an addition funnel and a 
condenser (with a drying tube) was charged with dichloromethane (40 mL) and AlCl3 (1.19 g, 
8.95 mmol).  The resulting suspension was stirred and cooled to 0 oC (ice bath), and a solution of 
68c (1.00 g, 5.26 mmol) in dichloromethane (10 mL) was added dropwise.  The reaction was 
gradually warmed to room temperature and stirring was continued for 65 h.  The resulting brown 
solution was added to a mixture of ice and saturated aq NaCl, the layers were separated, and the 
aqueous layer was extracted with dichloromethane (40 mL).  The combined organic extracts were 
washed with saturated aq NaCl (2 × 50 mL), dried (MgSO4), and concentrated to give a brown 
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oil, which was purified on a 30 cm × 2.5 cm silica gel column eluted with increasing 
concentrations (2-10%) of ether in hexanes to give four bands:  band 1 (highest Rf), 1-(2-
hydroxy-4-methylphenyl)-3-methyl-2-buten-1-one (70c, 181 mg, 0.95 mmol, 18%) as a yellow 
oil;  band 2, 3-methylphenyl 3-methyl-2-butenoate (68c, 51 mg, 0.26 mmol, 5%); band 3, 2,2,7-
trimethyl-4-chromanone (71c, 648 mg, 3.41 mmol, 65%) as a white solid, mp 69-70 oC; and band 
4, 4,4,7-trimethyl-2-chromanone (69c, 21 mg, 0.011 mmol, 2%) as a yellow oil.  The spectral 
data were as follows:   
Band 1 (70c):  IR: 3200-2700 (broad), 1640, 1583 cm-1; 1H NMR (400 MHz, CDCl3): δ 12.9 (s, 
1H), 7.65 (d, J = 8.0 Hz, 1H), 6.78 (s, 1H), 6.74 (s, 1H), 6.68 (d, J = 8.0 Hz, 1H), 2.34 (s, 3H), 
2.20 (s, 3H), 2.03 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 195.8, 163.4, 157.1, 147.3, 126.8, 
120.1, 119.8, 118.5, 118.4, 28.2, 21.9, 21.3; HRMS (ESI) m/z Calcd for [C12H14O2 + H]+: 
191.1072; found: 191.1065. 
Band 2 (68c, recovered starting material):  The spectral data matched those reported for 68c 
above. 
Band 3 (71c):  The spectral data matched those reported for 71c below. 
Band 4 (69c):  IR: 1772, 1625, 1581 cm-1; 1H NMR (400 MHz, CDCl3): δ 7.19 (d, J = 7.8 Hz, 
1H), 6.96 (dd, J = 7.8, 1.7 Hz, 1H), 6.87 (d, J = 1.7 Hz, 1H), 2.60 (s, 2H), 2.33 (s, 3H), 1.33 (s, 
6H); 13C NMR (100 MHz, CDCl3): δ 168.5, 150.5, 138.5, 128.7, 125.5, 124.2, 117.5, 43.8, 33.0, 
27.8, 21.0; HRMS (ESI) m/z Calcd for [C12H14O2 + H]+: 191.1072; found: 191.1069. 
General procedure for the preparation of 4-chromanones from aryl 3,3-dimethylacrylates.  
A solution of the aryl 3,3-dimethylacrylate (68, 1.00 mmol) and bismuth(III) triflate (131 mg, 20 
mol%) in 8 mL of toluene was boiled for 12-24 h and monitored by TLC.  Each reaction was 
worked up by cooling, removing the solvent, diluting with 1 mL of chloroform, and applying the 
crude product mixture directly to a 20 cm × 20 cm PTLC plate.  After the chloroform had been 
dried, the plate was eluted with 5% ether in hexanes (8-10% ether in hexanes for the methoxy-
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substituted products) to give three major bands.  The bright blue fluorescent band (the 4-
chromanone) was accompanied by small amounts of the starting ester (a faster moving band) and 
the corresponding phenol (a slower moving band).  For 2-isopropyl-5-methylphenol, the 4-
chromanone (40%) was accompanied by larger quantities of aryl 3,3-dimethylacrylate (12%) and 
phenol (30%).  The spectra for all of the 4-chromanones and some of the aryl esters isolated are 
listed below.   
Conversion of Fries product 70c to 4-chromanone 71c.  A toluene solution of 1-(2-hydroxy-4-
methylphenyl)-3-methyl-2-buten-1-one (70c, 60 mg, 0.31 mmol) and bismuth(III) triflate (41 mg, 
0.06 mmol, 20 mol%) was heated at reflux for 15 min.  The solvent was removed under vacuum 
and the remaining oil was filtered through a short plug of silica gel using 5% ether in hexanes.  
Removal of the solvent under vacuum afforded 2,2,7-trimethyl-4-chromanone (71c, 57 mg, 0.30 
mmol, 95%).  The spectral data matched those reported for 71c below. 
General procedure for the preparation of 4-chromanones from the phenol and the 
carboxylic acids.  To a solution of the phenol (72, 1.0 mmol) and the dimethylacrylic acid or 
crotonic acid (1.0 mmol) in 8 mL of toluene was added bismuth(III) triflate (41 mg, 0.06 mmol, 
20 mol%).  The reaction was heated under reflux for 12-24 h and then cooled. Removal of the 
solvent under vacuum and purification by PTLC eluted with 5% ether in hexane (8-10% ether in 
hexanes for the methoxy-substituted products) showed several bands. The major band (bright 
fluorescent blue) was isolated and extracted with ether to give the 4-chromanone 71 or 73. The 
other bands consisted of varying amounts of the aryl ester of the carboxylic acid and unreacted 
phenol. The following compounds were prepared by this method. 
2,2,6-Trimethyl-4-chromanone (71b):  Yield: 140 mg (0.74 mmol, 74%) as a colorless oil (lit152 
reports a mp of 67 oC); IR: 1692, 1619 cm-1; 1H NMR: δ 7.65 (s, 1H), 7.28 (d, J = 8.4 Hz, 1H), 
6.83 (d, J = 8.4 Hz, 1H), 2.69 (s, 2H), 2.34 (s, 3H), 1.45 (s, 6H); 13C NMR: δ 192.8, 158.0, 137.2, 
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130.0, 126.1, 119.8, 118.1, 79.0, 48.9, 26.6, 20.4; HRMS (ESI) m/z Calcd for [C12H14O2 + H]+: 
191.1072; found: 191.1077. 
2,2,7-Trimethyl-4-chromanone (71c):  Yield: 129 mg (0.68 mmol, 68%) as a white solid, mp 
69-70 oC (lit153 mp 70 oC); IR: 1686, 1617 cm-1; 1H NMR: δ 7.75 (d, J = 8.0 Hz, 1H), 6.79 (d, J = 
8.0 Hz, 1H), 6.73 (s, 1H), 2.69 (s, 2H), 2.30 (s, 3H), 1.44 (s, 6H); 13C NMR: δ 192.2, 160.0, 
149.6, 126.4, 122.0, 118.3, 118.0, 79.1, 48.8, 26.7, 21.9; HRMS (ESI) m/z Calcd for [C12H14O2 + 
H]+: 191.1072; found: 191.1074. 
2,2,5,7-Tetramethyl-4-chromanone (71d):  Yield: 140 mg (0.69 mmol, 69%) as a white solid, 
mp 61-63 oC; IR: 1682, 1614 cm-1; 1H NMR: δ 6.60 (s, 1H), 6.57 (s, 1H), 2.67 (s, 2H), 2.59 (s, 
3H), 2.28 (s, 3H), 1.43 (s, 6H); 13C NMR: δ 194.1, 161.5, 146.3, 141.8, 125.6, 116.9, 116.8, 78.4, 
50.8, 27.0, 23.1, 22.1; HRMS (ESI) m/z Calcd for [C13H16O2 + H]+: 205.1229; found: 205.1223. 
2,2,5-Trimethyl-8-isopropyl-4-chromanone (71e):  Yield: 102 mg (0.44 mmol, 44%; 54% 
brsm—based on recovered phenol) as a white solid, mp 73-75 oC; IR: 1684, 1578 cm-1; 1H NMR: 
δ 7.23 (d, J  = 7.7 Hz, 1H), 6.71 (d, J = 7.7 Hz, 1H), 3.25 (septet, J = 6.9 Hz, 1H), 2.70 (s, 2H), 
2.59 (s, 3H), 1.45 (s, 6H), 1.21 (d, J = 6.9 Hz, 6H); 13C NMR: δ 194.6, 158.1, 138.5, 135.3, 131.3, 
123.4, 118.6, 77.8, 50.3, 26.9, 26.6, 22.7, 22.4; HRMS (ESI) m/z Calcd for [C15H20O2 + H]+: 
233.1542; found: 233.1541.  A faster moving band contained 2-isopropyl-5-methylphenyl 3-
methyl-2-butenoate [68e (X= 2-i-Pr-5-Me), 51 mg, 0.22 mmol, 22%; 27% brsm] as a colorless 
oil.  The spectral data matched those reported above. 
7-Fluoro-2,2-dimethyl-4-chromanone (71f):  Yield: 126 mg (0.65 mmol, 65%) as a colorless 
oil; IR: 1694, 1616 cm-1; 1H NMR: δ 7.78 (dd, J = 8.8, 6.8 Hz, 1H), 6.69 (td, J = 8.5, 2.4 Hz, 1H), 
6.62 (dd, J = 10.1, 2.4 Hz, 1H), 2.71 (s, 2H), 1.46 (s, 6H); 13C NMR: δ 191.1, 167.8 (d, J = 238.4 
Hz), 161.7 (d, J = 13.6 Hz), 129.0 (d, J = 11.4 Hz), 117.8 (d, J = 2.5 Hz), 109.7 (d, J = 22.7 Hz), 
105.7 (d, J = 24.3 Hz), 80.1, 48.6, 26.6; HRMS (ESI) m/z Calcd for [C11H11FO2 + H]+: 195.0821; 
found: 195.0815. 
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7-Methoxy-2,2-dimethyl-4-chromanone (71g):  Yield: 93 mg (0.45 mmol, 45%) as a colorless 
solid, mp 79-81 oC (lit154 mp 81-82 oC); IR: 2838, 1681, 1609 cm-1; 1H NMR: δ 7.79 (d, J = 8.8 
Hz, 1H), 6.55 (dd, J = 8.8, 2.4 Hz, 1H), 6.38 (d, J = 2.4 Hz, 1H), 3.83 (s, 3H), 2.67 (s, 2H), 1.46 
(s, 6H); 13C NMR: δ 191.1, 166.2, 162.0, 128.3, 114.1, 109.3, 101.1, 79.6, 55.4, 48.6, 26.7; 
HRMS (ESI) m/z Calcd for [C12H14O3 + H]+: 207.1021; found: 207.1012. 
2,2,5,8-Tetramethyl-4-chromanone (71h):  Yield: 51 mg (0.25 mmol, 25%; 42% brsm) as a 
colorless oil; IR: 1688, 1586 cm-1; 1H NMR: δ 7.16 (d, J = 7.5 Hz, 1H), 6.64 (d, J = 7.5 Hz, 1H), 
2.69 (s, 2H), 2.58 (s, 3H), 2.17 (s, 3H), 1.44 (s, 6H); 13C NMR: δ 193.5, 159.0, 138.7, 135.5, 
125.0, 123.0, 118.4, 77.9, 50.3, 26.7, 22.6, 16.0; HRMS (ESI) m/z Calcd for [C13H16O2 + H]+: 
205.1229; found: 205.1225.  A faster moving band contained 2,5-dimethylphenyl 3-methyl-2-
butenoate [68h (X = 2,5-diMe), 45 mg, 0.22 mmol, 22%; 37% brsm] as a colorless oil.  IR: 1734, 
1649 cm-1; 1H NMR: δ 7.10 (d, J = 7.7 Hz, 1H), 6.94 (d, J = 7.7 Hz, 1H), 6.83 (s, 1H), 5.94 
(apparent t, J = 0.7 Hz, 1H), 2.31 (s, 3H), 2.23 (d, J = 0.7 Hz, 3H), 2.13 (s, 3H), 1.99 (d, J = 0.7 
Hz, 3H); 13C NMR: δ 164.8, 159.6, 149.1, 136.7, 130.7, 127.0, 126.5, 122.6, 115.1, 27.6, 20.9, 
20.5, 15.8; HRMS (ESI) m/z Calcd for [C13H16O2 + H]+: 205.1229; found: 205.1221. 
2,2,6,7-Tetramethyl-4-chromanone (71i):  Yield: 178 mg (0.87 mmol, 87%) as a white solid, 
mp 69-71 oC; IR: 1688, 1621 cm-1; 1H NMR: δ 7.59 (s, 1H), 6.72 (s, 1H), 2.67 (s, 2H), 2.25 (s, 
3H), 2.20 (s, 3H), 1.43 (s, 6H); 13C NMR: δ 192.9, 158.7, 147.0, 129.7, 126.9, 119.3, 118.4, 79.4, 
49.3, 27.1, 20.9, 19.2; HRMS (ESI) m/z Calcd for [C13H16O2 + H]+: 205.1229; found: 205.1228. 
2,2,6,8-Tetramethyl-4-chromanone (71j):  Yield: 155 mg (0.76 mmol, 76%) as a white solid, 
mp 63-65 oC; IR: 1689, 1614 cm-1; 1H NMR: δ 7.51 (s, 1H), 7.16 (s, 1H), 2.69 (s, 2H), 2.26 (s, 
3H), 2.18 (s, 3H), 1.44 (s, 6H); 13C NMR: δ 193.3, 156.3, 138.1, 129.2, 127.3, 123.6, 119.4, 78.6, 
49.8, 26.7, 20.3, 15.7; HRMS (ESI) m/z Calcd for [C13H16O2 + H]+: 205.1229; found: 205.1221. 
2,2,7,8-Tetramethyl-4-chromanone (71k):  Yield: 177 mg (0.87 mmol, 87%) as a white solid, 
mp 52-54 oC; IR: 1688, 1604 cm-1; 1H NMR: δ 7.62 (d, J = 8.0 Hz, 1H), 6.78 (d, J = 8.0 Hz, 1H), 
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2.67 (s, 2H), 2.29 (s, 3H), 2.14 (s, 3H), 1.45 (s, 6H); 13C NMR: δ 193.5, 158.3, 146.0, 125.9, 
123.7, 122.7, 118.5, 49.1, 27.3, 21.2, 11.9; HRMS (ESI) m/z Calcd for [C13H16O2 + H]+: 
205.1229; found: 205.1233. 
3,3-Dimethyl-2,3-dihydro-1H-benzo[f]chromen-1-one (71l):  Yield: 174 mg (0.77 mmol, 77%) 
as a light yellow solid, mp 78-80 oC; IR: 1672, 1618 cm-1; 1H NMR: δ 9.44 (d, J = 8.7 Hz, 1H), 
7.89 (d, J = 9.0 Hz, 1H), 7.72 (d, J = 8.0 Hz, 1H), 7.61 (t, J = 7.9 Hz, 1H), 7.40 (t, J = 7.5 Hz, 
1H), 7.05 (d, J = 9.0 Hz, 1H), 2.82 (s, 2H), 1.51 (s, 6H); 13C NMR: δ 193.6, 162.0, 137.3, 131.3, 
129.5, 128.8, 128.3, 125.5, 124.5, 119.4, 111.4, 79.4, 50.1, 26.3; HRMS (ESI) m/z Calcd for 
[C15H14O2 + H]+: 227.1072; found: 227.1068. 
2,2-Dimethyl-2,3,6,7,8,9-hexahydro-4H-benzo[g]chromen-4-one (71m): Yield: 193 mg (0.84 
mmol, 84%) as a white solid, mp 75-76 oC; IR: 1687, 1618 cm-1; 1H NMR: δ 7.56 (s, 1H), 6.63 (s, 
1H), 2.76 (m, 4H), 2.67 (s, 2H), 1.77 (m, 4H), 1.43 (s, 6H); 13C NMR: δ 192.6, 157.6, 147.1, 
129.9, 126.3, 118.2, 117.7, 78.8, 49.0, 30.7, 28.4, 26.7, 23.2, 22.7; HRMS (ESI) m/z Calcd for 
[C15H18O2 + H]+: 231.1385; found: 231.1377. 
7-Chloro-2,2-dimethyl-4-chromanone (71n):  Yield: 84 mg (0.40 mmol, 40%; 48% brsm) as a 
white solid, mp 69-70 oC; IR: 1694, 1599 cm-1; 1H NMR: δ 7.79 (d, J = 9.0 Hz, 1H), 6.95 (m, 
2H), 2.71 (s, 2H), 1.46 (s, 6H); 13C NMR: δ 191.5, 160.4, 141.9, 127.8, 121.5, 118.7, 118.5, 80.0, 
48.7, 26.6; HRMS (ESI) m/z Calcd for [C11H11ClO2 + H]+: 211.0526; found: 211.0529.  A faster 
moving band contained 3-chlorophenyl 3-methyl-2-butenoate [68n (X = 3-Cl), 55 mg, 0.26 
mmol, 26%; 31% brsm] as a colorless oil.  IR:  1742, 1649 cm-1; 1H NMR: δ 7.30 (t, J = 8.1 Hz, 
1H), 7.20 (dm, J = 9.0 Hz, 1H), 7.15 (t, J = 2.4 Hz, 1H), 7.01 (dm, J = 8.1 Hz, 1H), 5.89 (s, 1H), 
2.24 (s, 3H), 2.00 (s, 3H); 13C NMR: δ 164.4, 160.9, 151.2, 134.6, 130.1, 125.8, 122.5, 120.2, 
114.8, 27.7, 20.6; HRMS (ESI) m/z Calcd for [C11H11ClO2 + H]+: 211.0526; found: 211.0520. 
6-Methoxy-2,2-dimethyl-4-chromanone (71o):  Yield: 165 mg (0.80 mmol, 80%) as a light 
yellow solid, mp 69-71 oC; IR: 2834, 1686, 1619 cm-1; 1H NMR: δ 7.29 (s, 1H), 7.08 (d, J = 9.0 
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Hz, 1H), 6.85 (d, J = 9.0 Hz, 1H), 3.79 (s, 3H), 2.70 (s, 2H), 1.44 (s, 6H); 13C NMR: δ 193.1, 
155.1, 154.0, 125.8, 120.4, 120.1, 107.4, 79.5, 56.2, 49.3, 27.0; HRMS (ESI) m/z Calcd for 
[C12H14O3 + H]+: 207.1021; found: 207.1015. 
(±)-2,6-Dimethyl-4-chromanone (73b):  Yield: 114 mg (0.65 mmol, 65%) as a yellow oil; IR: 
1691, 1618 cm-1; 1H NMR: δ 7.67 (d, J = 2.4 Hz, 1H), 7.28 (dd, J = 8.4, 2.4 Hz, 1H), 6.87 (d, J = 
8.4 Hz, 1H), 4.55 (m, 1H), 2.67 (AB pattern, J = 16.9 Hz, 1H), 2.65 (s, 1H), 2.30 (s, 3H), 1.51 (d, 
J = 6.3 Hz, 3H); 13C NMR: δ 192.8, 159.8, 137.1, 130.6, 126.5, 120.4, 117.7, 74.2, 44.7, 21.0, 
20.4; HRMS (ESI) m/z Calcd for [C11H12O2 + H]+: 177.0916; found: 177.0913.  
(±)-2,7-Dimethyl-4-chromanone (73c):  Yield: 91 mg (0.52 mmol, 52%) as a light yellow oil; 
IR: 1689, 1615 cm-1; 1H NMR: δ 7.77 (d, J = 8.0 Hz, 1H), 6.82 (d, J = 8.0 Hz, 1H), 6.77 (s, 1H), 
4.56 (m, 1H), 2.66 (AB pattern, J = 16.5 Hz, 1H), 2.64 (s, 1H), 2.35 (s, 3H), 1.50 (d, J = 6.3 Hz, 
3H); 13C NMR: δ 192.3, 161.7, 147.5, 126.8, 122.6, 118.6, 117.9, 74.3, 44.6, 21.9, 21.0; HRMS 
(ESI) m/z Calcd for [C11H12O2 + H]+: 177.0916; found: 177.0921.  
(±)-2,5,7-Trimethyl-4-chromanone (73d):  Yield: 159 mg (0.84 mmol, 84%) as a white solid, 
mp 53-54 oC; IR: 1681, 1613 cm-1; 1H NMR: δ 6.64 (s, 1H), 6.60 (s, 1H), 4.51 (m, 1H), 2.65-2.58 
(obscured pattern, 2H), 2.60 (s, 3H), 2.29 (s, 3H), 1.47 (d, J = 6.3 Hz, 3H); 13C NMR: δ 193.6, 
162.8, 145.8, 141.8, 125.8, 117.1, 115.9, 73.5, 46.1, 22.7, 21.7, 20.9; HRMS (ESI) m/z Calcd for 
[C12H14O2 + H]+: 191.1072; found: 191.1070.  
(±)-2,5-Dimethyl-8-isopropyl-4-chromanone (73e):  Yield: 72 mg (0.33 mmol, 33%; 40% 
brsm) as a white solid, mp 64-65 oC; IR: 1685, 1579 cm-1; 1H NMR: δ 7.24 (d, J = 7.8 Hz, 1H), 
6.75 (d, J = 7.7 Hz, 1H), 4.52 (m 1H), 3.28 (septet, J = 6.9 Hz, 1H), 2.68 (AB pattern, J = 16.8 
Hz, 1H), 2.65 (s, 1H), 2.60 (s, 3H), 1.51 (d, J = 6.2 Hz, 3H), 1.21 (d, J = 6.9 Hz, 6H); 13C NMR: δ 
195.1, 160.5, 139.5, 135.5, 131.7, 124.5, 119.8, 73.8, 46.6, 27.2, 23.2, 23.0, 22.9, 21.4; HRMS 
(ESI) m/z Calcd for [C14H18O2 + H]+: 219.1385; found: 219.1388. A faster moving band 
contained 2-isopropyl-5-methylphenyl (E)-2-butenoate [79e (X = 2-i-Pr-5-Me), 72 mg, 0.33 
154 
 
mmol, 33%; 40% brsm] as a light yellow oil; IR: 1739, 1659 cm-1; 1H NMR: δ 7.24-7.14 
(complex, 2H), 7.02 (d, J = 7.9 Hz, 1H), 6.83 (s, 1H), 6.07 (dd, J = 15.5, 1.5 Hz, 1H), 2.98 
(septet, J = 6.9 Hz, 1H), 2.32 (s, 3H), 1.97 (dd, J = 7.0, 1.8 Hz, 3H), 1.19 (d, J = 6.9 Hz, 6H); 13C 
NMR: δ 165.1, 147.9, 146.7, 137.1, 136.5, 127.0, 126.4, 122.8, 122.1, 27.1, 23.0, 20.8, 18.2; 
HRMS (ESI) m/z Calcd for [C14H18O2 + H]+: 219.1385; found: 219.1378.  
(±)-7-Fluoro-2-methyl-4-chromanone (73f):  Yield: 128 mg (0.71 mmol, 71%) as a light yellow 
oil; IR: 1695, 1612 cm-1; 1H NMR: δ 7.89 (dd, J = 8.8, 6.6 Hz, 1H), 6.72 (td, J = 8.4, 2.4 Hz, 1H), 
6.65 (dd, J = 10.1, 2.4 Hz, 1H), 4.61 (m, 1H), 2.68 (s, 1H), 2.66 (AB, J = 16.4 Hz, 1H), 1.51 (d, J 
= 6.3 Hz, 3H); 13C NMR: δ 191.1, 167.4 (d, J = 256.0 Hz), 163.3 (d, J = 13.7 Hz), 129.4 (d, J = 
11.4 Hz), 117.7 (d, J = 2.6 Hz), 109.6 (d, J = 22.7 Hz), 104.6 (d, J = 24.3 Hz), 74.9, 44.1, 20.8; 
HRMS (ESI) m/z Calcd for [C10H9FO2 + H]+: 181.0664; found: 181.0661.  
(±)-7-Methoxy-2-methyl-4-chromanone (73g): Yield: 105 mg (0.55 mmol, 55%) as a yellow 
solid, mp 67-69 oC; IR: 2839, 1682, 1607 cm-1; 1H NMR: δ 7.52 (d, J = 8.8 Hz, 1H), 6.57 (dd, J = 
8.8, 2.4 Hz, 1H), 6.42 (d, J = 2.4 Hz, 1H), 4.59 (m, 1H), 3.83 (s, 3H), 2.64 (AB, J = 16.8 Hz, 1H), 
2.62 (s, 1H), 1.51 (d, J = 6.3 Hz, 3H); 13C NMR: δ 191.1, 166.0, 163.6, 128.7, 114.8, 109.8, 
100.7, 74.7, 55.6, 44.3, 21.0; HRMS (ESI) m/z Calcd for [C11H12O3 + H]+: 193.0865; found: 
193.0859. 
(±)-2,5,8-Trimethyl-4-chromanone (73h):  Yield: 80 mg (0.42 mmol, 42%; 47% brsm) as a 
light yellow oil; IR: 1685, 1583 cm-1; 1H NMR: δ 7.17 (d, J = 7.5 Hz, 1H), 6.68 (d, J = 7.5 Hz, 
1H), 4.53 (m, 1H), 2.67 (AB pattern, J = 16.6 Hz, 1H), 2.64 (s, 1H), 2.59 (s, 3H), 2.19 (s, 3H), 
1.50 (d, J = 6.3 Hz, 3H); 13C NMR:  194.9, 161.3, 139.6, 135.9, 125.1, 124.0, 118.8, 73.8, 46.5, 
23.2, 21.4, 16.3; HRMS (ESI) m/z Calcd for [C12H14O2 + H]+: 191.1072; found: 191.1066.  A 
faster moving band contained 2,5-dimethylphenyl (E)-2-butenoate [79h (X = 2,5-diMe), 67 mg, 
0.35 mmol, 35%; 39% brsm] as a colorless oil; IR: 1739, 1656 cm-1; 1H NMR:  7.16 (dq, J = 
15.5, 6.9 Hz, 1H), 7.10 (d, J = 7.7 Hz, 1H), 6.94 (d, J = 7.7 Hz, 1H), 6.84 (s, 1H), 6.07 (dq, J = 
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15.5, 1.7 Hz, 1H), 2.31 (s, 3H), 2.12 (s, 3H), 1.96 (dd, J = 6.9, 1.7 Hz, 3H); 13C NMR: δ 164.7, 
149.2, 146.7, 136.8, 130.8, 127.0, 126.7, 122.5, 122.0, 20.9, 18.2, 15.8; HRMS (ESI) m/z Calcd 
for [C12H14O2 + H]+: 191.1072; found: 191.1062.   
(±)-2,6,7-Trimethyl-4-chromanone (73i):  Yield: 136 mg (0.72 mmol, 72%) as a tan solid, mp 
73-75 oC; IR: 1681, 1621 cm-1; 1H NMR: δ 7.61 (s, 1H), 6.76 (s, 1H), 4.55 (m, 1H), 2.64 (AB 
pattern, J = 16.9 Hz, 1H), 2.62 (s, 1H), 2.26 (s, 3H), 2.21 (s, 3H), 1.49 (d, J = 6.3 Hz, 3H); 13C 
NMR: δ 192.5, 160.0 146.5, 129.8, 126.9, 118.6, 118.3, 74.2, 44.6, 21.0, 20.5, 18.8; HRMS (ESI) 
m/z Calcd for [C12H14O2 + H]+: 191.1072; found: 191.1075.  
(±)-2,6,8-Trimethyl-4-chromanone (73j):  Yield: 68 mg (0.36 mmol, 36%; 44% brsm) as a light 
yellow solid, mp 48-51 oC; IR: 1692,1616 cm-1; 1H NMR: δ 7.53 (s, 1H), 7.16 (s, 1H), 4.54 (m, 
1H), 2.65 (apparent s, 1H), 2.63 (s, 1H), 2.26 (s, 3H), 2.21 (s, 3H), 1.52 (d, J = 6.3 Hz, 3H); 13C 
NMR: δ 193.2, 158.1, 138.0, 129.8, 126.8, 124.0, 120.1, 74.0, 44.6, 21.0, 20.4, 15.6; HRMS 
(ESI) m/z Calcd for [C12H14O2 + H]+: 191.1072; found: 191.1064.  A faster moving band 
contained 2,4-dimethylphenyl (E)-2-butenoate [79j (X = 2,4-diMe), 57 mg, 0.30 mmol, 30%; 
37% brsm] as a light yellow oil;  IR: 1740, 1657 cm-1; 1H NMR: δ 7.19 (dq, J = 16.9, 6.9 Hz, 1H), 
7.03 (s, 1H), 7.00 (d, J = 8.1 Hz, 1H), 6.90 (d, J = 8.1 Hz, 1H), 6.07 (dd, J = 16.9, 1.8 Hz, 1H), 
2.30 (s, 3H), 2.13 (s, 3H), 1.96 (dd, J = 6.9, 1.8 Hz, 3H); 13C NMR: δ 164.8, 147.1, 146.6, 135.4, 
131.7, 129.8, 127.4, 122.0, 121.6, 20.8, 18.2, 16.1; HRMS (ESI) m/z Calcd for [C12H14O2 + H]+: 
191.1072; found: 191.1066. 
(±)-2,7,8-Trimethyl-4-chromanone (73k): Yield: 152 mg (0.80 mmol, 80%) as a yellow oil; IR: 
1688, 1604 cm-1; 1H NMR: δ 7.66 (d, J = 8.0 Hz, 1H), 6.82 (d, J = 8.0 Hz, 1H), 4.55 (m, 1H), 
2.65 (s, 1H), 2.63 (AB, J = 16.5 Hz, 1H), 2.30 (s, 3H), 2.16 (s, 3H), 1.53 (d, J = 6.3 Hz, 3H); 13C 
NMR: δ 192.8, 159.5, 145.3, 124.9, 123.5, 122.6, 118.5, 73.9, 44.2, 20.9, 20.5, 11.2; HRMS 
(ESI) m/z Calcd for [C12H14O2 + H]+: 191.1072; found: 191.1067.  
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(±)-3-Methyl-2,3-dihydro-1H-benzo[f]chromen-1-one (73l):  Yield: 159 mg (0.75 mmol, 75%) 
as a white solid, mp 66-68 oC; IR: 1667, 1618 cm-1; 1H NMR: δ 9.45 (d, J = 8.1 Hz, 1H), 7.91 (d, 
J = 9.0 Hz, 1H), 7.74 (d, J = 8.1 Hz, 1H), 7.63 (d, J = 7.8 Hz, 1H), 7.42 (t, J = 7.5 Hz, 1H), 7.10 
(d, J = 9.0 Hz, 1H), 4.71 (m, 1H), 2.87-2.69 (complex, 2H), 1.57 (d, J = 6.0 Hz, 3H); 13C NMR: δ 
193.4, 163.6, 137.2, 131.1, 129.4, 128.9, 128.1, 125.6, 124.6, 118.7, 112.2, 74.2, 45.6, 20.5; 
HRMS (ESI) m/z Calcd for [C14H12O2 + H]+:  213.0916; found: 213.0909.  
(±)-2-Methyl-2,3,6,7,8,9-hexahydro-4H-benzo[g]chromen-4-one (73m):  Yield: 112 mg (0.52 
mmol, 52%) as a light yellow solid, mp 60-61 oC; IR: 1686, 1618 cm-1; 1H NMR: δ 7.58 (s, 1H), 
6.67 (s, 1H), 4.51 (m, 1H), 2.72 (dm, J = 15.8 Hz, 4H), 2.64 (AB, J = 15.8 Hz, 1H), 2.62 (s, 1H), 
1.77 (m, 4H), 1.48 (d, J = 6.3 Hz, 3H); 13C NMR: δ 192.6, 159.3, 146.9, 130.5, 126.7, 118.8, 
117.2, 74.1, 44.7, 30.1, 28.5, 23.1, 22.7, 21.0; HRMS (ESI) m/z Calcd for [C14H16O2 + H]+: 
217.1229; found: 217.1232.  
(±)-7-Chloro-2-methyl-4-chromanone (73n): Yield: 52 mg (0.26 mmol, 36%; 46% brsm) as a 
white solid, mp 53-55 oC; IR: 1690, 1598 cm-1; 1H NMR: δ 7.81 (d, J = 8.2 Hz, 1H), 7.00 (s, 1 H), 
6.99 (dd, J = 8.2, 2.0 Hz, 1H), 4.61 (m, 1H), 2.69 (s, 1H), 2.67 (AB pattern, J = 16.8 Hz, 1H), 
1.52 (d, J = 6.3 Hz, 3H),; 13C NMR: δ 191.2, 161.8, 141.6, 128.0, 121.9, 119.2, 117.9, 74.7, 44.2, 
20.7; HRMS (ESI) m/z Calcd for [C10H9ClO2 + H]+: 197.0369; found: 197.0376.  A faster moving 
band contained 3-chlorophenyl (E)-2-butenoate [79n (X = 3-Cl), 43 mg, 0.22 mmol, 22%; 28% 
brsm] as a light yellow oil; IR: 1736, 1655 cm-1; 1H NMR: δ 7.30 (t, J = 8.1 Hz, 1H), 7.24-7.14 
(complex, 3H), 7.03 (d, J = 8.2 Hz, 1H), 6.03 (d, J = 15.5 Hz, 1H), 1.98 (dd, J = 6.9, 1.7 Hz, 3H); 
13C NMR: δ 164.2, 151.1, 147.4, 134.4, 129.9, 125.8, 122.2, 121.5, 119.9, 18.1; HRMS (ESI) m/z 
Calcd for [C10H9ClO2 + H]+: 197.0369; found: 197.0362.    
(±)-6-Methoxy-2-methyl-4-chromanone (73o): Yield: 99 mg (0.52 mmol, 52%) as an orange 
solid, mp 58-61 oC; IR: 2834, 1689, 1621 cm-1; 1H NMR: δ 7.31 (d, J = 3.2 Hz, 1H), 7.09 (dd, J = 
9.0, 3.2 Hz, 1H), 6.91 (d, J = 9.0 Hz, 1H), 4.55 (m, 1H), 3.80 (s, 3H), 2.67 (apparent br s, 1H), 
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2.65 (s, 1H), 1.51 (d, J = 6.3 Hz, 3H); 13C NMR: δ 193.1, 156.9, 154.4, 125.7, 121.7, 119.6, 
107.7, 74.8, 56.3, 45.0, 21.4; HRMS (ESI) m/z Calcd for [C11H12O3 + H]+: 193.0865; found: 
193.0866.  
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APPENDICES 
Appendix A: X-ray data for ethyl  (E)-4-{3-oxo-3-[(2,2,4,4-tetramethylthiochroman-6-
yl)amino]prop-1-en-1-yl}benzoate (31a) 
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Appendices B: X-ray data for 6-acetyl-2-nitrobenzo[4,5]imidazo[2,1-b]quinazolin-12(6H)-
one (26a) 
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Table 1. Crystal data and structure refinement for GKK/006/070. 
Empirical formula 
Formula weight 
Crystal system 
Space group 
Unit cell dimensions 
 
 
 
 
Volume 
Z, Z' 
 C16H10N4O4 
322.28 
monoclinic 
P21 
a = 4.940(6) Å α= 90° 
b = 15.552(18) Å β= 92.092(16)° 
c = 8.944(10) Å γ= 90° 
686.7(14) Å3 
2, 1 
Density (calculated)  1.559 Mg/m3 
Wavelength  0.71073 Å 
Temperature  100(2) K 
F(000)  332 
Absorption coefficient  0.116 mm-1 
Absorption correction  semi-empirical from equivalents 
Max. and min. transmission  0.993 and 0.986 
Theta range for data collection  2.279 to 25.973° 
Reflections collected  5819 
Independent reflections  2294 [R(int) = 0.0889] 
Data / restraints / parameters  2294 / 1 / 217 
wR(F2 all data)  wR2 = 0.1906 
R(F obsd data)  R1 = 0.0743 
Goodness-of-fit on F2  0.975 
Observed data [I > 2(I)]  1436 
Absolute structure parameter  -2.3(10) 
Largest and mean shift / s.u.  0.005 and 0.001 
Largest diff. peak and hole  0.422 and -0.336 e/Å3 
 
 
 
  
wR2 = {Σ[w(Fo2-Fc2)2] / Σ [w(Fo2)2]}1/2 
R1 = Σ|| Fo|-|Fc|| / Σ |Fo| 
Table 2.  Atomic coordinates and equivalent isotropic displacement parameters 
for GKK/006/070. U(eq) is defined as one third of the trace of the orthogonalized 
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Uij tensor. 
 
x y z U(eq) 
 
 
O(1) 
 
0.2740(10) 
 
0.3343(3) 
 
0.5038(6) 
 
0.0324(14) 
O(2) 1.0394(11) 0.4114(3) 0.1677(6) 0.0369(15) 
O(3) 1.1275(12) 0.5467(4) 0.1232(6) 0.0380(15) 
O(4) -0.3607(11) 0.6269(4) 0.9290(7) 0.0416(16) 
N(1) 0.2381(12) 0.5949(4) 0.6031(8) 0.0267(15) 
N(2) -0.0998(12) 0.5478(4) 0.7748(7) 0.0267(15) 
N(3) 0.0994(12) 0.4478(4) 0.6360(7) 0.0237(16) 
N(4) 0.9969(13) 0.4895(4) 0.1858(7) 0.0298(17) 
C(1) -0.4138(15) 0.4440(5) 0.9094(9) 0.0294(19) 
C(2) -0.4745(16) 0.3553(5) 0.9197(9) 0.035(2) 
C(3) -0.3455(17) 0.2938(5) 0.8368(10) 0.033(2) 
C(4) -0.1525(16) 0.3173(5) 0.7332(10) 0.0301(19) 
C(5) 0.2759(15) 0.4125(5) 0.5301(9) 0.0258(18) 
C(6) 0.6347(14) 0.4520(5) 0.3558(8) 0.0229(17) 
C(7) 0.7875(15) 0.5145(5) 0.2907(9) 0.0255(19) 
C(8) 0.7563(16) 0.6030(5) 0.3231(9) 0.0271(19) 
C(9) 0.5742(16) 0.6266(5) 0.4258(8) 0.0283(19) 
C(10) -0.2183(14) 0.4667(5) 0.8101(9) 0.0264(19) 
C(11) -0.0869(15) 0.4044(5) 0.7257(9) 0.029(2) 
C(12) 0.0931(14) 0.5355(5) 0.6660(9) 0.0256(18) 
C(13) 0.4444(15) 0.4773(4) 0.4609(9) 0.0230(18) 
C(14) 0.4139(15) 0.5658(5) 0.4990(9) 0.0229(18) 
C(15) -0.1733(16) 0.6276(5) 0.8456(9) 0.032(2) 
C(16) -0.0100(18) 0.7062(5) 0.8116(11) 0.040(2) 
     
     
 
 
 
 
 
 
 
Table 3.  Bond lengths [Å] and angles [°] for GKK/006/070. 
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O(1)-C(5) 
 
1.239(9) 
 
C(3)-H(3) 
 
0.9500 
O(2)-N(4) 1.243(8) C(4)-C(11) 1.395(11) 
O(3)-N(4) 1.244(8) C(4)-H(4) 0.9500 
O(4)-C(15) 1.210(10) C(5)-C(13) 1.459(10) 
N(1)-C(12) 1.309(10) C(6)-C(7) 1.373(10) 
N(1)-C(14) 1.373(9) C(6)-C(13) 1.410(10) 
N(2)-C(12) 1.400(9) C(6)-H(6) 0.9500 
N(2)-C(10) 1.431(10) C(7)-C(8) 1.416(11) 
N(2)-C(15) 1.446(10) C(8)-C(9) 1.359(11) 
N(3)-C(12) 1.391(10) C(8)-H(8) 0.9500 
N(3)-C(11) 1.414(10) C(9)-C(14) 1.410(11) 
N(3)-C(5) 1.421(9) C(9)-H(9) 0.9500 
N(4)-C(7) 1.474(10) C(10)-C(11) 1.403(11) 
C(1)-C(10) 1.382(11) C(13)-C(14) 1.428(10) 
C(1)-C(2) 1.416(12) C(15)-C(16) 1.501(12) 
C(1)-H(1) 0.9500 C(16)-H(16A) 0.9799 
C(2)-C(3) 1.380(12) C(16)-H(16B) 0.9800 
C(2)-H(2) 0.9500 C(16)-H(16C) 0.9800 
C(3)-C(4) 1.402(11)   
C(12)-N(1)-C(14) 115.3(6) O(1)-C(5)-N(3) 120.3(6) 
C(12)-N(2)-C(10) 109.1(6) O(1)-C(5)-C(13) 126.8(7) 
C(12)-N(2)-C(15) 127.6(6) N(3)-C(5)-C(13) 112.9(7) 
C(10)-N(2)-C(15) 123.3(6) C(7)-C(6)-C(13) 118.4(7) 
C(12)-N(3)-C(11) 109.8(6) C(7)-C(6)-H(6) 120.8 
C(12)-N(3)-C(5) 121.7(6) C(13)-C(6)-H(6) 120.8 
C(11)-N(3)-C(5) 128.4(6) C(6)-C(7)-C(8) 122.4(7) 
O(3)-N(4)-O(2) 123.2(7) C(6)-C(7)-N(4) 119.5(6) 
O(3)-N(4)-C(7) 119.0(6) C(8)-C(7)-N(4) 118.1(7) 
O(2)-N(4)-C(7) 117.8(6) C(9)-C(8)-C(7) 118.7(7) 
C(10)-C(1)-C(2) 116.5(7) C(9)-C(8)-H(8) 120.6 
C(10)-C(1)-H(1) 121.8 C(7)-C(8)-H(8) 120.6 
C(2)-C(1)-H(1) 121.8 C(8)-C(9)-C(14) 122.0(7) 
C(3)-C(2)-C(1) 122.5(7) C(8)-C(9)-H(9) 119.0 
C(3)-C(2)-H(2) 118.8 C(14)-C(9)-H(9) 119.0 
C(1)-C(2)-H(2) 118.8 C(1)-C(10)-C(11) 121.2(7) 
C(2)-C(3)-C(4) 120.9(7) C(1)-C(10)-N(2) 131.9(7) 
C(2)-C(3)-H(3) 119.5 C(11)-C(10)-N(2) 106.8(6) 
C(4)-C(3)-H(3) 119.5 C(4)-C(11)-C(10) 122.2(7) 
C(11)-C(4)-C(3) 116.7(7) C(4)-C(11)-N(3) 130.4(7) 
C(11)-C(4)-H(4) 121.6 C(10)-C(11)-N(3) 107.4(7) 
C(3)-C(4)-H(4) 121.6 N(1)-C(12)-N(3) 126.4(7) 
N(1)-C(12)-N(2) 126.8(7) O(4)-C(15)-C(16) 124.2(8) 
N(3)-C(12)-N(2) 106.8(6) N(2)-C(15)-C(16) 117.7(7) 
C(6)-C(13)-C(14) 120.5(6) C(15)-C(16)-H(16A) 109.3 
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C(6)-C(13)-C(5) 119.6(6) C(15)-C(16)-H(16B) 109.5 
C(14)-C(13)-C(5) 119.9(7) H(16A)-C(16)-H(16B) 109.5 
N(1)-C(14)-C(9) 118.3(6) C(15)-C(16)-H(16C) 109.6 
N(1)-C(14)-C(13) 123.7(6) H(16A)-C(16)-H(16C) 109.5 
C(9)-C(14)-C(13) 118.0(7) H(16B)-C(16)-H(16C) 109.5 
O(4)-C(15)-N(2) 118.1(7)   
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Table 4.  Anisotropic displacement parameters (Å2x 103) for GKK/006/070.  
The anisotropic displacement factor exponent takes the form: 
-2 π2[ h2 a*2 U11 + ... + 2 h k a* b* U12] 
 
U11 U22 U33 U23 U13 U12 
 
 
O(1) 
 
 
43(3) 
 
 
12(3) 
 
 
43(4) 
 
 
6(2) 
 
 
14(3) 
 
 
2(2) 
O(2) 47(3) 21(3) 44(4) -2(3) 14(3) 4(3) 
O(3) 44(3) 32(3) 39(4) 7(3) 13(3) -5(3) 
O(4) 50(4) 25(3) 51(4) 1(3) 23(3) 8(3) 
N(1) 33(4) 14(3) 33(4) 4(3) 3(3) -3(3) 
N(2) 34(4) 18(3) 29(4) -1(3) 8(3) 3(3) 
N(3) 32(3) 12(3) 28(4) 4(3) 8(3) 0(3) 
N(4) 30(4) 25(4) 34(5) 4(3) 4(3) -1(3) 
C(1) 31(4) 31(5) 27(5) -1(4) 1(4) 0(4) 
C(2) 38(5) 36(5) 32(5) 3(4) 9(4) -7(4) 
C(3) 38(5) 28(5) 34(5) 6(4) 8(4) -3(4) 
C(4) 35(4) 19(4) 36(5) 2(4) 2(4) 1(3) 
C(5) 28(4) 20(4) 29(5) 4(4) 0(4) 5(3) 
C(6) 29(4) 17(4) 23(5) -1(3) 0(4) 1(3) 
C(7) 25(4) 29(5) 22(5) -2(3) -2(3) 1(3) 
C(8) 35(4) 16(4) 31(5) 2(3) 5(4) -1(3) 
C(9) 37(5) 13(4) 35(5) 1(4) 2(4) 0(3) 
C(10) 27(4) 24(4) 28(5) 4(3) 0(4) -1(3) 
C(11) 26(4) 26(4) 35(5) 1(4) 1(4) 0(3) 
C(12) 30(4) 18(3) 28(5) -1(4) 0(4) 3(4) 
C(13) 28(4) 14(4) 27(5) -1(3) 0(4) -2(3) 
C(14) 25(4) 24(4) 19(5) -1(3) -1(4) 2(3) 
C(15) 42(5) 21(4) 33(5) 1(4) -2(4) 7(4) 
C(16) 51(6) 17(4) 53(6) -8(4) 17(5) 2(4) 
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Table 5.  Hydrogen coordinates and isotropic displacement parameters for 
GKK/006/070. 
 
x y z U(eq) 
 
 
H(1) 
 
-0.5027 
 
0.4857 
 
0.9677 
 
0.035 
H(2) -0.6092 0.3374 0.9862 0.042 
H(3) -0.3880 0.2348 0.8501 0.040 
H(4) -0.0704 0.2759 0.6712 0.036 
H(6) 0.6567 0.3931 0.3306 0.027 
H(8) 0.8607 0.6450 0.2740 0.033 
H(9) 0.5543 0.6858 0.4489 0.034 
H(16A) -0.0603 0.7529 0.8786 0.060 
H(16B) -0.0468 0.7235 0.7075 0.060 
H(16C) 0.1833 0.6934 0.8268 0.060 
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Table 6.  Torsion angles [°] for GKK/006/070. 
 
 
C(10)-C(1)-C(2)-C(3) 
 
0.6(13) 
 
C(12)-N(3)-C(11)-C(10) 
 
1.8(9) 
C(1)-C(2)-C(3)-C(4) -2.4(13) C(5)-N(3)-C(11)-C(10) -178.9(7) 
C(2)-C(3)-C(4)-C(11) 3.9(12) C(14)-N(1)-C(12)-N(3) -0.8(11) 
C(12)-N(3)-C(5)-O(1) -178.8(7) C(14)-N(1)-C(12)-N(2) 180.0(7) 
C(11)-N(3)-C(5)-O(1) 2.0(12) C(11)-N(3)-C(12)-N(1) -179.7(7) 
C(12)-N(3)-C(5)-C(13) 0.5(10) C(5)-N(3)-C(12)-N(1) 0.9(12) 
C(11)-N(3)-C(5)-C(13) -178.7(7) C(11)-N(3)-C(12)-N(2) -0.4(8) 
C(13)-C(6)-C(7)-C(8) -1.4(11) C(5)-N(3)-C(12)-N(2) -179.7(6) 
C(13)-C(6)-C(7)-N(4) 177.2(7) C(10)-N(2)-C(12)-N(1) 178.1(7) 
O(3)-N(4)-C(7)-C(6) 177.4(7) C(15)-N(2)-C(12)-N(1) -2.7(12) 
O(2)-N(4)-C(7)-C(6) -4.7(11) C(10)-N(2)-C(12)-N(3) -1.2(8) 
O(3)-N(4)-C(7)-C(8) -4.0(11) C(15)-N(2)-C(12)-N(3) 178.0(7) 
O(2)-N(4)-C(7)-C(8) 173.9(7) C(7)-C(6)-C(13)-C(14) -0.5(10) 
C(6)-C(7)-C(8)-C(9) 2.1(12) C(7)-C(6)-C(13)-C(5) 179.0(7) 
N(4)-C(7)-C(8)-C(9) -176.5(7) O(1)-C(5)-C(13)-C(6) -2.2(12) 
C(7)-C(8)-C(9)-C(14) -0.8(12) N(3)-C(5)-C(13)-C(6) 178.6(6) 
C(2)-C(1)-C(10)-C(11) -0.6(12) O(1)-C(5)-C(13)-C(14) 177.3(8) 
C(2)-C(1)-C(10)-N(2) -177.3(8) N(3)-C(5)-C(13)-C(14) -2.0(10) 
C(12)-N(2)-C(10)-C(1) 179.5(8) C(12)-N(1)-C(14)-C(9) 179.3(7) 
C(15)-N(2)-C(10)-C(1) 0.2(13) C(12)-N(1)-C(14)-C(13) -0.9(11) 
C(12)-N(2)-C(10)-C(11) 2.3(8) C(8)-C(9)-C(14)-N(1) 178.9(7) 
C(15)-N(2)-C(10)-C(11) -176.9(7) C(8)-C(9)-C(14)-C(13) -0.9(11) 
C(3)-C(4)-C(11)-C(10) -3.9(12) C(6)-C(13)-C(14)-N(1) -178.2(7) 
C(3)-C(4)-C(11)-N(3) 179.0(8) C(5)-C(13)-C(14)-N(1) 2.3(12) 
C(1)-C(10)-C(11)-C(4) 2.3(12) C(6)-C(13)-C(14)-C(9) 1.6(11) 
N(2)-C(10)-C(11)-C(4) 179.8(7) C(5)-C(13)-C(14)-C(9) -177.9(7) 
C(1)-C(10)-C(11)-N(3) 180.0(7) C(12)-N(2)-C(15)-O(4) 174.2(7) 
N(2)-C(10)-C(11)-N(3) -2.5(8) C(10)-N(2)-C(15)-O(4) -6.7(11) 
C(12)-N(3)-C(11)-C(4) 179.2(8) C(12)-N(2)-C(15)-C(16) -6.3(11) 
C(5)-N(3)-C(11)-C(4) -1.5(13) C(10)-N(2)-C(15)-C(16) 172.8(7) 
 
 
 
 
 
 
 
184 
 
Table 7. Hydrogen bonds for GKK/006/070[Å and °]. 
 
 
   D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
 
C(1)-H(1)...O(3)#1 0.95 2.52 3.415(10) 156.7 
C(1)-H(1)...O(4) 0.95 2.33 2.861(10) 114.4 
C(4)-H(4)...O(1) 0.95 2.48 3.006(10) 114.9 
C(9)-H(9)...O(1)#2 0.95 2.49 3.370(10) 154.0 
Symmetry transformations used to generate equivalent atoms: 
#1 x-2, y, z+1 #2 -x+1, y+1/2, -z+1 
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Appendices C: X-ray data for methyl (±)-R,R-1-(2-(4-nitrophenyl)propyl)-2-
oxocyclopentane-1-carboxylate [(±)-R,R-57b]
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